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Abnormal glutamatergic neurotransmission is strongly implicated in the pathophysiology of 
schizophrenia. The main technique available for assessing central glutamate function in 
man in vivo is proton magnetic resonance spectroscopy (1H-MRS), which can be used to 
measure glutamate, its metabolite glutamine, or their combination (Glx). Although around 
sixty 1H-MRS studies in schizophrenia have been published, the findings have been 
inconsistent, and the extent to which these vary with the brain region examined, the stage 
of the disorder, the severity of symptoms and the effects of treatment is unclear. 
Nevertheless, data from recent cross-sectional studies suggest that glutamate 
concentrations may relate to the degree to which patients respond to antipsychotic 
medication.  However, it is not yet known whether glutamate is predictive of the future 
therapeutic response, or whether glutamate concentrations change as a consequence of 
treatment. This issue can be addressed through the longitudinal assessment of glutamate 
concentrations in patients with psychosis before and after antipsychotic treatment. 
A meta-analysis of the entire literature to date indicates that schizophrenia is associated 
with elevated 1H-MRS glutamate metabolites in the medial temporal cortex, basal ganglia, 
and thalamus, and that these findings vary with the stage of the disorder.  
The relationship between 1H-MRS glutamate metabolites and symptom severity was 
examined in a large dataset of individual patient data, pooled from multiple research 
samples. However this did not identify robust associations between glutamate measures 
and symptom scores, consistent with the findings from a systematic review of studies that 
had examined this issue. 
To investigate whether glutamatergic differences between antipsychotic responders and 
non-responders are predictive or consequential to the therapeutic response, a longitudinal 
(10 month) 1H-MRS study in FEP was conducted. This revealed that Glx levels in the 
thalamus declined with antipsychotic treatment in patients who responded well, but did 
not change in patients with a poor response after both 5 weeks and 10 months. Parallel 
work involving repeated 1H-MRS scanning of healthy volunteers indicated that these 
findings were not attributable to non-specific time effects. 
Overall, the results from this thesis suggest that alterations in glutamatergic function are 
evident in a number of brain regions in schizophrenia, and that these differ between 
patients who do and do not respond to treatment with antipsychotic medication. These 
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findings have implications for our understanding of the pathophysiology of the disorder, 
the stratification of patients, and the development of novel treatments.
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CHAPTER 1 - Introduction 
1.1. Schizophrenia 
Schizophrenia is a common, severe mental health disorder which affects 0.7% of the 
world’s population (Saha et al., 2005). Schizophrenia  is one of the leading causes of adult 
disease burden; it greatly affects an individual’s quality of life and increases the risk of 
premature mortality (Whiteford et al., 2015). In addition to the personal costs of 
schizophrenia, it also incurs large costs to the economy,  costing £11.8 billion per year in 
England (Elert, 2014).  
Schizophrenia is characterised by the presence of psychotic symptoms such as delusions 
and hallucinations, negative symptoms such as apathy and social withdrawal, and cognitive 
deficits such as poor working memory and executive function. Schizophrenia emerges 
during late adolescence, with the average age of onset being 26 years in males and 30 
years in females, with a second period of onset in females around the time of menopause 
(Häfner et al., 1993). Lifetime risk does not differ between genders, although a greater 
proportion of males are diagnosed from adolescence to around 35 years old (Häfner, 2003).   
In 1952 the first antipsychotic medication, chlorpromazine, was discovered. 
Chlorpromazine was identified as a D2 receptor antagonist twenty years later, leading to 
the dopamine hypothesis of schizophrenia (Carlsson, 1977; I. Creese et al., 1976; 
Matthysse, 1973; Seeman and Lee, 1975). At present, all FDA-approved antipsychotic drugs 
act at the D2 receptor (Elert, 2014). Despite the success of dopamine antagonism as the 
mainstay treatment of schizophrenia, one third of patients do not respond to current 
medicines (Lehman et al., 2004), and so it has been proposed that other neurotransmitter 
systems may also play a role in schizophrenia aetiology.  
1.1.1. The Dopamine hypothesis of Schizophrenia 
The dopamine hypothesis of schizophrenia proposes that psychotic symptoms result from 
excessive dopaminergic signalling in the striatum (Carlsson and Lindqvist, 1963). The 
mechanism of action of antipsychotic drugs formed the basis of the dopamine hypothesis, 
as all antipsychotic drugs target the D2 receptor (Elert, 2014), and the potency of D2 
antagonism strongly correlates with the dosage needed for clinical efficacy (I Creese et al., 
1976; Seeman and Lee, 1975). Furthermore, dopamine enhancing drugs such as 
amphetamine possess psychotomimetic properties (Lieberman et al., 1987). Firstly, 
repeated exposure to amphetamine in healthy individuals can induce psychosis, with a 
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single exposure producing transient positive symptoms, predominantly those of paranoid 
ideation and auditory hallucinations (Angrist and Gershon, 1970; Bell, 1973). Secondly, low 
doses of amphetamine exacerbate psychotic symptoms in patients with schizophrenia 
(Lieberman et al., 1987).  
PET studies have confirmed increased dopamine synthesis and release in patients in vivo 
(Howes et al., 2012a). The former is evidenced by increased uptake and storage of fluorine 
18–labelled dopamine in the striatum, which corresponds to increased activity of the 
enzyme dopa-decarboxylase which is involved in dopamine synthesis (Dao-Castellana et al., 
1997; Hietala et al., 1999, 1995; Lindström et al., 1999; McGowan et al., 2004; Meyer-
Lindenberg et al., 2002; Reith et al., 1994). Increased striatal dopamine release in patients 
with schizophrenia is evident following amphetamine challenge (Abi-Dargham et al., 1998; 
Breier et al., 1997; Laruelle et al., 1996) and following dopamine depletion in patients (Abi-
Dargham et al., 2000; Lawrence S Kegeles et al., 2010). The extent of increased dopamine 
release depends on illness stage; emerging during the prodromal phase (Howes et al., 
2009) and being most prominent during the onset of illness and in patients experiencing an 
exacerbation of disease, rather than those in remission (Laruelle et al., 1999). Furthermore 
the degree of striatal dopamine release is correlated with the worsening of positive 
symptoms (Laruelle et al., 1999). These effects have been localised to the associative 
striatum, rather than the ventral or sensorimotor striatum (Lawrence S Kegeles et al., 
2010). It is therefore proposed that excessive dopamine release in the striatum may 
underlie schizophrenia.  
In contrast with the striatum, there is some evidence that dopamine release may be 
blunted in the DLPFC of patients with schizophrenia (Davis et al., 1991; Slifstein et al., 
2015). As prefrontal dopamine is related to cognitive performance, it has been suggested 
that hypodopaminergia may contribute to cognitive deficits in schizophrenia (Goldman-
Rakic and Selemon, 1997). A reformulation of the dopamine hypothesis suggests that 
reduced prefrontal dopamine levels may be causally linked with striatal 
hyperdopaminergia, (Weinberger, 1987) as cortical dopamine inhibits striatal dopamine 
release (Deutch et al., 1990; Karreman and Moghaddam, 1996; Kolachana et al., 1995; 
Wilkinson, 1997). This can also be incorporated into a stress diathesis model of 
schizophrenia, as deficient prefrontal dopamine levels are no longer protective against 
stress-induced dopamine release in the striatum, which is reported in both clinical high risk 
and antipsychotic-naive SZ patients but not in healthy controls (Mizrahi et al., 2012). 
 16 
 
The phenomenological consequences of excessive striatal dopamine release and their 
relevance to symptoms in schizophrenia have been discussed in terms of aberrant salience 
(Kapur, 2003). Kapur’s hypothesis builds upon extensive research implicating dopamine in 
mediating reward prediction, suggesting a role of dopamine in attributing salience to 
rewarding stimuli (Berridge 2007). In this way, excessive dopaminergic activity would result 
in an individual assigning meaning to innocuous stimuli leading to hallucinations, and these 
aberrant stimuli then being cognitively rationalised through the development of delusions 
(Kapur, 2003). This is further supported by a meta-analysis report of reduced fMRI 
activation in the ventral striatum during reward anticipation, which indicates a reduced 
response to rewarding stimuli in contrast to neutral stimuli of patients (Juckel et al., 2012) 
1.1.2. Limitations of the dopamine hypothesis. 
Firstly, although D2 receptor antagonists are efficacious in the treatment of positive 
symptoms in schizophrenia, with equivalent effect sizes to common medical drugs (Leucht 
et al., 2012), up to one third of patients do not respond to D2 receptor antagonists 
(Lehman et al., 2004). Medication resistance may result from accelerated drug metabolism 
(McCutcheon et al., 2015), but in medication resistant patients high levels of D2 receptor 
blockade can still be associated with no therapeutic effect (Pilowsky et al., 1993). 
Furthermore, clozapine is the most efficacious treatment for schizophrenia but it has less 
affinity for D2 receptors than many conventional antipsychotics (Pilowsky et al., 1992). 
These findings suggest that non-dopaminergic targets may be involved in the 
pathophysiology of schizophrenia.  
About 50% of patients with poor responses to typical and atypical antipsychotics show an 
improvement when switched to treatment with clozapine, despite what is often a 
reduction in D2R occupancy (Pilowsky et al., 1992). The unique efficacy of clozapine may be 
attributed to agonism of the glycine modulatory site (Javitt, 2004). In recovered clozapine-
treated patients, the addition of D-cycloserine, a partial glycine site agonist, exacerbates 
negative symptoms (Goff et al., 1999, 1996), which does not occur with the use of full 
agonists such as glycine and D-serine (Evins et al., 2000; Tsai et al., 1999). A recent study 
found that non-responders to medication do not possess elevated dopamine levels in the 
striatum (Demjaha et al., 2012), but have elevated glutamate in the anterior cingulate 
cortex (ACC) (Demjaha et al., 2014; Mouchlianitis et al., 2015).  
Secondly, D2 blockade improves positive symptoms but has little effect on negative 
symptoms, impaired cognition or loss of vocational and social function (Javitt, 1999; Kim et 
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al., 2013; Murphy et al., 2006). This is despite patients often finding these the most 
debilitating aspects of disease, with their severity predicting social and functional outcome 
(Ventura et al., 2009). Reduced dopamine in the prefrontal cortex has been proposed to 
underlie cognitive symptoms in schizophrenia (Davis et al., 1991), however there is a lack of 
direct evidence for cortical dopaminergic alterations in schizophrenia (Kambeitz et al., 
2014). Striatal hyperdopaminergia may underlie impairments in incentive motivation and 
cognition as indicated by animal models (Simpson et al., 2010; Ward et al., 2012), however 
amphetamine is found to improve negative and cognitive symptoms in patients (Barch and 
Carter, 2005; Laruelle et al., 1999). Thirdly, the dopamine hypothesis fails to explain 
neuroimaging hallmarks of schizophrenia, namely grey matter loss in cortical and medial 





1.2 Glutamate  
1.2.1 The NMDAR hypofunction hypothesis of schizophrenia 
The N-Methyl-D-Aspartate  receptor (NMDAR) hypofunction hypothesis was proposed on 
the basis of the psychotomimetic effects of PCP and ketamine, which are NMDAR 
antagonists  (Anis et al., 1983). Administration of these drugs in healthy volunteers can 
induce positive and negative symptoms as well as cognitive impairments that are similar to 
those seen in patients with schizophrenia (Javitt and Zukin, 1991). When given to patients 
with schizophrenia, they can exacerbate these symptoms (Javitt and Zukin, 1991). The 
effects of PCP and ketamine thus bear a closer resemblance to the clinical features of 
schizophrenia than those of amphetamines (Krystal et al., 2005). These observations led to 
the suggestion that schizophrenia may involve hypofunction at NMDARs (Olney and Farber, 
1995). 
It is proposed that this NMDAR hypofunction primarily occurs on parvalbumin-expressing 
GABA-ergic interneurons (chandelier and basket cells) (Lisman et al., 2008), found in the 
cortex, hippocampus, thalamus and cerebellum (Celio, 1990; Conti et al., 1997). These cells 
play a pivotal role in the control of glutamatergic pyramidal cell firing, as they synapse at 
the perisomatic region where action potentials are initiated (Benes and Berretta, 2001). 
Loss of GABAergic control of pyramidal cells results in excessive glutamate release, which 
can act through postsynaptic AMPA glutamate receptors to trigger excitotoxic damage, see 
Figure 1 (Lisman et al., 2008). Excitotoxic cell loss provides a plausible mechanism for the 
robust cortical and hippocampal volume reductions documented in patients (Steen et al., 
2006; Tregellas, 2014), although there is no direct evidence from human studies that 
excitotoxicity is responsible.  
NMDAR function mediates hippocampal long term potentiation and long term depression 
required for learning and memory (Malenka and Bear, 2004), and could thus contribute to 
the development of cognitive impairments in schizophrenia. Parvalbumin-expressing GABA-
ergic interneurons mediate theta and gamma oscillations in the brain (Buzsáki and 
Draguhn, 2004; Wulff et al., 2009), which bind inputs from multiple brain regions to 
facilitate cognitive functioning (Buzsáki and Wang, 2012) and perceptual organisation 
(Singer, 1999), which are disrupted in schizophrenia (Uhlhaas and Silverstein, 2005).  
The NMDAR receptor is formed of four subunits, with at least one NR1 subunit, and a 
combination of NR2 subunits (NR2A-D) and NR3 subunits (NR3A and NR3B); with each 
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conformation possessing different electrophysiological properties (Dingledine et al., 1999; 
Matsuda et al., 2003). The NR1 subunit of the NMDAR is highly expressed throughout the 
brain (Moriyoshi et al., 1991), whereas NR2 subunits differ in their regional and 
developmental expression (Monyer et al., 1994). NR2C and NR2D subunits, preferentially 
expressed by hippocampal GABA-ergic interneurons, are more sensitive to glutamate and 
antagonist binding than their NR2A and NR2B counterparts (Dingledine et al., 1999; Grunze 
et al., 1996). Genetic and environmental risk factors for schizophrenia, such as hypoxic 
insults at birth, could modify NMDAR expression during development via excitotoxic or 





Figure 1 Glutamate hypothesis of schizophrenia, adapted from McGuire et al., 2008. 
A reduction in functional NMDA receptors on Parvalbumin-expressing GABA-ergic interneurons (chandelier or 





1.2.2 Indirect evidence for the NMDA hypofunction model of schizophrenia  
Multiple lines of evidence support the involvement of glutamate dysfunction in the 
pathophysiology of schizophrenia.   
Genetic risk loci 
A recent study combined data from all previous genome-wide association studies, and 
identified a number of schizophrenia-associated genetic loci that converge on targets 
necessary for glutamatergic neurotransmission, specifically: GRM3; mGluR3 metabotrophic 
glutamate receptor, GRIN2A; NR2A subunit of the NMDAR, GRIA1; GluR1 subunit of the 
AMPAR, CLCN3; CLC-3 chloride channel located next to glutamate receptors in the 
hippocampus, SLC38A7; SNAT7 glutamine transporter involved in the cycling of 
neurotransmitter glutamate, SRR; Serine racemase catalyses D-serine, a co-agonist on 
NMDAR, and CACNA1I subunit of a T-type calcium channel, which induces LTP when co-
activated with NR2B containing NMDAR (Ripke et al., 2014).  As sample sizes increase, 
polygenic risk scores may provide future insights into the common genetic basis of 
schizophrenia (Dudbridge, 2013).  
Post mortem findings 
GABA 
Post-mortem studies report reductions in presynaptic GABA-ergic interneuron markers in 
schizophrenia, consistent with the notion of impaired GABAergic control of glutamatergic 
pyramidal neurons (Coyle, 2006). Glutamic acid decarboxylase 67 (GAD67; an enzyme that 
synthesises GABA) in parvalbumin-expressing cells is reduced in both the prefrontal and 
cingulate cortex (Akbarian et al., 1995; Hashimoto et al., 2008, 2003) and the hippocampus 
of patients (Heckers et al., 2002). Moreover, reductions in GAD67 are localised to 
parvalbumin cells that co-express the NR2A subunit (Woo et al., 2004). Reduced expression 
of the GABA membrane transporter GAT-1 in the prefrontal cortex (Woo et al., 1998) and 
reduced expression of parvalbumin in the hippocampus are also found (Zhang and 
Reynolds, 2002) (for reviews see Benes & Berretta, 2001; Lewis, Volk, & Hashimoto, 2004; 
Marín, 2012). This reduction in presynaptic GABA synthesis may lead to an upregulation of 
GABA(A) receptors on the axon initial segments of pyramidal cells (Volk et al., 2002). The 
link between a loss of GABA-ergic interneuron function and NMDAR hypofunction is 
supported by data from animal models: chronic treatment with NMDAR antagonists 
downregulates GAD and GAT in the frontal cortex (Paulson et al., 2003) and reduces 




Post mortem studies suggest that in the frontal cortex, NMDAR subunit mRNA and protein 
expression vary according to the specific location and subunit investigated (Kristiansen et 
al., 2007). Both increased (Dracheva et al., 2001) and reduced  (Sokolov, 1998) NR1 subunit 
mRNA expression have been reported in frontal regions, with one study finding no 
difference in NMDAR subunit mRNA levels, although patients possessed a higher 
proportion of NR2D mRNA in the prefrontal cortex (Akbarian et al., 1996). NMDA receptors 
containing the NR2D subunit are more sensitive to ligand binding than conformations 
containing the NR2A and NR2B subunits (Monyer et al., 1994), which could make patients 
more vulnerable to excitotoxic damage in the prefrontal cortex.  In regards to subunit 
protein expression, NR1, N2A and N2B subunits are reduced in the prefrontal cortex of 
patients (Errico et al., 2013), although in the orbitofrontal cortex there was no change in 
NR1 subunit protein expression (Toro and Deakin, 2005). 
Changes in the proportion but not number of subunits may explain why a large number of 
studies find no difference in NMDAR ligand binding in frontal cortex (Kornhuber et al., 
1989; Noga et al., 2001; Scarr et al., 2005; Simpson et al., 1991; Weissman et al., 1991). 
Although increased [3H]TCP and [3H]MK801 binding to the ion channel site of the NMDAR 
were found in orbitofrontal cortex (Simpson et al., 1991) and anterior cingulate (Zavitsanou 
et al., 2002), and increased [3H]glycine binding has been found in multiple frontal cortical 
sites (Ishimaru et al., 1994).  
In the hippocampus, numerous post-mortem studies have found reduced NR1 subunit 
mRNA expression (Gao et al., 2000; Humphries et al., 1996; Law and Deakin, 2001) but no 
change in NR1 protein expression (McCullumsmith et al., 2007; Toro and Deakin, 2005). 
Increased NR2B mRNA expression  (Gao et al., 2000) and [3H]ifenprodil binding to 
NR1/NR2B subunits (Grimwood et al., 1999) has been reported in patients with 
schizophrenia, which contrasts with one study finding no difference in 2A, 2B, 2C and 2D 
subunit expression (McCullumsmith et al., 2007). No differences in NMDAR ligand binding 
in the hippocampus have been found (Gao et al., 2000; Kerwin et al., 1990; Kornhuber et 
al., 1989; McCullumsmith et al., 2007; Simpson et al., 1991). This contrasts with an in vivo 
SPET study, which found reduced NMDAR binding in medication-free patients (Pilowsky et 




In the striatum, no differences in NMDAR subunit expression (Errico et al., 2013; Meador-
Woodruff et al., 2001), and NMDAR ligand binding (Meador-Woodruff et al., 2001; Noga et 
al., 1997; Weissman et al., 1991) have been found in patients with schizophrenia, however 
glycine and MK-801 binding is increased in the putamen, but not caudate or accumbens of 
patients (Aparicio-Legarza et al., 1998; Kornhuber et al., 1989). In the substantia nigra 
increased NR1 subunit mRNA expression was found in patients (Mueller et al., 2004).  
NMDAR subunit alterations are present in the thalamus, and may vary according to age 
with increased expression in young patients but reduced in older patients (Clinton et al., 
2006; Clinton and Meador-Woodruff, 2004a; Ibrahim et al., 2000). Changes in glycine/D-
serine and polyamine site ligand binding, but no differences in ion channel ligand binding 
are found (Ibrahim et al., 2000), which together indicate a change in NMDA receptor 
stoichiometry but not overall expression in the thalamus. 
In the right cerebellum, expression of the NR2D subunit was increased in schizophrenic 
patients (Schmitt et al., 2010).  
In summary, ligand binding studies suggest that NMDAR expression is not grossly altered in 
schizophrenia, however there are significant limitations due to the multiple ligand binding 
sites on the NMDAR, some of which are not accessible when the receptor is inactive. The 
reduction of NR1 in frontal and hippocampal brain regions infers a loss of functional 
NMDAR in schizophrenia, as the NR1 subunit is a necessary component of the NMDAR 
complex (Meador-Woodruff and Healy, 2000). Post-mortem investigation of the NMDAR is 
further complicated by alternative splicing of the NR1 gene, which gives rise to eight 
different NR1 isoforms (Goebel and Poosch, 1999),  the altered expression of which are 
beginning to be found in schizophrenia, in the ACC (Kristiansen et al., 2006) and superior 
temporal gyrus (Le Corre et al., 2000). 
AMPA and kainate 
In the hippocampus, reduced AMPAR subunit mRNA and protein expression (Breese et al., 
1995; Eastwood et al., 1997a, 1997b, 1995; Harrison et al., 1991) and reduced AMPAR 
ligand binding (Gao et al., 2000; Kerwin et al., 1990) are found in patients with 
schizophrenia. Similarly reduced expression of kainate receptor subunit mRNA (Porter et 
al., 1997) and kainate ligand binding are found in the hippocampus (Kerwin et al., 1990; 
Porter et al., 1997) although one study found no difference in kainate ligand binding (Gao 
et al., 2000). 
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The consistent finding of reduced AMPAR signalling in the hippocampus may reflect a 
compensatory downregulation in response to excessive postsynaptic stimulation; and the 
loss of kainate receptors, which act presynaptically to reduce glutamate release, would 
make patients more susceptible to excessive stimulation. Likewise, in the thalamus, AMPA 
and kainate receptor subunit mRNA expression levels are reduced in patients with 
schizophrenia (Ibrahim et al., 2000). 
In the striatum, AMPAR (Freed et al., 1993; Healy et al., 1998; Meador-Woodruff et al., 
2001) and kainate receptors appear to be unchanged (Meador-Woodruff et al., 2001; 
Nishikawa et al., 1983; Noga et al., 1997).  
In frontal cortical areas, AMPAR findings are inconsistent; no differences in AMPAR binding 
or subunit mRNA levels are found In the prefrontal cortex (Freed et al., 1993; Healy et al., 
1998; O’Connor et al., 2007; Scarr et al., 2005), or cingulate cortex (Breese et al., 1995), 
which contrasts with reports of increased AMPA ligand binding in the anterior cingulate 
(Zavitsanou et al., 2002) and DLPFC (Noga et al., 2001). Reduced mRNA expression of GluR1 
in the left superior frontal gyrus has also been reported (Sokolov, 1998).    
Results are also inconsistent for kainate receptors in frontal brain regions; kainate receptor 
subunit mRNA is reduced in the left superior frontal gyrus (Sokolov, 1998) but no 
differences in mRNA subunit expression (Breese et al., 1995) or kainate ligand binding 
(Zavitsanou et al., 2002) are seen in the cingulate, or the DLPFC (Noga et al., 2001). 
However, increased kainate ligand binding is found in the frontal cortex (Deakin et al., 
1989; Scarr et al., 2005). 
Metabotropic glutamate receptors 
A loss of mGluR2/3 receptors may predispose individuals to psychosis, as they act 
presynaptically to reduce glutamate release (Hackler et al., 2010). In the DLPFC however, 
no differences in mGluR2/3 (Frank et al., 2011) and mGluR5 ligand binding or protein levels 
were found in patients with schizophrenia (Matosin et al., 2013). Increased mGluR5 was 
found in the pyramidal cell layers of orbitofrontal cortex  of patients with schizophrenia 
(Ohnuma et al., 1998). 
In conclusion, post-mortem studies find changes in NMDA receptor stoichiometry in the 
frontal, hippocampal and thalamic regions, in patients with schizophrenia, as well as 
reduced AMPA and kainate receptors in the hippocampus and thalamus and increased 
presynaptic metabotrophic glutamate receptors in the orbitofrontal cortex. Alterations in 
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NMDAR signalling and upregulated presynaptic metabotrophic glutamate receptors could 
increase the vulnerability to excitotoxic damage and lead to compensatory changes, such 
as the downregulation of AMPA and kainate receptors . 
EEG markers 
Patients with schizophrenia show robust deficits in mismatch negativity (MMN); an event-
related potential measured using electroencephalography (EEG) (Javitt, 2015). MMN 
generation is reliant upon NMDAR signalling, as the application of NMDAR antagonists to 
the auditory cortex in monkeys (Javitt et al., 1996), and administration of ketamine to 
healthy volunteers (Umbricht et al., 2000), both significantly attenuate the MMN signal. In 
schizophrenia, deficits in auditory sensory processing may impact upon bottom-up 
cognitive and attentional processing (Javitt, 2009). In healthy controls, reduced MMN 
amplitudes predict the severity of psychotic symptoms induced by ketamine (Umbricht et 
al., 2002), and in high-risk subjects predicts conversion to psychosis (Bodatsch et al., 2011).  
EEG studies have shown that brain oscillations are abnormal in patients with schizophrenia 
(see Uhlhaas & Singer, 2010 for review). NMDAR hypofunction would be expected to 
disrupt brain oscillations, as their generation is reliant upon GABAergic interneurons, with 
parvalbumin-expressing interneurons specifically implicated in the generation of theta (5-
10 Hz) and gamma (35-85 Hz) rhythms (Wulff et al., 2009). Abnormal gamma oscillations in 
the prefrontal cortex during working-memory task performance (Barr et al., 2010; 
Haenschel et al., 2009) as well as disruption of long-range gamma oscillation coordination 
at rest are found in patients, implicating a disconnection of frontal brain gamma with global 
gamma activity (Kikuchi et al., 2011). Disturbances in theta oscillations are also observed, 
which are responsible for establishing synchronisation across more distal brain regions 
(Schmiedt et al., 2005). Gamma oscillations mediate perceptual binding, necessary for face 
processing, selective attention, working memory, and social cognition, all of which are 
impaired in patients with schizophrenia (Silverstein and Keane, 2011).  
Grey matter volume loss 
Putative NMDAR hypofunction may lead to excessive glutamate release in the cortex, 
thalamus and hippocampus (Kim et al., 2011; Lisman et al., 2008; Moghaddam et al., 1997), 
the excitotoxic effects of which could underlie grey matter volume reductions in 
schizophrenia, as well as hippocampal functional hyperactivity (Konick and Friedman, 2001; 
Steen et al., 2006; Tregellas, 2014). Furthermore, abnormalities in hippocampal structure 
and function in patients relate to impairments in cognitive function (Schobel et al., 2009a) 
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and symptom severity (Friston et al., 1992; Schobel et al., 2009b). Chronic ketamine-
challenge mice display analogous hippocampal hyperactivity and subsequent atrophy to 
those seen in patients. Excessive glutamate release may mediate these changes, as they are 
prevented by administration of LY379268; a presynaptic inhibitor of glutamate release 
(Schobel et al., 2009a).  
1.2.3 Direct evidence for the NMDA hypofunction model of schizophrenia 
NMDAR autoantibodies 
More recently an autoimmune disorder associated with autoantibodies to the NMDAR has 
been associated with psychotic symptoms (Dalmau et al., 2008), and NMDAR 
autoantibodies are evident in a small proportion of patients with schizophrenia (Beck et al., 
2014; Hammer et al., 2014; Steiner et al., 2013; Zandi et al., 2010). 
Pharmacological models 
Pharmacological models of schizophrenia, administering PCP and ketamine to healthy 
volunteers to cause psychotic symptoms, were fundamental to the original development of 
the NMDAR hypofunction hypothesis, as described in section 1.2.1 (Javitt and Zukin, 1991). 
The combination of pharmacological models with neuroimaging techniques has facilitated a 
better understanding of the mechanisms which may underlie schizophrenia. These will be 
outlined in the next section. 
1.2.4 The effects of NMDAR-antagonists on brain function 
NMDAR-antagonist administration in animals 
Administration of NMDAR-antagonists in animals can inform us of the brain circuitry and 
neurotransmitter systems implicated in the action of these psychotomimetic drugs (for 
review, see Jentsch and Roth, 1999). 
NMDAR antagonists increase brain metabolism, particularly in the medial frontal, thalamic 
and hippocampal brain regions, and to a lesser extent in the basal ganglia (Gozzi et al., 
2008). Microdialysis studies (Lorrain et al., 2003; Moghaddam et al., 1997) and 13C/1H-
MRS studies in rats (Chowdhury et al., 2012; Iltis et al., 2009) show that PCP induces 
glutamate release (as well as dopamine and serotonin) in the prefrontal cortex. When 
NMDAR antagonist application is restricted to the mPFC, glutamate release does not occur 
(Lorrain et al., 2003). It is postulated that cortical glutamate release is mediated by the 
thalamus (Kargieman et al., 2008) or hippocampus (Jodo, 2013; Jodo et al., 2005), via 
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disinhibited pyramidal projections. Furthermore, NMDAR antagonism localised to the 
anterior thalamus, but not the limbic cortex, causes damage to pyramidal neurons in the 
limbic cortex (Olney et al., 1989; Sharp et al., 2001). 
The above results examine the acute effects of NMDAR antagonists. When chronically 
administered, NMDAR antagonists induce hypofunction in the medial frontal cortex and 
thalamus, and reduce medial frontal glutamate levels (Bustillo et al., 2012; Cochran et al., 
2003; Pratt et al., 2008; Wesseling et al., 2013; Zuo et al., 2006) which may result from 
dendritic spine loss (Hajszan et al., 2006) or compensatory alterations in GABA function 
(Amitai et al., 2012). However, two other studies found chronic administration to increase 
medial frontal glutamate levels (Amitai et al., 2012; Chatterjee et al., 2012). 
NMDAR-antagonist administration in humans 
Acute administration of ketamine in healthy volunteers increases blood flow and glucose 
metabolism in the thalamus and in frontal regions, particularly the anterior cingulate 
(Holcomb et al., 2005, 2001, Långsjö et al., 2005, 2004, 2003; Rowland et al., 2010). This is 
replicated by fMRI reports of increased BOLD response (De Simoni et al., 2013; Malhotra et 
al., 1997). 1H-MRS studies find increases in both glutamate (Stone et al., 2012) and 
glutamine (Rowland et al., 2005) in the anterior cingulate, although one study found no 
differences (Taylor et al., 2012). Prefrontal cortical dysconnectivity in healthy volunteers 
following acute ketamine treatment better reflects the dysconnectivity observed in early 
rather than chronic schizophrenia patients (Anticevic et al., 2015). 
Few fMRI studies have been conducted in chronic users, with two preliminary reports of 
reduced frontal perfusion in PCP users (Hertzmann et al., 1990; Wu et al., 1991). Chronic 
ketamine users  have reduced grey matter and white matter integrity in the frontal cortex 
(Edward Roberts et al., 2013; Liao et al., 2011, 2010). However, an 1H-MRS study found no 
differences in ACC glutamate levels relative to controls (Stone et al., 2014).  
In summary, acute NMDAR antagonism causes glutamate release in the anterior cingulate 
and induces activity in the medial frontal cortex and the thalamus. This finding is consistent 
in both humans and animals. The effects of chronic NMDAR antagonism differ from those 
seen with acute administration; functional studies suggest that frontal hypometabolism 
may occur but measures of frontal glutamate release are less consistent. Thus, if acute and 
chronic NMDAR antagonism have differential effects on brain circuitry, glutamate function 
in schizophrenia may depend on the clinical stage of disease.  
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1.3. Interactions between glutamate and dopamine in 
schizophrenia  
1.3.1. The effects of limbic glutamate on striatal dopamine  
It has been suggested that striatal hyperdopaminergia in schizophrenia is secondary to 
NMDAR dysfunction (Grace, 1991). PET studies suggest that phasic, rather than tonic 
dopamine levels are increased in schizophrenia, as radioligand displacement occurs at 
intrasynaptic rather than extrasynaptic receptors in the striatum (Abi-Dargham et al., 
2000). The original model outlined by Grace proposed that reduced tonic dopamine levels 
in schizophrenia were compensated by an increased sensitivity of the phasic dopamine 
response (Grace, 1991). However, additional work revealed that concurrent increases in 
the tonic and phasic dopamine response cause an additive effect on phasic dopamine 
release (Lodge and Grace, 2006).  
The hippocampus, via outputs from the ventral subiculum, regulates context-dependent 
responses in the striatum, by adjusting the number of spontaneously firing DA neurons in 
the VTA (Grace, 1991). In the MAM model of schizophrenia, disinhibited glutamatergic 
projections from the hippocampus cause excessive glutamate release in the ventral 
striatum. This leads to increased tonic dopamine release in the ventral striatum via a 
multisynaptic pathway, involving the disinhibition of VTA dopaminergic neurons by the 
ventral pallidum, see Figure 2 (Floresco et al., 2001). The number of spontaneously active 
dopaminergic neurons regulates the intensity of burst firing, which is NMDAR-dependent 
and mediated by glutamatergic input from the pedunculopontine tegmental nucleus (PPTg) 
(see Figure 2) (Chergui et al., 1993). PPTg activity can be altered by the prefrontal cortex 
and amygdala. Thus, NMDAR hypofunction can increase the ‘gain’ of the dopaminergic 
system via increased activity in descending hippocampal projections to the striatum 
(Floresco et al., 2003; Lodge and Grace, 2006). It is proposed that in patients with 
schizophrenia, increased dopaminergic tone allows more dopaminergic neurons to burst 





Figure 2 Adapted from Sesack and Grace, Neuropsychopharmacology, 2010 (35) 27-47.  
Two pathways can alter the gain and signal of dopamine neurons in the ventral tegmental area (VTA) which 
project to the ventral striatum. Firstly glutamatergic drive from the ventral subiculum increases tonic dopamine 
levels in the ventral striatum, via disinhibition of ventral pallidum projections to allow spontaneous firing of 
dopamine neurons in the VTA. Secondly, the pedunculopontine tegmentum (PPTg) provides direct 
glutamatergic drive to increase phasic dopamine release in the ventral striatum. This requires the laterodorsal 





1.3.2. The effects of striatal dopamine on limbic glutamate  
Excessive dopaminergic signalling in the associative striatum (L S Kegeles et al., 2010) may 
modulate activity in glutamatergic inputs from the cortex. Stimulation of D2 receptors 
downregulates glutamatergic input from the DLPFC onto striatal medium spiny neurons, 
reducing the influence of the DLPFC on the striatum, see Figure 3 (Laruelle et al., 2003; 
O’Donnell and Grace, 1994). Dysfunctional NMDAR signalling on medium spiny neurons 
may also contribute to this psychopathology, which has implications for cognitive 
functioning (Goldman-Rakic and Selemon, 1997; Weinberger and Berman, 1996).  
 
 
Figure 3 Adapted from Laruelle (2003), Annals of the New York Academy of Sciences 1003; 138-158.  
Cortical input to the striatum is differentially modulated by D1 and D2 receptor stimulation. Excess D2 
stimulation in schizophrenia reduces glutamatergic input to the striatum. 
 
 
Excessive dopaminergic signalling in the striatum would also be expected to affect thalamic 
functioning, as this is the major output target of the striatum via the globus pallidum 
(Sesack and Grace, 2010). Altered glutamatergic signalling of thalamic efferents and/or 
NMDAR hypofunction of cortical target neurons, may underlie the reduced structural and 
functional connectivity of thalamo-prefrontal circuits in schizophrenia (Pergola et al., 2015; 
Wagner et al., 2015, 2013; Zhang et al., 2014). The thalamus is well placed to mediate 
many aspects of schizophrenia psychopathology, most notably sensorimotor and cognitive 
deficits (Allen et al., 2009).  
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1.3.3. Acute effects of NMDAR antagonism on striatal dopamine release 
PET studies have been able to test the effects of NMDAR hypofunction on dopamine 
release, as postulated above. Three PET studies found that the NMDAR antagonist 
ketamine increases dopamine release in the striatum in healthy volunteers (Breier et al., 
1998; Smith et al., 1998; Vollenweider et al.), but another three studies found no effect 
(Aalto et al., 2002; Kegeles et al., 2002; L S Kegeles et al., 2000). The latter result is 
consistent with preclinical findings, with only a small increase detected using microdialysis 
techniques in rats (Miller and Abercrombie, 1996), and awake rhesus monkeys (Adams et 
al., 2002). If dopamine levels are increased following NMDAR antagonism, the changes 
appear to be much smaller in magnitude than those induced by amphetamine (Adams and 
Moghaddam, 1998; Hertel et al., 1995). NMDAR antagonists do not directly stimulate the 
VTA, as NMDAR antagonists localised to this region do not induce striatal dopamine release 
(Freeman and Bunney, 1984; French, 1986; Zhang et al., 1992).  
However, when ketamine pre-treatment is combined with an amphetamine challenge, the 
dopamine release induced by amphetamine is doubled (L S Kegeles et al., 2000; Miller and 
Abercrombie, 1996). The same results are also found when presynaptic glutamate release 
is blocked by mGlu2/3 agonists (van Berckel et al., 2006). This is consistent with evidence 
that dopamine release following amphetamine challenge in patients with schizophrenia is 
greater than in controls (Abi-Dargham et al., 1998; Breier et al., 1997; Laruelle et al., 1996; 
Laruelle and Abi-Dargham, 1999). Exaggerated dopamine release may occur because 
GABAergic inhibition of striatal dopamine release is reliant on glutamatergic signalling 
between the PFC and VTA. This lead to the proposal that abnormalities in prefrontal control 
systems may lead to striatal hyperdopaminergia in schizophrenia (Carlsson et al., 1999). 
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1.4. Neuroimaging studies of the glutamate system 
1.4.1.  Positron Emission Tomography  
Development of PET tracers to investigate NMDAR is challenging, as current radiotracers 
show high non-specific binding and poor signal to noise ratios (Bressan and Pilowsky, 2000; 
Waterhouse, 2003). To date, there has been one study using the SPET [123I]CNS-1261 
radiotracer in schizophrenia; where total NMDAR binding in clozapine treated patients 
(Bressan et al., 2005) and NMDAR binding in the hippocampus of medication-free patients 
were reduced relative to controls (Pilowsky et al., 2006). Reduced total NMDAR binding 
approached significance in patients treated with typical antipsychotics, and negatively 
correlated with total and negative PANSS score (Bressan et al., 2005; Pilowsky et al., 2006). 
However these NMDAR PET ligands have been difficult to validate, as the channels must be 
open for ligand binding to occur.  Further NMDAR PET tracers are currently in development 
(McGinnity et al., 2015, 2014), as well as probes for metabotrophic glutamate receptors, 
which may serve to validate these studies in the future (Fuchigami et al., 2015; Li et al., 
2012). An alternative strategy to measure brain glutamate levels is to use Proton Magnetic 
Resonance Spectroscopy (1H-MRS). 
1.4.2.  Proton Magnetic Resonance Spectroscopy (1H-MRS) 
1H-MRS is a non-invasive technique that is able to measure brain metabolites above 
0.5mmol, including; N-acetyl-aspartate (NAA); implicated in neuronal integrity and 
function, creatine (Cr); involved in energy homeostasis, myo-inositol; forms intracellular 
second messengers and acts as a glial marker, choline; indicates membrane turnover, and 
lactate; which signals anaerobic glycolysis, see Figure 4. 1H-MRS is also able to measure 
certain neurotransmitters; glutamate, the major excitatory neurotransmitter, and its 
metabolite glutamine, and their combination Glx, and most recently GABA, the major 
inhibitory neurotransmitter, using specialised editing sequences. In single voxel 
spectroscopy (SVS), metabolites are measured in a predetermined voxel of interest, 
whereas MRSI (magnetic resonance spectroscopic imaging) acquires metabolite data from 
a whole brain slice. MRS can utilise the resonant frequencies of numerous elements; 
phosphorus (31P) (to assess cell membrane integrity), carbon (13C) (to determine 
glutamate metabolism), fluorine (19F), sodium (23Na) and protons (1H), with the latter 
method being the most widely used due to the abundance of protons in organic tissue 
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metabolites (van der Graaf, 2010). Single voxel 1H-MRS measurement of glutamate and its 
metabolites will be the focus of this thesis. 
1.4.3.  1H-MRS signal acquisition and analysis  
1H-MRS is an extension of MRI imaging; when a tissue is exposed to an external magnetic 
field (B0), protons align along the direction of the applied field and resonate at a frequency 
that is given by the Larmor equation, with the Larmor frequency depending on the external 
magnetic field (B0) and the local microenvironment. When an additional magnetic field is 
applied in a perpendicular orientation (B1) in the form of a radiofrequency pulse, the 
protons will flip orientation. The proton will return back to the original orientation and 
precess back around B0, which induces current to produce a signal. This signal decreases 
(free induction decay) and is converted into a magnetic resonance spectrum via Fourier 
transform (Marsman, 2013). (See http://www.drcmr.dk/MR for animation)  
The interactions of protons with the surrounding molecules cause a change in the local magnetic field, 
leading to a change of the proton’s Larmor frequency (called chemical shift). The chemical shift gives 
information about the molecular group carrying the proton and is expressed in parts per million (ppm). Ppm 
is independent of field strength, ie at both 1.5T and 3T, glutamate peaks are present at 2.35ppm and 
3.75ppm, corresponding to the coupled spins of the C2–C4 hydrogen nuclei (see  
 
Figure 5). Thus individual metabolites have signature chemical shifts. The range of chemical 
shifts for physiological metabolites is narrow (2-4ppm) and so metabolite chemical shifts 











Field strengths below 3T cannot resolve well the resonant frequencies of glutamate from 
those of glutamine, and so these metabolites are instead reported in their combination as 
Glx. At field strengths of 1.5 to 3 T, the glutamate signal accounts for the majority (80-90%) 
of the Glx signal (Snyder and Wilman, 2010a). At 3T the glutamate and glutamine peaks can 
be largely resolved, although the overlap still makes it difficult to accurately obtain 
glutamine values, as 20% of the glutamine signal is contaminated by glutamate, whereas 
only 10% of the glutamate signal is contaminated by glutamine (Snyder and Wilman, 
2010a). At 4.7T and above, glutamine resonant frequencies are clearly separate from those 
of glutamate and so measures can be obtained of both (Snyder and Wilman, 2010a).  1H-
MRS provides a measure of total concentrations within a relatively large region of interest 
(typically 2mm x 2mm x 2mm), and thus the concentration estimates reflect both 
intracellular and extracellular glutamate, as well as in grey matter, white matter and CSF 
(depending on its location). Furthermore 1H-MRS cannot differentiate between glutamate 
that is involved in metabolism, and that involved  in neurotransmission (Rothman et al., 
2011). Glutamine, however, can act as an indirect measure of neurotransmitter glutamate 
turnover, as 80% of glutamine is used for glutamate neurotransmitter cycling (Rothman et 
al., 2011).  
As well as field strength, there are a number of methodological parameters to consider 
when using 1H-MRS. For high spectral resolution, short echo times at high field strengths 
increase the signal to noise, field homogeneity must be maximised by ‘shimming’ direct 
currents in the gradient and shim coils, and the large water signals that arise from high 
water concentrations should be supressed. The acquisition sequence, Point Resolved 
Spectroscopy (PRESS), has a better signal to noise ratio than Stimulated Echo Acquisition 
Mode (STEAM), however STEAM can achieve shorter echo times with more precise volume 
selection (Schwerk et al., 2014). The edited PRESS sequence MEGA-PRESS is designed to 
resolve GABA whereas the PRESS sequence is more suited to measuring glutamate (Henry, 
Lauriat et al. 2011).  
The selection of analysis software may also affect the output measures, as the model used 
to fit the spectra will vary between programs. One study found that the output from 
LCModel version 6.1-4F was more reproducible when measuring Glx compared to the 
Amares algorithm in jMRUI software (O'Gorman, Michels et al. 2011). LCModel compares 
spectra to a basis set acquired using a phantom (Provencher, 2015). The area under the 
spectrum peak is proportional to a metabolites concentration. A metabolites value is 
normalised by scaling metabolites to the unsuppressed water peak and reported as 
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‘institutional units’. If absolute concentrations are unknown, concentration ratios are 
reported. Creatine is commonly used as a reference as it is relatively stable in the brain. 
LCModel estimates the standard deviations of fitted metabolites (Cramer-Rao lower 
bounds: CRLB) expressed in percent of the estimated concentrations.  A metabolite 
concentration with a CRLB of <20% is considered acceptable. Lastly, as the presence of 
cerebrospinal fluid (CSF) in the voxel would underestimate metabolite concentrations when 

















Figure 5 1H-MRS PRESS spectra, adapted from Schubert, Gallinat, Seifert, & Rinneberg, 2004.  
PRESS spectra (echo time = 80ms) from a healthy volunteers’ brain is shown in comparison to phantom acquisitions of 
individual metabolites, to allow visualisation of overlapping peaks. Chemical shifts for the coupled spins of the C2–C4 
hydrogen nuclei in glutamate and glutamine are shown. Quantification of glutamine and glutamate targets the C4 proton 


















































Figure 4 1H-MRS spectra acquired at 3T (PRESS) from the brain of a healthy control.  
The main metabolites are labelled. LCModel (Provencher) fits the output (black) to a basis set of 16 metabolites to create a modelled 
spectra (red) to acquire metabolite estimates. 
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1.4.4. 1H-MRS regions of interest  
The anterior cingulate cortex (ACC) integrates information from the emotional limbic 
system (predominantly rostral ACC) and cognitive prefrontal regions (predominantly caudal 
ACC), see Figure 6 (Stevens et al., 2011). The rostral ACC is connected to many regions 
implicated in schizophrenia psychopathology, namely the hippocampus, ventral striatum 
and amygdala (see section 1.3 for an outline of how this circuitry may be compromised in 
schizophrenia). According to the NMDAR hypofunction model of schizophrenia, acute 
NMDAR antagonist administration to healthy controls increases both 1H-MRS measures of 
glutamate (Stone et al., 2012) and glutamine (Rowland et al., 2005) in the anterior 
cingulate cortex (see section 1.2.4). Furthermore grey matter reductions in the ACC have 
been reported in patients with schizophrenia (Fornito et al., 2009).  
The thalamus processes and integrates sensory input with information from higher-order 
limbic regions via a series of modality specific thalamo-cortical loops. The thalamus is 
therefore well placed to underlie the disturbances in sensory experience seen in 
schizophrenia (Pergola et al., 2015). Thalamo-cortical projections are glutamatergic, 
whereas thalamic tone is maintained by GABAergic interneurons (Clinton and Meador-
Woodruff, 2004b). The thalamus is strongly implicated in the NMDAR hypofunction model 
of schizophrenia, as NMDAR antagonist induced glutamate release in the medial frontal 
region is thought to be mediated by the thalamus (Kargieman et al., 2008). Furthermore 
post-mortem studies report reduced ionotropic glutamate receptor subunit gene 
expression in thalamocortical relay neurons (Sodhi et al., 2011). 
Lastly, NMDAR antagonist administration to healthy volunteers increases metabolism in the 
anterior cingulate and thalamus (Deakin et al., 2008; De Simoni et al., 2013; Holcomb et al., 
2005, 2001). The ACC and thalamus are therefore suitable regions of interest to investigate 
the presence of glutamatergic metabolite alterations in schizophrenia, and thus will be 





Figure 6 Adapted from Ullsperger et al., Physiological Reviews (2014) 94, 1, 35-79.  
The cingulate cortex has been divided into rostral (grey) and caudal (pink) portions, the posterior cingulate 
cortex (PCC) is also shown. The rostral anterior cingulate cortex is subdivided into the subcallosal (sACC) and 
pregenual (pACC) anterior cingulate cortices. The caudal ACC is further subdivided into the anterior and 




1.5. 1H-MRS glutamate findings in schizophrenia  
The previous meta-analysis of 1H-MRS glutamate measures in schizophrenia found 
decreases in glutamate and increases in glutamine in the medial frontal cortex of patients 
compared to controls (Marsman et al., 2013). Furthermore, medial frontal glutamate and 
glutamine in schizophrenia decreased with age at a faster rate relative to controls 
(Marsman et al., 2013). These findings indicate increased glutamate turnover in 
schizophrenia, as glutamate is converted into glutamine (Bak et al., 2006). This is consistent 
with the NMDAR hypofunction model, as acute ketamine was found to increase 1H-MRS 
measures of glutamate (Stone et al., 2012) and glutamine (Rowland et al., 2005) in the 
anterior cingulate of healthy controls. 
This meta-analysis examined studies published up until 2011, and therefore an update of 
the literature is needed. Glutamatergic differences in the basal ganglia and cerebellum 
could not be examined due to insufficient studies at the time, and glutamine was not 
examined in the thalamus and medial temporal lobe. Previous studies comparing patient 
groups indicate that glutamate metabolite differences may vary with the stage of the 
disorder (Natsubori et al., 2014; Ohrmann et al., 2007, 2005; Stanley et al., 1996; Szulc et 
al., 2004), however clinical groups could not be analysed separately in the meta-analysis 
due to insufficient study numbers. It is not currently established whether antipsychotic 
medication affects glutamate levels. Longitudinal MRS studies have not found effects of 
antipsychotic treatment on medial frontal glutamatergic measures (Bustillo et al., 2010; 
Theberge et al., 2007), although medication effects have been reported in the striatum (de 
la Fuente-Sandoval et al., 2013). One previous study reported higher medial frontal Glx in 
unmedicated relative to medicated patients (Kegeles et al., 2012). Lastly, numerous studies 
have tested the relationship between glutamate measures and symptom severity, 
however, a review of the literature has not yet been conducted.   
Therefore, I will conduct an updated case-control meta-analysis of all published reports of 
regional glutamatergic measures in high risk, first-episode psychosis and schizophrenia 
(Chapter 2.2). In addition, I will assess the influences of age, symptom severity, and 
antipsychotic treatment on 1H-MRS glutamate measures using systematic review (Chapter 




1.6. Predicting the response to antipsychotic medication 
Approximately one third of patients with schizophrenia do not respond to antipsychotic 
treatment, despite sufficient blockade of D2 receptors (Pilowsky et al., 1993). This presents 
an important clinical challenge, as these patients have poorer outcomes and incur large 
economical costs  (Caspi et al., 2004). At present treatment response cannot be predicted 
on the basis of clinical features. Instead, treatment response has to be determined 
empirically, by a lengthy process of evaluating one antipsychotic followed by at least one 
other. In practice, many patients are not fully adherent, the doses prescribed are not 
optimal, or the drug is not given long enough to work (Kane, 2012). There is thus a great 
need for tools that are able to predict drug response before treatment starts. This would 
allow non-responders to be fast tracked to receive clozapine. Clozapine is currently the 
only drug licensed for treatment-resistant patients, however due to its risk for serious 
adverse events that require close monitoring, its use is often delayed as other 
antipsychotics are trialled first (Howes et al., 2012b). 
Neuroimaging measures of dopamine and glutamate function offer promising candidates in 
the prediction of treatment response. Recent findings suggest that striatal dopamine levels 
may not be elevated in treatment non-responders (Demjaha et al., 2012), but instead may 
be characterised by elevated glutamate levels in the anterior cingulate cortex (Demjaha et 
al., 2014; Egerton et al., 2012). However, it is not yet known whether glutamate differences 
between responders and non-responders predate antipsychotic treatment or were 
secondary to this. Of the two methods that may be used as predictive tools, 1H-MRS 
measurement of glutamate is less invasive and less expensive than PET, and requires a 3T 
MRI scanner which are widely available. PET is far superior in its molecular specificity; it can 
specifically measure dopamine synthesis or release, whereas MRS provides the average 
concentration of glutamate and glutamine in a voxel (discussed above in section 1.4.4). 
However, there are relatively few PET scanners, even in developed countries, with scans 
costing £3-8,000 per subject, compared to £500 for a 1H-MRS scan.  A further disadvantage 
of PET is that it involves exposing the subject to radiation, limiting the number of scans per 




1.7. Glutamatergic drug targets for the treatment of 
schizophrenia 
Because of the evidence implicating glutamate dysfunction in schizophrenia, there has 
been great interest in evaluating the effects of drugs that act on the glutamate system in 
schizophrenia patients. The glycine/D-serine modulatory site on the NMDAR provides a 
suitable target, and compounds including glycine, D-serine, or D-cycloserine, and glycine 
transport inhibitors have been assessed. In addition mGluR2/3 agonists may be effective in 
preventing neurotoxicity as they reduce presynaptic release of glutamate (Javitt et al., 
2012).  
To date, effects of glutamatergic compounds have been small to modest; D-serine shows a 
moderate effect in reducing negative, but not positive symptoms (Tuominen et al., 2005), 
however recent trials of an mGluR2/3 agonist (Downing et al., 2014) and glycine reuptake 
inhibitor, Bitopertin, have been negative (Goff, 2014). Small to moderate effect sizes may 
be due to trials mainly recruiting chronic patients who are already receiving antipsychotics, 
and compounds acting on glutamatergic targets may be more effective in medication naïve 
first episode patients (Grace, 2015). Indeed, in a monotherapy trial of sarcosine (a glycine 
transporter-I inhibitor), 5 of 11 acutely symptomatic patients showed a 20% improvement 
in PANSS total scores. Of the patients who responded, all of these were antipsychotic-
naïve, whereas all non-responders had previous antipsychotic exposure (Lane et al., 2008). 
Recent evidence suggests that sodium nitroprusside augmentation of nitric oxide levels, a 
downstream product of NMDAR activation, may have therapeutic effects in schizophrenia 
(Hallak et al., 2013). Minocycline also has therapeutic effects in schizophrenia, and is 
thought to indirectly modulate NMDAR due to its ability to prevent NMDAR-antagonist 
induced neutotoxicity and injury in cell culture, and reduce NMDAR-antagonist cognitive 
deficits in animal models (Chaves et al., 2009). Further studies in larger patient samples are 
needed to replicate efficacious findings in patients.  
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1.8. Conclusions and study rationale 
Predictive tools are needed in schizophrenia to identify the third of patients who will not 
respond to treatment. This would facilitate immediate access to clozapine which effectively 
treats this patient cohort, which is not usually prescribed until two other antipsychotics 
have been trialled. Recent studies implicate that 1H-MRS glutamate levels differ in 
responders and non-responders to treatment (Demjaha et al., 2014; Egerton et al., 2012; 
Mouchlianitis et al., 2015). However these findings are in medicated patients, and so it is 
unclear whether glutamate levels predict response in antipsychotic naïve patients. The 
differences between groups may instead reflect differences in symptomatology at 
presentation, or represent a longitudinal reduction in glutamate in those who respond. 
Therefore, longitudinal studies following antipsychotic naïve patients are needed to 
determine whether baseline 1H-MRS glutamatergic measures predict treatment response.  
Aims and Objectives 
This thesis aims 
1. To critically review and conduct a meta-analysis of the glutamate proton magnetic 
resonance (1H-MRS) literature in schizophrenia. 
2. To investigate the relationships between regional glutamate concentrations and 
symptom severity, in a large multicentre dataset. 
3. To investigate the repeated-measures reproducibility and reliability of using proton 
magnetic resonance spectroscopy (1H-MRS) to measure glutamate in vivo. 
4. To examine the relationship between 1H-MRS glutamate measures and the acute 
and medium-term response to antipsychotic medication. 
Outline of this thesis 
Chapter 2 presents two published papers and a multicentre analysis. The first paper 
reviews the relationship between published reports of glutamate and symptom severity, as 
well as cognitive function. The second paper provides a meta-analysis of all published 
reports of regional glutamatergic measures in those at high risk for schizophrenia, with first 
episode psychosis and in chronic schizophrenia. The final section of Chapter 2 outlines a 
multicentre analysis, which examines the relation of 1H-MRS glutamate measures to 
symptom severity and medication status in a large dataset of individual patient data 
collected at multiple centres. 
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In Chapter 3, the reliability and reproducibility of 1H-MRS measures of glutamate, 
glutamine and Glx were assessed over a long time period of several months. CSF-corrected 
Glx was found to be the most reliable measure, and a power analysis informed the study 
design presented in Chapter 4. Chapter 4 describes the first longitudinal study that 
examines 1H-MRS glutamate measures and the acute and medium-term response to 




CHAPTER 2 - Proton Magnetic Resonance Spectroscopy (1H-
MRS) in Schizophrenia 
This chapter comprises 2 published papers and an additional study, all of which aim to 
summarise the current findings of 1H-MRS studies measuring glutamate in schizophrenia. 
The first paper (section 2.1) reviews studies which have examined glutamate levels in 
schizophrenia and the relationship with symptom severity and cognitive function. The 
second paper (section 2.2) provides a meta-analysis of all published reports of regional 
glutamatergic measures in schizophrenia. The third study (section 2.3) builds from the 
previous sections and examines the relation of 1H-MRS glutamate measures to symptom 
severity and medication status in a large dataset of individual patient data collected at 
multiple centres. 
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The glutamate hypothesis of schizophrenia, proposed over two decades ago, originated 
following the observation that administration of drugs that block NMDA glutamate receptors, 
such as ketamine, could induce schizophrenia-like symptoms. Since then, this hypothesis has 
been extended to describe how glutamate abnormalities may disturb brain function and 
underpin psychotic symptoms and cognitive impairments. The glutamatergic system is now a 
major focus for the development of new compounds in schizophrenia. Relationships between 
regional brain glutamate function and symptom severity can be investigated using proton 
magnetic resonance spectroscopy (1H-MRS) to estimate levels of glutamatergic metabolites in 
vivo. Here we briefly review the 1H-MRS studies that have explored relationships between 
glutamatergic metabolites, symptoms, and cognitive function in clinical samples. While some of 
these studies suggest that more severe symptoms may be associated with elevated 
glutamatergic function in the anterior cingulate, studies in larger patient samples selected on 
the basis of symptom severity are required. 
Keywords: schizophrenia, psychosis, glutamate, NMDA, MRS, spectroscopy, imaging 
 
INTRODUCTION 
Accumulating evidence suggests that glutamatergic 
dysfunction may contribute to the pathogenesis of 
schizophrenia, and the symptoms and cognitive deficits 
associated with the disorder (1). The glutamatergic system 
presents an attractive therapeutic target, as dopaminergic 
antipsychotics have little effect on negative symptoms or 
cognitive impairment, yet these features are better 
predictors of social and functional outcome than positive 
symptoms (2, 3). Here we briefly review the existing 
evidence linking abnormal glutamatergic transmission to 
cognitive, negative, and positive symptoms of 
schizophrenia. 
The observation that administration of antagonists at the 
N-methyl-d-aspartate glutamate receptor complex 
(NMDAR) such as phencyclidine (PCP) or ketamine to 
healthy volunteers induces effects which resemble aspects 
of schizophrenia symptomatology forms a cornerstone of 
the glutamate hypothesis of schizophrenia (4–6). NMDAR 
antagonists also worsen positive, negative, and cognitive 
symptoms in patients with schizophrenia (7, 8). While 
dopamine-stimulating drugs such as amphetamine also 
produce positive “psychotic”-like effects, negative-type 
symptoms, and cognitive deficits are far more prominently 
elicited by ketamine than amphetamine administration (9). 
Neuroimaging studies indicate that these effects of 
ketamine are mediated by changes in activity in the frontal 
and cingulate cortices and the thalamus (10–13). 
While pharmacological studies have provided evidence 
linking NMDAR dysfunction to these symptom domains, 
direct associations between glutamatergic function and 
symptom severity may be provided by neuroimaging 
studies. In a single photon emission tomography study 
using the NMDAR radiotracer 123ICNS-1261 in 
schizophrenia, the availability of NMDAR in the 
hippocampus was negatively associated with the severity of 
symptoms, especially negative symptoms (14). A ketamine 
challenge study in healthy volunteers using the same 
radiotracer linked regional NMDAR binding to the induction 
of negative (but not positive) symptoms, particularly in the 
thalamus (15). These approaches are currently limited by a 
lack of availability of suitable radiotracers (1). 
An alternative is to use proton magnetic resonance 
spectroscopy (1H-MRS) to estimate the concentration of 
glutamatergic metabolites. MRI scanners with field 
strengths of 3T or above can resolve glutamate, at least for 
the most part, from its metabolite glutamine (16). At lower 
field strengths glutamate and glutamine are reported in 
combination, as Glx. A limitation of 1H-MRS is that the 
glutamate concentration estimates are not specific to 
neuronal glutamate, and that changes in glutamate levels 
cannot be specifically attributed to altered 
neurotransmission over other metabolic processes (17). 
However the majority (~80%) of glutamine synthesis 
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reflects cycling of neurotransmitter glutamate (17), and 
clinical studies at 4T in minimally treated patients with 
schizophrenia have reported higher Gln/Glu ratios (18) or 
higher glutamine levels (19) in the anterior cingulate cortex 
(ACC). This is consistent with increased glutamatergic 
neurotransmission, but could also result from a deficiency 
in the conversion of glutamine to glutamate. However the 
majority of 1H-MRS studies in psychosis have used field 
strengths <4T and thereby were unable to accurately 
quantify glutamine concentrations. Thus, the results from 
these studies at lower field strengths cannot be specifically 
attributed to changes in glutamate neurotransmission. 
Nonetheless, increases in frontal glutamatergic 
neurotransmission in schizophrenia are broadly consistent 
with the NMDA receptor hypofunction hypothesis, as 
administration of NMDAR antagonists to rats increases 
glutamate release as detected by microdialysis (20), and 
1H-MRS studies report elevated Gln/Glu ratios (21), or 
increased glutamate levels with no changes in glutamine 
(22). 1H-MRS studies with ketamine in man at 4T reveal 
increased ACC glutamine (23), and at 3T reveal increased 
ACC glutamate (24). One mechanism through which 
increases in glutamate release may occur is via NMDAR 
dysfunction on GABA-ergic interneurons, leading to the 
disinhibition of glutamatergic pyramidal cells, as described 
by the NMDAR hypofunction hypothesis (25). 
Individual 1H-MRS glutamate studies in schizophrenia 
have produced some inconsistent findings. In general, 
studies at higher field strengths suggest that frontal 
glutamine function is elevated in the early stages of 
psychosis (18, 19), whereas the findings in chronic 
schizophrenia are more variable (26–30). This could reflect 
effects of antipsychotic medication. For example, one 
crosssectional and one longitudinal study reported higher 
Glx levels in the PFC of unmedicated, but not medicated 
schizophrenia, in comparison to controls (31, 32), although 
longitudinal studies have reported no effect of medication 
on anterior cingulate glutamate or glutamine levels (18, 33, 
34). It could be that symptom severity contributes to 
variability in glutamatergic metabolites between patients 
early or late in the illness, as samples involving patients in 
the early phase of psychosis usually comprise non- or 
minimally medicated patients who are relatively 
symptomatic, whereas studies in chronic schizophrenia 
often involve patients who have been treated for long 
periods and have less severe or more stable symptoms (1). 
In relation to this, a recent meta-analysis of 1H-MRS 
glutamatergic studies in major depressive disorder found 
lower levels of Glx in the ACC which were only significant 
when remitted patients were excluded from the analysis 
(35). 
In order to better understand the possible relationships 
between 1H-MRS glutamate, glutamine, and Glx levels and 
symptom severity, we identified publications that have 
reported associations with severity along symptom 
domains. These included studies in individuals at risk of 
psychosis, and patients with first-episode psychosis or 
established schizophrenia (Table 1). 
RELATIONSHIPS BETWEEN 
GLUTAMATE FUNCTION AND 
POSITIVE SYMPTOMS 
Several studies have investigated associations between 
regional glutamatergic metabolite levels and the severity of 
positive psychotic symptoms (Table 1), and most found no 
association between regional Glx, glutamate or glutamine 
levels and positive symptom severity, in either high genetic 
or clinical risk populations (36, 37), first-episode psychosis 
(18, 19, 37–40) or chronic schizophrenia (26–28, 30, 41–46). 
However, many of these studies involved small patient 
samples, relied on post hoc correlational analyses, and 
patients in whom the severity and/or the variance in 
severity of symptoms was low, due to either being sub-
clinical threshold in the at risk studies or due to the 
presence of antipsychotic medication in established 
schizophrenia. A recent study pooling both medicated and 
unmedicated patients, where unmedicated patients 
possessed elevated Glx in medial prefrontal cortex (mPFC), 
detected an association between positive symptom severity 
and mPFC Glx, although this did not survive correction for 
multiple comparisons (31). Another study in the PFC found 
that treatment reduced the level of Glx/Cr in chronic 
patients, and associated the change in Glx with 
improvement in total BPRS score (32). Moreover a recent 
study found that 4 weeks of antipsychotic treatment in 
first-episode psychosis patients reduced Glx in the striatum, 
and this was associated with improvement in PANSS score 
(47). 
A notable exception is the study of Ota et al.(48), which 
directly compared patients experiencing exacerbated 
psychotic symptoms to healthy controls and stable patients, 
and found that increases in Glx in inferior parietal white 
matter were specific to the group currently experiencing 
exacerbated psychotic symptoms (48). In line with this, our 
own studies which have compared glutamate levels in 
patients according to symptom severity have found higher 
ACC glutamate levels in first-episode psychosis patients 
who are still symptomatic following treatment compared to 
those in remission (38) and in patients with treatment-
resistant schizophrenia compared to those who respond to 
medication (49). These differences may be independent of 
medication effects, as groups either did not differ according 
to medication (38, 49) or the symptomatic group were 
actually receiving higher medication doses (48), and as 
longitudinal studies have not reported changes in cortical 
glutamate in relation to changes in positive symptoms 
following antipsychotic treatment (18, 33, 34). This suggests 
that glutamate and Glx levels may be selectively elevated in 
patients whose positive symptoms are not well controlled 
by conventional antipsychotic medication. 
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RELATIONSHIPS BETWEEN 
GLUTAMATE FUNCTION AND 
NEGATIVE SYMPTOMS 
We recently reported that greater severity of PANSS 
negative symptoms was associated with higher levels of 
glutamate in the ACC in first-episode psychosis (38). 
Although there were several methodological differences, 
this contrasts with the study of Reid et al. (26), which 
reported that negative symptoms were associated with 
lower levels of ACC Glx in chronic schizophrenia. Other 
studies investigating correlations between ACC 
glutamatergic metabolites and negative symptoms have 
found no significant relationship (18, 19, 28, 42, 46, 50). We 
are not aware of any studies which have specifically 
compared regional levels of glutamatergic metabolites in 
patient groups selected according to differences in negative 
symptom severity. 
As listed in Table 1, in brain regions other than the ACC 
many studies have failed to detect significant relationships 
between negative symptoms and regional glutamate, 
glutamine, or Glx levels in high genetic or clinical risk groups 
(36, 37), first-episode  
Table 1 | Summary of articles reporting high levels of glutamate metabolites associated with greater or lesser severity of symptoms. 
Reference Field strength Population n Brain region Metabolite Measure Direction 
Tandon et al. (54) 1.5 Familial high risk 23 Thalamus Glx SIPS 
CSS 
+ NS 
    Caudate Glx SIPS, CSS + 
    ACC Glx SIPS, CSS NS 
Yoo et al. (36) 1.5 GHR 22 ACC, DLPFC, thal Glx PANSS, BPRS NS 
de la Fuente-Sandoval et 
al. (37) 
3 





Glu PANSS, SIPS NS 
de la Fuente-Sandoval et 
al. (47) 






PANSS + NS 
Egerton et al. (38) 3 FE 32 ACC Glu/Cr PANSS negative + 
      PANSS positive NS 
    Thalamus Glu/Cr PANSS NS 








PANSS + NS 
Ohrmann et al. (42) 1.5 Chronic 43 ACC, DLPFC Glx PANSS, CDSS, CGI NS 
Tayoshi et al. (28) 3 Chronic 30 ACC, basal ganglia Glu, Gln PANSS NS 
Wood et al. (30) 3 Chronic 15 
Dorsal, rostral cingulate 
Glx PANSS NS 
Kegeles et al. (31) 3 Chronic 32 mPFC (inclu ACC) Glx PANSS negative NS 
      PANSS positive + # 
Szulc et al. (62) 1.5 Chronic 42 Frontal lobe Glx/Cr PANSS + 
Ohrmann et al. (41) 1.5 Chronic 39 DLPFC Glx PANSS NS 
Ongur et al. (50) 4 Chronic 17 ACC, POC Gln/Glu PANSS, MADRS, YMRS NS 
Stanley et al. (39) 1.5 
FE 14wk 
treatment 
37 DLPFC Gln SANS, SAPS NS 
Bartha et al. (40) 1.5 FE 10 mPFC (inclu ACC) Glu, Gln SANS, SAPS NS 
Theberge et al. (19) 4 FE 21 ACC, thal Glu, Gln SANS, SAPS NS 
Bustillo et al. (18) 4 FE Min treated 14 ACC, thal Gln/Glu SANS, SAPS NS 
Bustillo et al. (43) 4 Chronic 30 Whole brain slice Glx SANS − 
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      SAPS NS 
Olbrich et al. (67) 2 FE 9 DLPFC Glu SANS, BPRS − 
    Hippocampus Glu SANS, BPRS NS 
Shirayama et al. (27) 3 Chronic 19 mPFC (inclu ACC) Gln/Glu SANS, BPRS NS 
Rowland et al. (44) 3 Chronic 20 
mPFC, inferior parietal 
Glx SANS, BPRS NS 
Rowland et al. (46) 3 Chronic 21 ACC, CSO Glx SANS, BPRS NS 
Choe et al. (32) 1.5 Chronic 34 PFC Glx/Cr BPRS + 
Reid et al. (26) 3 Chronic 26 ACC Glx BPRS negative − 
      BPRS positive NS 
(Continued) 
Table 1 | Continued 
Reference Field strength Population n Brain region Metabolite Measure Direction 
Reid et al. (45) 3 Chronic 35 Substantia nigra Glx/Cr BPRS NS 
Tandon et al. (54) 1.5 
Familial high risk 
23 ACC, thal, caudate Glx WCST NS 
Rusch et al. (53) 2 FE + Chronic 29 Hippocampus Glu WCST + 
Shirayama et al. (27) 3 Chronic 19 mPFC (inclu ACC) Gln/Glu WCST, DSDT + 
      Stroop, VF, IGT NS 
Ohrmann et al. (42) 1.5 Chronic 43 ACC Glx WCST − 
    ACC, DLPFC Glx AVLT NS 
Ohrmann et al. (55) 4 FE + Chronic 35 DLPFC Glx AVLT − 
Kegeles et al. (31) 3 Chronic 32 mPFC (inclu ACC) Glx N-back NS 
Reid et al. (26) 3 Chronic 26 ACC Glx RBANS NS 
Reid et al. (45) 3 Chronic 35 Substantia nigra Glx/Cr RBANS NS 
Rowland et al. (44) 3 Chronic 20 
mPFC, inferior parietal 
Glx RBANS NS 
Rowland et al. (46) 3 Chronic 21 ACC, CSO Glx RBANS NS 
Bustillo et al. (43) 4 Chronic 30 Whole brain slice Glx Combined neuropsych − 
Yoo et al. (36) 1.5 GHR 22 ACC, DLPFC, thal Glx GAF NS 
Tibbo et al. (59) 3 GHR 20 mPFC Glx/Cr GAF − 
Egerton et al. (38) 3 FE 32 ACC Glu/Cr GAF + 
Egerton et al. (38) 3 FE 32 Thalamus Glu/Cr GAF NS 
Shirayama et al. (27) 3 Chronic 19 mPFC (inclu ACC) Gln/Glu GAF NS 
Tebartz van Elst et al. 
(60) 
2 Chronic 21 DLPFC Glu GAS + 
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Aoyama et al. (34) 4 Chronic 17 Thalamus Total Gln + Glu LSPR − 
# Did not survive correction for the six comparisons (PANSS total, positive, and negative symptom subscales in two regions for each neurochemical). 
Index: + denotes a positive relationship where higher levels of glutamate were associated with greater symptom severity or worse overall functioning; − denotes a 
negative relationship where higher levels of glutamate were associated with lesser symptom severity or better overall functioning. NS, not significant; ACC, anterior 
cingulate cortex; POC, parieto-occipital cortex; DLPFC, dorsolateral prefrontal cortex; MPFC, medial prefrontal cortex;Thal, thalamus; CSO, centrum semiovale; GHR, 
genetic high risk; RBANS, repeatable battery for the assessment of neuropsychological status; WCST, Wisconsin card sorting test; DSDT, the digit span distraction 
test;TMT, trail making test; IGT, Iowa gambling task; VF, verbal fluency; AVLT, auditory verbal learning test; BPRS, brief psychiatric rating scale; GAF, global 
assessment of functioning; CGI, clinical global impression scale; GAS, global assessment scale; SIPS, structured interview for prodromal symptoms; CSS, Chapman 
schizotypy scales; CDSS, Calgary Depression Scale for Schizophrenia; LSPR, life skills profile rating. 
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psychosis (18, 37, 39, 40), or chronic schizophrenia (27, 30, 
31, 41, 44, 45, 48). A general consideration of studies 
investigating relationships between glutamate markers and 
positive and negative symptoms is the scale used to score 
symptom severity. As detailed in Table 1, scores on a 
number of scales have been used and while these scales are 
highly correlated there are also some important differences 
in the clinical items included (51). As most studies 
examining relationships between brain glutamate measures 
and symptoms have relied on post hoc correlational 
analysis, it is of note that additional items are included on 
the SAPS/SANS compared to the PANSS, which in turn has 
additional items compared to the BPRS. Therefore use of 
the SAPS/SANS may be preferable as they provide a more 
detailed assessment of symptoms. 
RELATIONSHIPS BETWEEN 
GLUTAMATE MEASURES AND 
COGNITIVE DYSFUNCTION 
Relatively few studies have investigated relationships 
between glutamate measures and cognitive dysfunction in 
schizophrenia. The most commonly investigated task has 
been the Wisconsin card sort test (WCST): in schizophrenia, 
deficits on this task are associated with abnormal activation 
in the ACC and DLPFC (52). In a study of 19 patients with 
chronic schizophrenia at 3T, poor performance on the 
WCST was associated with higher Gln/Glu ratios in the 
mPFC (including the ACC) (27). In contrast, a larger study of 
43 patients with chronic schizophrenia at 1.5T found that 
ACC, but not DLPFC, Glx levels were positively associated 
with WCST learning potential (42). In first-episode 
psychosis, an association between hippocampal, but not 
DLPFC, glutamate, and WCST errors was reported (53), and 
in a small sample of 16 genetic high risk individuals, no 
correlations between WCST performance and Glx levels in 
the caudate, ACC, or thalamus were detected (54). 
Other tasks investigated include the Stroop, digit span 
distractibility test, auditory verbal learning test (AVLT), N-
back task, Iowa gambling task and verbal fluency test (Table 
1). Of these, there are reports of a positive association 
between mPFC Gln/Glu ratio and impairments on the digit 
span distraction test, which probes short-term memory and 
selective attention (27), and of DLPFC Glx and verbal 
learning and memory on the AVLT (55). Overall, the findings 
have been inconsistent and further studies with larger 
sample sizes are required. While the above studies used a 
voxel of interest method, using whole brain slice proton 
echo planar spectroscopy at 4T in 30 patients Bustillo et al. 
(43) detected a positive correlation between general 
cognitive performance in schizophrenia and Glx. 
Furthermore, subsequent path analyses suggested that the 
relationship between glutamate and cognitive performance 
may be associated with negative symptoms and 
unemployment (43). 
The relationship between glutamate and cognition in 
schizophrenia has been further investigated by combining 
1H-MRS with functional magnetic resonance imaging (fMRI) 
of the blood oxygen level dependent (BOLD) response to 
measure changes in regional brain activation as participants 
perform cognitive tasks. In subjects at clinical high risk of 
developing psychosis, reductions in thalamic glutamate 
were correlated with an elevated BOLD response in the 
prefrontal cortex during a verbal fluency task, whereas the 
converse association was observed in controls (56). In a 
study by Valli et al. (57), medial temporal lobe glutamate 
levels were correlated with hippocampal BOLD response 
during an episodic memory task in controls, whereas this 
coupling was absent in clinical high risk subjects (57). Finally 
one study showed that hippocampal Glx was related to 
inferior frontal gyrus activation during episodic memory in 
controls, and suggested that the absence of this positive 
coupling in medicated schizophrenia patients may underlie 
episodic memory deficits, reflecting the results seen in Valli 
et al. (57, 58). Further investigation of the relationships 
between regional levels of glutamatergic metabolites and 
abnormalities in regional brain activation during cognitive 
tasks may provide a more sensitive means to characterize 
the relationship between glutamate and cognition in 
schizophrenia. 
RELATIONSHIPS BETWEEN 
GLUTAMATE MEASURES AND 
SOCIAL AND OCCUPATIONAL 
FUNCTIONING 
Several studies have also reported correlations between 
brain glutamate levels and overall level of social and 
occupational functioning (Table 1). In genetically high risk 
subjects, lower levels of Glx/Cr in the mPFC were associated 
with lower levels of overall functioning (59). A longitudinal 
study at 4T showed that loss of glutamate and glutamine in 
the thalamus, but not the ACC, over 7 years since first 
presentation correlated with impaired social functioning 
(34). In contrast, in first-episode psychosis higher levels of 
glutamate in the ACC, but not the thalamus, were 
associated with worse overall functioning (38), and in 
chronic schizophrenia higher DLPFC glutamate levels were 
also associated with worse overall functioning (60). Other 
studies have found no association between glutamate 
measures and overall functioning in chronic schizophrenia 
(27) or genetic high risk subjects (36). 
SUMMARY AND FUTURE 
DIRECTIONS 
1H-MRS studies relating regional glutamate measures to 
symptoms in schizophrenia have produced inconsistent 
findings. There may be several methodological reasons for 
this, including differences in the brain region investigated, 
and between samples such as medication, illness stage, and 
symptom severity. The use of sub-optimal technical 
approaches such as low field strengths together with small 
sample sizes may also underlie the conflicting findings. A 
recent study at 4T indicates that elevations in the ratio of 
Gln/Glu are present in schizophrenia patients, consistent 
with elevated glutamatergic neurotransmission (18). 
However the majority of 1H-MRS studies in schizophrenia 
use field strengths <4T which cannot reliably measure 
glutamine, and glutamate and Glx measures cannot be 
specifically attributed to glutamate neurotransmission (17). 
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The increasing availability of higher field strength scanners 
may resolve some of the apparent in consistencies in the 
literature. 
The majority of studies that have investigated 
relationships between glutamate levels and symptom 
severity have applied correlational analysis, usually post hoc 
to the main study findings. A few studies have directly 
compared glutamatergic metabolite levels in patient groups 
on the basis of symptom severity, specifically those who 
were or were not currently experiencing symptom 
exacerbation (48), were or were not in symptomatic 
remission following initial treatment (38) or did or did not 
have treatment resistant illness (49). All found higher levels 
of glutamate or Glx in the more symptomatic patient group. 
The field would benefit from further studies pre-
selecting groups of patients who differ in severity of 
negative symptoms or cognitive impairment, or longitudinal 
studies comparing within-subjects glutamate levels during 
periods of illness stability compared to relapse. Studies of 
the relationships between cognitive dysfunction and 
glutamate in schizophrenia may benefit from combination 
with fMRI to determine the efficiency of glutamate in 
supporting networks that subserve cognitive function. To 
date there are only a handful of published studies of this 
type. Finally, relationships between glutamate levels and 
symptom severity may be indirect; for example Stone et al. 
showed that hippocampal glutamate may interact with 
striatal dopamine to determine risk of psychosis (61), and a 
path analysis has suggested that negative symptoms may 
be secondary to poor cognition associated with low brain 
Glx (43). 
One question is whether baseline levels of glutamate, 
glutamine, or Glx are predictive of subsequent outcome or 
response to treatment in schizophrenia. A recent study 
showed that elevated frontal Glx at baseline was associated 
with poor response after 4 weeks of antipsychotic 
treatment (62). This is consistent with the above findings of 
glutamatergic elevations in patients with schizophrenia 
whose symptoms have not responded well to treatment 
(38, 49). 
The suggestion that symptoms that do not respond well 
to conventional antipsychotic treatment may have a 
glutamatergic basis (38, 49) warrants further investigation, 
as compounds that target the glutamatergic system may 
have particular efficacy in these patients. Meta-analyses 
conclude that of the agents which may improve NMDA 
receptor-mediated neurotransmission, the NMDAR co-
agonist d-serine and the glycine transporter type 1 inhibitor 
sarcosine reduce total and negative symptoms as an 
adjuvant to antipsychotic medication (63, 64). Lamotrigine, 
which may inhibit glutamate release, blocks the 
psychomimetic effects of ketamine in healthy volunteers 
(65) and small trials of lamotrigine in chronic, often 
treatment-resistant or clozapine-treated patients found 
that it is beneficial in reducing symptoms (63, 66). Further 
work is required to determine the relationship between 
regional glutamate concentrations and the expression of 
symptoms at different stages of psychotic illness. This area 
may benefit from meta-analyses of the previously published 
findings and from new studies selecting patient samples a 
priori on the basis of symptom severity. 
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eFigure2: Study effect sizes of glutamatergic differences between cases and 
controls.  
Shown are Hedges g effect size and 95% confidence intervals (95%CI) for each study. Each circle represents a study, and circle 
size is proportional to the number of patients and controls. White circles represent studies of high risk subjects, pink circles 
represent studies of first episode psychosis, blue circles represent studies of patients with chronic schizophrenia. The summary 












































Funnel plots are presented for regions in which significant glutamatergic differences were 
found between cases and controls in the meta-analysis. The effect size estimates from 
individual studies are plotted against their standard error. Standard error is plotted on an 
inverse scale, so more powerful studies appear at the top of graph. As the variance of the 
effect estimate is not the same for all studies, each estimate has been divided by its 
standard error.  
 
Funnel plots can be useful in assessing publication bias, as studies with larger variance will 
scatter along the bottom of the graph, whereas more precise studies will aggregate 
towards the true effect size. Asymmetric funnel plots may indicate publication bias, as 
smaller studies that did not find significant differences are not published.  
 
A funnel plot asymmetry test is recommended when there are at least 10 studies included 
in the meta-analysis, and so funnel plots are not presented for glutamate in the basal 
ganglia (4 studies) and glutamine in the thalamus (3 studies). As publication bias does not 
necessarily cause asymmetry in funnel plots, Egger’s regression test has also been 
performed (see Chapter 2.2) which is a more quantitative method of assessing publication 
bias. Small study bias, which may be evident of publication bias, was evident for reports of 




Figure 7 Funnel plot of studies standardised effect sizes for Glx differences between cases and controls in the 


























Figure 8 Funnel plot of studies standardised effect sizes for Glx differences between cases and controls in the 






Figure 9 Funnel plot of studies standardised effect sizes for Glx differences between high risk subjects and 
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2.3. A Multicentre analysis of proton magnetic resonance spectroscopy studies 
and their relation to symptoms 
The aim of this study was to investigate the relation of 1H-MRS glutamate measures to 
symptom severity and medication status in a large dataset of individual patient data 
collected at multiple centres. While the meta-regression (section 2.2) did not find evidence 
of relationships with symptom severity or medication, analysis of individual patient data 
will have greater power to detect these effects as meta-regression relies on group mean 
values. I hypothesised that more symptomatic patients would possess higher glutamatergic 
metabolite levels, based on findings from previous studies comparing patients on the basis 
of symptom severity (Egerton et al., 2012; Ota et al., 2012). I also predicted that the dose of 
antipsychotic medication would directly correlate with frontal and striatal glutamate 
metabolite concentrations, on the basis of recent findings of lower medial prefrontal Glx in 
unmedicated patients relative to both medicated patients and healthy controls (Kegeles et 
al., 2012) and reduced striatal glutamate levels in FEP patients following treatment (de la 
Fuente-Sandoval et al., 2013). Consistent with the aims of the meta-analysis (section 2.2), 
this study aimed to investigate differences in glutamate levels between patients and 
controls, and whether these differences vary according to illness stage. Based on the meta-
analysis findings we expect that patients with schizophrenia are associated with elevations 
in glutamatergic metabolites, and that these vary with the stage of disorder. 
2.3.1.  Methods  
The authors of the published studies included in the meta-analysis (see section 2.2) were 
contacted and asked to provide individual glutamate and Glx values for schizophrenia 
patients and controls, as well as individual creatine (Cr) values to allow Cr-scaling of 
glutamatergic metabolites. PANSS positive, negative and general subscores, CPZ equivalent 
doses and medication status for each subject were also requested.  
Studies which did not report healthy control comparisons, and had therefore not been 
included in the main meta-analysis (section 2.2), were also contacted (Egerton et al., 2012; 
Goff et al., 2002; Szulc et al., 2005), as healthy volunteer data were not necessary for 
analyses of symptom severity and medication exposure within a patient group. The 
radiofrequency-pulse edited metabolite values reported in (Kegeles et al., 2012) could not 
be included as these are not comparable to non-edited spectra values obtained in the 
majority of studies. The primary outcome measures were CSF-corrected glutamate, 
glutamine and Glx values. However Cr-scaled glutamatergic metabolites were assessed 
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instead if a greater number of studies provided Cr-scaled than CSF-corrected values for a 
brain region.  
Statistical analysis was performed in SPSS version 22.0 (SPSS, Chicago, IL, USA). Univariate 
ANOVA determined whether glutamatergic metabolite values significantly differed 
between sites. As some sites used more than one scanner, site was defined according to 
the specific MRI scanner used at a geographical site. Differences in glutamatergic 
metabolite levels between cases and healthy controls were assessed using linear mixed-
effects models controlling for site as a random factor. To determine whether glutamatergic 
abnormalities were specific to a clinical stage of disease, secondary analyses assessed high 
risk subjects, FEP and chronic schizophrenia patients separately in comparison to their 
corresponding controls. 
Linear mixed-effects models were used to assess the relationships between glutamatergic 
measures in schizophrenia patients and continuous outcomes (symptom scores and CPZ 
equivalent doses) or categorical outcomes (presence or absence of medication), with site 
entered as a random factor. Correlations between glutamatergic metabolites and symptom 
scores (PANSS positive, negative and general subscales) were corrected for multiple 
comparisons, giving an adjusted threshold of P=0.017. High risk subjects were excluded 
from symptom score, CPZ equivalent dose and medication analyses, as this group generally 
have lower psychotic symptom severities than patients with schizophrenia, and are not 
usually treated with antipsychotic medication.  
2.3.2.  Results 
Table 1 lists the studies and measures acquired from multiple sites. Individual data were 
contributed by 17 studies (de la Fuente-Sandoval et al., 2013, 2011; Demjaha et al., 2014; 
Egerton et al., 2014, 2012; Galińska et al., 2009; Goto et al., 2012; Lawrence S Kegeles et 
al., 2000; Natsubori et al., 2014; Stone et al., 2010; Szulc et al., 2011; Theberge et al., 2002; 
Théberge et al., 2003; Tibbo et al., 2013; Wood et al., 2008, 2007; Yamasue et al., 2003), 
which reflected 10 sites, and values in 531 cases and 404 controls.  
Studies identified as using the same scanner at a particular site were: Galinska (2009) and 
Szulc (2011); Wood (2007) and Wood (2008); Theberge (2002) and Theberge (2003); 
Fuente-Sandoval (2011) and Fuente-Sandoval (2013); and finally Stone (2009), Egerton 
(2012), Egerton (2014), and Demjaha (2013). Yamasue (2003) and Natsubori (2013) used 
different scanners at the same site and so were coded separately. Glutamatergic values 
were available for more than 3 studies for the following brain regions:  medial frontal 
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cortex, thalamus, striatum and medial temporal lobe. Univariate ANOVA analyses revealed 
significant site differences in glutamate and Glx values for all brain regions. Therefore, site 
was included as a random factor in the linear mixed-effects models. 
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Table 1 Multicentre data for 1H-MRS glutamate measures in a number of brain regions.  
Linear mixed-effects model analysis assessed the difference in glutamate measures in cases, high risk subjects, FEP and schizophrenia patients relative to controls. Glutamate metabolite 
differences between medicated and unmedicated patients were also assessed. Mean and standard errors (SE) adjusted for site are shown. “-“ indicates values were only available for one 
study. 
Medial Frontal Cortex                   
    # Studies # Sites Cases 
 
  Controls Sig 
        n Mean SE n Mean SE F P 
Glutamate (CSF-corrected)                   
All cases   5 3 206 12.01 2.16 179 12.22 2.16 0.54 0.46 
High risk    2 2 101 10.76 2.59 82 10.69 2.60 0.03 0.87 
FEP   3 3 48 12.70 2.35 96 12.58 2.34 0.08 0.78 
Chronic   3 3 57 10.20 2.11 59 11.12 2.11 4.15 0.04 
Medicated  3 2 40 12.29 1.41       8.01 0.01 
Medication-free 2 2 24 14.73 1.50         
Glx (CSF-corrected)                     
All cases   3 2 170 15.05 2.67 140 14.84 2.67 0.17 0.68 
High risk    2 2 103 15.72 2.80 83 15.27 2.81 0.40 0.53 
FEP   2 2 28 15.95 3.16 77 15.17 3.11 0.73 0.39 
Chronic   2 2 39 12.00 0.67 39 12.69 0.68 1.31 0.26 
Medicated  3 2 62 13.49 2.03         - 
Medication-free 1 1 5 16.60 2.64         
Glutamine (CSF-corrected)                     
All cases   5 2 79 7.94 0.30 63 7.74 0.34 0.20 0.66 
High risk    1 1 25 8.78 0.64 19 7.37 0.74   - 
FEP   2 2 27 8.34 0.40 39 7.40 0.33 3.32 0.07 
Chronic   2 2 27 6.27 1.07 24 7.65 1.10 4.34 0.04 
Medicated  4 2 32 7.00 0.39       4.72 0.03 
Medication-free 3 2 22 8.34 0.48           
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Thalamus                       
    # Studies # Sites Cases 
 
  Controls Sig 
        n Mean SE n Mean SE F P 
Glutamate (CSF corrected)                   
All cases   4 2 136 10.25 3.19 105 10.48 3.19 0.93 0.34 
High risk    1 1 80 7.01 0.97 57 7.65 0.97   - 
FEP   2 2 26 10.80 3.22 76 10.82 3.20 0.00 0.97 
Chronic   2 2 30 9.85 3.43 29 9.52 3.43 0.60 0.44 
Medicated  3 2 35 9.99 3.11      1.99 0.17 
Medication-free 2 2 21 10.98 3.14         
Glx (CSF corrected)                     
All cases   2 1 97 8.64 0.23 65 9.03 0.28 1.17 0.28 
High risk    1 1 76 8.74 0.26 57 9.35 0.30   - 
FEP   1 1 9 8.47 0.84 57 9.35 0.33   - 
Chronic   1 1 12 8.09 0.58 8 6.73 0.71   - 
Medicated  2 1 17 8.18 1.32        - 









Striatum                       






  Controls   Sig   
        n Mean SE n Mean SE F P 
Glutamate (CSF corrected)                   
All cases   2 1 60 29.21 0.59 58 25.38 0.60 20.53 <0.001 
High risk    1 1 18 27.54 2.71 40 24.09 2.63   - 
FEP   2 1 42 29.93 0.70 58 25.38 0.60 24.62 <0.001 
Chronic   0 0 0 - -          
Medicated  0 0 0 - -         - 
Medication-free 2 1 42 29.93 4.00           
Glx (Cr scaled)                     
All cases   4 3 94 1.33 0.35 91 1.27 0.35 4.52 0.04 
High risk    1 1 18 1.88 0.04 40 1.88 0.03   - 
FEP   3 2 60 1.30 0.61 76 1.24 0.61 2.82 0.10 
Chronic   1 1 16 1.42 0.14 15 1.30 0.14   - 
Medicated  2 2 34 1.07 0.34       1.90 0.40* 
Medication-free 2 1 42 1.89 0.49           
*medication status is not independent from site.  
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Medial temporal Lobe                   
    # Studies # Sites Cases 
 
  Controls Sig 
        n Mean SE n Mean SE F P 
Glx (Cr scaled)                     
All cases   5 4 129 1.60 0.29 74 1.64 0.30 0.32 0.57 
High risk    1 1 24 1.65 0.07 27 1.59 0.07   - 
FEP   2 2 59 2.10 0.43 37 2.06 0.43 0.18 0.67 
Chronic   2 2 46 1.48 0.57 10 1.40 0.58   - 
Medicated  2 2 22 1.35 0.37       1.04 0.31 
Medication-free 2 2 22 1.25 0.36         
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Table 2 Multicentre data for PANSS and CPZ dose equivalents in schizophrenia patients (excluding high risk subjects).  
Linear mixed-effects model analyses assessed the relation between glutamate measures and PANSS and CPZ dose equivalents. “NS” denotes no significant correlation between 
glutamatergic metabolites and PANSS positive, negative and general scores. “-“ indicates values were only available for one study. 
 
Metabolite PANSS sub scales # Studies # Sites PANSS   Sig # Studies # Sites CPZ Sig 
  
n P   
 
n F P 
Medial Frontal Cortex                   
Glutamate All PANSS sub-scales 3 2 64 NS 2 2 35 3.704 0.06  
Glx 3 2 64 NS 1 1 14 - - 
Glutamine 3 1 13 NS 2 2 27 1.245 0.28 
Thalamus                     
Glutamate All PANSS sub-scales 2 1 18 NS 2 2 30 0.576 0.45 
Glx 2 1 21 NS 1 1 12 - - 
Striatum                     
Glutamate All PANSS sub-scales 2 1 42 NS 0 0 0 - - 
Glx/Cr 4 3 76 NS 1 1 15 - - 
Medial temporal Lobe                   
Glx/Cr PANSS Positive 3 2 93 0.09 2 2 43 0.664 0.42 
  PANSS Negative 3 2 85 0.003        




2.3.2.1.  Medial Frontal Cortex  
Glutamate 
In the medial frontal cortex, CSF-corrected glutamate measures were available from 5 
studies (3 sites) of 206 cases (101 high risk, 48 FEP and 57 chronic schizophrenia patients) 
and 179 controls (Demjaha et al., 2014; Egerton et al., 2014; Natsubori et al., 2014; 
Theberge et al., 2002; Théberge et al., 2003). Glutamate concentrations did not 
significantly differ between cases and controls (see Table 1). When clinical groups were 
analysed separately, the high risk group (Egerton et al., 2014; Natsubori et al., 2014) and 
the FEP patient group (Egerton et al., 2014; Natsubori et al., 2014; Theberge et al., 2002) 
did not significantly differ from controls, but significantly lower glutamate levels were 
found in chronic patients relative to controls (F(112)=4.154, P=0.044; Figure 10) (Demjaha 






Figure 10 CSF-corrected glutamate (institutional units) in the medial frontal cortex in controls and chronic 
schizophrenia patient groups.  
Glutamate levels were significantly lower in chronic schizophrenia patients than controls (P=0.044). Site is 




When patients were categorised according to antipsychotic medication status, medication-
free patients had significantly higher glutamate levels than medicated patients 
(F(62)=8.012, P = 0.006; Figure 11) (Demjaha et al., 2014; Egerton et al., 2014; Theberge et 
al., 2002; Théberge et al., 2003). (The Natsubori et al., 2014 study only examined 
medicated patients, and so was not included to avoid site bias). Furthermore, there was a 
trend for a negative relationship between glutamate levels and CPZ equivalent dose 
(F(32)=3.704, P=0.063; Figure 12) (Demjaha et al., 2014; Théberge et al., 2003). No 
significant association was found between CSF-corrected glutamate values and PANSS 
subscale scores (64 patients) (Demjaha et al., 2014; Egerton et al., 2014; Natsubori et al., 
2014) (see Table 2).  
 
 
Figure 11 CSF-corrected glutamate (institutional units) in the medial frontal cortex in medication-free and 
medicated patient groups.  
Glutamate levels were significantly higher in medication-free patients than controls (P=0.006). Site is colour-





Figure 12 Trend for a negative correlation between CPZ equivalent dose and CSF-corrected glutamate 
(institutional units) in the medial frontal cortex of FEP and chronic schizophrenia subjects (P=0.063).  
Site is colour-coded. The index lists the authors of studies contributing data from each site. 
 
 




In the medial frontal cortex, CSF-corrected Glx measures were available from 3 studies (2 
sites) of 170 cases (103 high risk, 28 FEP and 39 chronic schizophrenia patients) and 140 
controls (Demjaha et al., 2014; Egerton et al., 2014; Natsubori et al., 2014). Glx 
concentrations did not significantly differ between cases and controls (see Table 1). When 
clinical groups were analysed separately, no significant difference relative to controls were 
found for high risk subjects (Egerton et al., 2014; Natsubori et al., 2014), FEP (Egerton et al., 
2012; Natsubori et al., 2014) or chronic schizophrenia patients (Demjaha et al., 2014; 
Natsubori et al., 2014).  
The effect of medication status and CPZ dose equivalents could not be assessed due to 
insufficient sample sizes. No significant association was found between CSF-corrected Glx 
values and PANSS positive, negative and general subscale scores (63 patients) (Demjaha et 
al., 2014; Egerton et al., 2012; Natsubori et al., 2014), see Table 2.  
 
Glutamine 
In the medial frontal cortex, CSF-corrected glutamine measures were available from 5 
studies (2 sites) of 79 cases (25 high risk, 27 FEP and 27 chronic schizophrenia patients) and 
63 controls (Demjaha et al., 2014; Egerton et al., 2014, 2012; Theberge et al., 2002; 
Théberge et al., 2003). Glutamine concentrations did not significantly differ between cases 
and controls (see Table 1). When clinical groups were analysed separately, a trend for 
higher glutamine levels were found in FEP patients than controls (F(64)=3.323, P=0.073; 
Figure 13) (Egerton et al., 2012; Theberge et al., 2002), whereas glutamine levels in chronic 
patients were lower than in controls (F(48)=4.355, P=0.042; Figure 14) (Demjaha et al., 
2014; Théberge et al., 2003). Only one study in high risk subjects was available (Egerton et 
al., 2014).  
When patients were categorised according to medication status, medication-free patients 
had significantly higher glutamine than medicated patients (F(52)=4.724, P=0.034; Figure 
15) (Demjaha et al., 2014; Egerton et al., 2014, 2012; Theberge et al., 2002; Théberge et al., 
2003). CPZ equivalent doses were not associated with glutamine (27 patients) (Demjaha et 
al., 2014; Théberge et al., 2003). No significant association was found between CSF-
corrected glutamine values and PANSS positive, negative and general subscale scores (13 






Figure 13 CSF-corrected glutamine (institutional units) in the medial frontal cortex in controls and first 
episode psychosis (FEP) patient groups.  
Glutamine levels were significantly higher in FEP patients than controls (P=0.048). Site is colour-coded. The 





Figure 14 CSF-corrected glutamine (institutional units) in the medial frontal cortex in controls and chronic 
schizophrenia patient groups.  
Glutamine levels were significantly lower in chronic schizophrenia patients than controls (P=0.042). Site is 





Figure 15 CSF-corrected glutamine (institutional units) in the medial frontal cortex in medication-free and 
medicated patient groups.  
Glutamine levels were significantly higher in medication-free patients than controls (P=0.034). Site is colour-




2.3.2.2. Thalamus  
Glutamate 
In the thalamus, CSF-corrected glutamate measures were available from 4 studies (2 sites) 
of 136 cases (80 high risk, 26 FEP and 30 chronic schizophrenia patients) and 105 controls 
(Demjaha et al., 2014; Egerton et al., 2014; Theberge et al., 2002; Théberge et al., 2003). 
Glutamate concentrations did not significantly differ between cases and controls (see Table 
1). When clinical groups were analysed separately, no significant difference relative to 
controls were found for FEP (Egerton et al., 2014; Theberge et al., 2002) and chronic 
schizophrenia patients (Demjaha et al., 2014; Théberge et al., 2003). Only one study 
reported thalamic glutamate values in high risk subjects (Egerton et al., 2014).  
Medication-free patients did not significantly differ from medicated patients (Demjaha et 
al., 2014; Egerton et al., 2014; Theberge et al., 2002; Théberge et al., 2003). No significant 
relationship was found between glutamate and PANSS positive, negative or general 
subscale scores (18 patients) and CPZ equivalent dose (30 patients) (Demjaha et al., 2014; 
Théberge et al., 2003), see Table 2. 
Glx 
CSF-corrected Glx measures were available from 2 studies (1 site) of 97 cases (76 high risk, 
9 FEP and 12 chronic schizophrenia patients) and 65 controls (Demjaha et al., 2014; Egerton 
et al., 2014). Glx concentrations did not significantly differ between cases and controls (see 
Table 1). Clinical groups and medication status groups could not be analysed separately, as 
data was not available for more than one study. 
No significant relationship was found between Glx and PANSS positive, negative or general 
subscale scores (21 cases) (Demjaha et al., 2014; Egerton et al., 2014). Only one study 
reported CPZ equivalent doses (Demjaha et al., 2014), see Table 2. 
2.3.2.3. Striatum  
Glutamate 
In the striatum, CSF-corrected glutamate measures were available from 2 studies (1 site) of 
60 cases (18 high risk, 42 FEP and 0 chronic schizophrenia patients) and 58 controls (de la 
Fuente-Sandoval et al., 2013, 2011). Glutamate concentrations were significantly higher in 
cases relative to controls (F(116)=20.527, P=<0.001; Figure 16). When clinical groups were 
analysed separately, significantly higher glutamate levels were found in FEP patients 
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(F(98)= 24.620, P=<0.001; Figure 17) (de la Fuente-Sandoval et al., 2013, 2011). Only one 
study reported striatal glutamate values in high risk subjects (de la Fuente-Sandoval et al., 
2011). Medication-status could not be investigated as all patients were medication-free. No 
significant relationship was found between glutamate and PANSS positive, negative or 




Figure 16 CSF-corrected glutamate (institutional units) in the striatum in controls and cases (high risk, FEP and 
chronic schizophrenia subjects).  
Glutamate levels were significantly higher in cases than controls (P=<0.001). Site is colour-coded. The index 





Figure 17 CSF-corrected glutamate (institutional units) in the striatum in controls and First Episode Psychosis 
patients.  
Glutamate levels were significantly higher in FEP patients than controls (P=<0.001). Site is colour-coded. The 




Glx/Cr measures were available from 4 studies (3 sites) of 94 cases (18 high risk, 60 FEP and 
16 chronic schizophrenia patients) and 91 controls (de la Fuente-Sandoval et al., 2013, 
2011; Goto et al., 2012; Yamasue et al., 2003). Glx/Cr concentrations were significantly 
higher in cases relative to controls (F(181)=4.516, P=0.035; Figure 18). When clinical groups 
were analysed separately, no significant difference relative to controls were found for FEP 
patients (de la Fuente-Sandoval et al., 2013, 2011; Goto et al., 2012). Only one study 
reported striatal Glx/Cr values in high risk subjects (de la Fuente-Sandoval et al., 2011) and 
chronic schizophrenia patients (Yamasue et al., 2003). Medication-free patients did not 
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significantly differ from medicated patients, although it should be noted that medication 
status is not independent from site (de la Fuente-Sandoval et al., 2013, 2011; Goto et al., 
2012; Yamasue et al., 2003). No significant relationship was found between glutamate and 
PANSS positive, negative or general subscale scores (76 cases) (de la Fuente-Sandoval et al., 




Figure 18 Glx/Cr (institutional units) in the striatum in controls and cases (high risk, FEP and chronic 
schizophrenia subjects).  
Glx/Cr ratio was significantly higher in cases than controls (P=0.035). Site is colour-coded. The index lists the 






2.3.2.4. Medial temporal lobe  
Glx 
Glx/Cr measures were available from 5 studies (4 sites) of 129 cases (24 high risk, 59 FEP 
and 46 chronic schizophrenia patients) and 74 controls (Galińska et al., 2009; Lawrence S 
Kegeles et al., 2000; Stone et al., 2009; Szulc et al., 2011; Wood et al., 2008). Glx/Cr did not 
significantly differ between cases and controls (see Table 1). When clinical groups were 
analysed separately, no significant difference relative to controls were found for FEP 
patients (Galińska et al., 2009; Wood et al., 2008). Only one study reported Glx/Cr values in 
high risk subjects (Stone et al., 2009) and control subjects were not available at all sites for 
studies examining patients with chronic schizophrenia (Lawrence S Kegeles et al., 2000; 
Szulc et al., 2011). Medication-free patients did not significantly differ from medicated 
patients (Lawrence S Kegeles et al., 2000; Wood et al., 2008). Glx/Cr and PANSS negative 
scores were positively correlated, and survived correction for multiple comparisons 
(F(82)=9.292, P=0.003, 85 cases; Figure 19) (Galińska et al., 2009; Szulc et al., 2011; Wood 
et al., 2008). No significant relationship was found for PANSS positive (93 cases) or general 
(85 cases) subscale scores, or CPZ equivalent dose (59 cases) (Galińska et al., 2009; Wood 





Figure 19 Positive correlation between PANSS negative score and Glx/Cr (institutional units) in the medial 
temporal lobe of FEP and chronic schizophrenia subjects (P=0.003).  
Increasing PANSS score denotes more severe symptoms. Site is colour-coded. The index lists the authors of 
studies contributing data from each site.
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2.3.3.  Discussion 
In the medial frontal cortex, glutamate and glutamine levels were lower in chronic patients 
than controls, and were lower in medicated patients than in patients who were 
medication-free. In addition there was a trend for a negative correlation between CPZ 
equivalent dose and glutamate, but not glutamine levels. However, all chronic patients 
were medicated and so these analyses cannot determine whether clinical stage or 
medication status play a role in lowered glutamate function.  
For glutamine in the medial frontal cortex, a trend for elevated levels in FEP patients and a 
significant reduction in glutamine in chronic patients were strongly influenced by a single 
study which contributed the majority of data (Theberge et al., 2002; Théberge et al., 2003 
respectively). Thus additional data is required for a true multicentre comparison.  The 
finding of elevated glutamine in medication-free patients largely reflected the comparison 
of unmedicated FEP patients from Theberge et al., 2002 with medicated chronic patients 
from Theberge et al., 2003, and so additional data in medicated FEP/unmedicated chronic 
patients is needed to clarify the role of medication. 
The trend for higher medial frontal glutamine in FEP patients than controls is consistent 
with the findings from the main meta-analysis (Chapter 2.2), although lower glutamine and 
glutamate were not detected in chronic patients. For Glx, no differences in the medial 
frontal cortex were found in FEP or chronic patient groups in both the present multicentre 
analysis and the main meta-analysis. However the meta-analysis found higher Glx levels in 
high risk subjects relative to controls. In the thalamus, the multicentre analysis did not 
detect any group differences for glutamate or Glx, however sufficient data were not 
available to examine glutamine, which was elevated in cases in the meta-analysis. It is of 
interest that Glx/Cr levels did not differ in the medial temporal lobe, as CSF-corrected Glx 
was elevated in both cases and chronic patients relative to controls in the meta-analysis. 
However, the multicentre analysis could not assess the chronic patient group separately 
due to an insufficient number of studies, and if effect-sizes were relatively large in this 
group, this could explain why significant differences were not detected in the cases overall.   
In the striatum, both the multicentre analysis and the meta-analysis found elevated 
glutamate and Glx levels in cases. The striatum is a region that has only been recently 
studied using 1H-MRS, so separate analyses in clinical groups were not feasible for all 
glutamatergic metabolites. Higher glutamate in the multicentre analysis and higher Glx in 
the meta-analysis were detected in the striatum of FEP patients. Chronic patients could not 
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be examined separately in either the multicentre or meta-analysis, and future studies in 
this patient group will confirm whether striatal glutamate changes are specific to the initial 
stages of disease or are stable over time. 
In summary, the multicentre analysis found altered glutamate metabolite levels in the 
medial frontal cortex and striatum of schizophrenia patients relative to controls. These 
findings are largely consistent with those of the meta-analysis, except that the multicentre 
analysis found lower medial frontal glutamate and glutamine in chronic patients. It is 
unclear whether the latter reflects an effect of illness stage or medication. For group 
comparisons, the meta-analysis had more statistical power than the multicentre analysis, 
as there were only a limited number of studies per region available for the latter. However, 
a multicentre analysis is better placed to assess the correlation between glutamate 
measures and symptom severity or CPZ dose equivalents. Overall, there was little evidence 
that PANSS symptom scores were related to glutamate metabolite levels, although 
increased Glx levels in the medial temporal lobe were correlated with the severity of 
negative symptoms. This finding in the MTL is in agreement with a SPET study which 
reported that reduced NMDAR binding in the hippocampus was associated with worsening 
negative symptoms (Pilowsky et al., 2006). The multicentre analysis was unable to examine 
how longitudinal changes in symptoms relate to changes in glutamate measures over time, 
which has been reported in a recent study (de la Fuente-Sandoval et al., 2013). As more 
longitudinal studies are conducted, sufficient data will become available for such analyses. 
The use of CPZ equivalent doses to explore medication effects is of limited utility, as patient 
reports of medication history may be inaccurate, medication effects on glutamate may not 
be dose-dependent, and may vary with the type of antipsychotic used. A further caveat is 
that they do not account for variations in medication adherence. Scanning antipsychotic-
naive first episode patients before and after the introduction of antipsychotic treatment 
would provide an ideal means of assessing 1) the effect of medication on glutamate 
metabolite levels, 2) the relationship between changes in symptom severity and 
longitudinal changes in glutamate measures and 3) the ability of glutamatergic measures to 
predict treatment response. I therefore adopted this experimental approach in the studies 
described in Chapter 4 and 5. 
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3. CHAPTER 3 – Reliability of longitudinal 1H-MRS measures of 
glutamate in healthy volunteers 
3.1. Introduction 
Longitudinal studies using serial 1H-MRS glutamate measurements must first ensure that 
these are reproducible and reliable. Reproducibility informs us of the precision of the mean 
within subject or between group measure, whereas reliability takes into account both 
within and between subject variation across the two timepoints (Bartlett and Frost, 2008). 
The test-retest reproducibility of 1H-MRS measures of glutamate concentrations and their 
reliability over short time periods have been assessed (see below), however the reliability 
of 1H-MRS glutamate measures over time periods exceeding two months, as would be 
generally required in a trial of antipsychotic treatment, remains to be reported.  
Reproducibility and reliability are calculated by dividing the difference in a measure over 
two timepoints by the mean value across timepoints. Reproducibility applies the 
calculation to the whole sample, and can be reported as a measure of variance, or as the 
mean coefficient of variation (CV%). Reliability on the other hand, applies the calculation to 
each individual and the mean is taken; this is known as the within-subjects CV%. 
Previous test-retest studies of 1H-MRS glutamate measurement error have reported 
reproducibility rather than reliability measures. The mean coefficient of variation (CV%) for 
glutamate and Glx is ~12%, measured in a number of brain regions, using different 
acquisition sequences, field strengths and test-retest time periods, see Table 3 (Bednařík et 
al., 2015; de la Fuente-Sandoval et al., 2013; Geurts et al., 2004; Hammen et al., 2005; Jang 
et al., 2005; Kaiser et al., 2005; Mullins et al., 2003; O’Gorman et al., 2011).  
Few studies have examined the test-retest reliability of glutamate measures over time 
using single voxel 1H-MRS, see Table 4 (Bartha et al., 2000; Srinivasan, 2005; Taylor et al., 
2010; Woermann et al., 1999). One study found a within-subjects CV of 8.9% for glutamate 
in the thalamus (Bartha et al., 2000) and another reported a within-subjects CV of 10.3% 
for glutamate in the parietal white matter (Srinivasan, 2005). However the test-retest scans 
in these studies were conducted within a few days of each other. Glutamate and Glx in the 
medial prefrontal cortex were found to be reliable over 7 days (within-subjects CV% < 7.4) 
(Taylor et al., 2010). One study investigated a longer time-frame of 1 day to 2 months, and 
reported that Glx measures were less reliable, with a within-subjects CV% of 35% 
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(Woermann et al., 1999). However this study examined the hippocampus, where it is 
difficult to acquire good quality spectra, and used a low field strength (1.5T) scanner.  
A number of analyses can assess test–retest reliability. Pearson’s product-moment 
correlation coefficient and intraclass correlation coefficient (ICC) are relative reliability 
measures which examine the consistency of an individual’s position in a group. Pearson’s r 
takes into account the linear relation of values regardless of the slope, and so does not 
provide information on the agreement of measures (Vaz et al., 2013). The intraclass 
correlation coefficient (ICC) measures the proportion of total variance that is due to 
differences between subjects and therefore its size depends on the variability in the 
sample. The within-subjects coefficient of variation is an absolute measure of reliability, 
which focuses on the degree to which individual measurements vary. The CV is most 
commonly reported in reliability studies of 1H-MRS measures and so will be reported here. 
In order to inform the study design of a longitudinal 1H-MRS investigation of glutamate 
(Chapter 4), test-retest investigations using long-term inter-scan durations are needed. 
Schizophrenia is a relapsing-remitting disorder, and glutamate dysfunction may be specific 
to the stage of the disorder or the medication status of the patient. To investigate these 
effects, the 1H-MRS study (Chapter 4) proposes to scan patients at a long-term timepoint. 
In summary, this chapter will examine the feasibility of measuring 1H-MRS glutamate in 
healthy controls with an inter-scan duration of several months, in order to inform the 
longitudinal (10 month) 1H-MRS study in FEP patients.  
The reliability estimates of glutamate, glutamine and Glx concentrations will inform which 
primary output measure will be used for the longitudinal (10 month) 1H-MRS study in FEP 
patients. This will take into account whether the correction method, commonly Cr-scaling 
or CSF-correction, affects the reliability of glutamate metabolite measures. In addition the 
reliability of glutamate measures using different versions of spectra quantification software 
will be assessed, as the most recent version of LCModel claims to better estimate 
metabolites with weaker signals, in particular glutamine.  
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Reproducibility        Mean CV% 




Brain regions Acquisition Analysis 
method 
Glu Glx Gln 
Bednařík 2015 Healthy Volunteers 3 10 x 2 Same day Hippocampus semi-LASER  LCModel 5.9   23.5 
de la Fuente-Sandoval 
2013 
Healthy Volunteers 3 18 x 2 4 weeks Dorsal Caudate PRESS LCModel 3.8     
        Cerebellum     9.7     
Geurts 2004 Healthy Volunteers 1.5 10 x 2 1 day to 2 
months 
Parietal grey matter   LCModel 8.6   22 
  
  





      10 x 2 Thalamus    21   71 
Hammen 2005 Healthy Volunteers 1.5 15 x 2 4–6 weeks Hippocampus PRESS LCModel   19.4   
Jang 2005  Healthy Volunteers 1.5 21 x 2 Within-session ACC PRESS LCModel 11 7.2   
Kaiser 2005 Healthy Volunteers 4 10 x 2 7 days Corona radiata STEAM Other 13.4   44.5 
          Mesial motor cortex     11.6   20.5 




15   
        Caudate nucleus     24   
O'Gorman 2011 Healthy Volunteers 3 14 x 4 Within-session DLPFC MEGA-PRESS LCModel 8 6   
Table 3 Previous reproducibility studies of 1H-MRS glutamate (Glu), Glx and glutamine (Gln) measures, assessed by mean percentage coefficient of variation (CV%).   









Reliability   
 
    Within-subjects 
CV% 




Brain regions Acquisition Analysis 
method 
Glu Glx Gln 
Bartha 2000 Healthy Volunteers 1.5 10 x 2 Same day Thalamus STEAM Other 8.9   16.9 
Srinivasan 2005 Healthy Volunteers 3 16 x 2 Days (not specified) Parietal white matter PRESS LCModel 10.3     
Woermann 1999 Healthy Volunteers 1.5 7 x 2 1 day to 2 months Hippocampus PRESS LCModel   35   
Taylor 2010 Healthy Volunteers 3 10 x 2 7 days Medial prefrontal cortex PRESS LCModel      7.4 6.8  
Table 4 Previous reliability studies of 1H-MRS glutamate (Glu), Glx and glutamine (Gln) measures, assessed by mean percentage coefficient of variation (CV%).   











3.2. Method  
3.2.1. Study objectives  
1. Assess the test-retest reproducibility and reliability of longitudinal 1H-MRS glutamate 
measures. 
2. On the basis of the above, select the LCModel software version giving the highest 
reliability and reproducibility of these measures. 
3. Investigate the effect of Cr-scaling and CSF-correction on glutamate reliability 
estimates. 
4. Perform a power analysis for the longitudinal 1H-MRS study. 
 
3.2.2. Ethical approval, data protection, informed consent and confidentiality  
Healthy control data were used from an ongoing study by A Egerton and J Stone, as part of 
a larger study comparing healthy controls with at risk mental health subjects (Egerton et 
al., 2014; Stone et al., 2009). The study was granted ethical approval by the Institute of 
Psychiatry Ethics Committee/South London and Maudsley NHS Trust Ethics Committee. All 
data was stored according to the Data Protection Act 1998, under anonymous 
identification numbers in locked storage and password protected documents.  
Healthy controls were obtained through email advertisements. Subjects were provided 
with written study information, and the study was explained in person, whereupon 
subjects were invited to give written consent. Subjects were aware that they could 
withdraw at any time, and that their details were confidential. Subjects agreed to their GP 
being contacted if medically significant results required further investigation.  
3.2.3. Sample  
Subjects were aged 18-40, right-handed and had no MRI contraindications and no previous 
diagnosis of a psychiatric disorder. 
32 subjects (mean age 24.4 years, SD 4.3; 15 males, 17 females) were scanned twice, with a 
mean elapsed time of 17 months (SD 6.78). This inter-scan interval is similar to that which 
will be used in the longitudinal 1H-MRS study in FEP (see Chapter 4).   
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3.2.4. 1H-MRS protocol  
All investigations were performed on a 3 Tesla General Electric (Milwaukee, Wisconsin) MRI 
scanner. The scan acquisition and analysis parameters match those used in the longitudinal 
1H-MRS study in FEP (see Chapter 4).   
An initial localiser scan was used to identify the anterior commissure-posterior commissure 
line (AC-PC) and interhemispheric angle. Structural images were acquired using an axial 2D 
T2-weighted Fast Spin Echo scan and an axial fast fluid-attenuated inversion recovery 
(FLAIR) scan. A whole brain 3D coronal IR-SPGR (inversion recovery prepared spoiled 
gradient echo) scan was obtained to localise 1H-MRS voxels, giving isotropic 1.1-mm voxels 
in a scan time of approximately 6 min (echo time (TE) = 2.82 msec; repetition time (TR) = 
6.96 msec; inversion time = 450 msec; excitation flip angle = 20°). 
1H-MRS spectra were acquired using a PRESS sequence (Point RESolved Spectroscopy), 
echo time TE=30msec; repetition time TR=3000msec, 96 averages. The standard GE PROton 
Brain Examination (PROBE) sequence was used to supress water signals via a standardised 
chemically selective suppression (CHESS) water suppression routine. Auto pre-scans were 
performed twice before each scan to optimise water suppression and shimming. Spectra 
were collected in left thalamus, where the ROI has a voxel resolution of 15 (right-left) x 20 
(anterior-posterior) x 20mm (superior-inferior), localised from sagittal and coronal 
localisers where the thalamus is widest with the least CSF contamination, obtaining a 
minimum water linewidth (full-width half maximum) of 10Hz after shimming. Spectra were 
also obtained from the anterior cingulate, localised from the midline sagittal localizer, with 
the centre of the 20 x 20 x 20mm ROI being placed 13mm above the anterior portion of the 
genu of the corpus callosum, 90º to the anterior commissure-posterior commissure line 
(AC-PC), and making sure to avoid the corpus callosum. A minimum water linewidth 
(FWHM) below 7Hz was obtained after shimming. A signal-to-noise ratio (S/N) ≥8 and 
linewidth of <0.1 ppm were required for inclusion.  
After subject scanning, PRESS spectra from a phantom containing standardised 
concentrations of brain metabolites (Provencher, 1993) were obtained to assess scanner 
drift or step-changes over the study.  
3.2.5. 1H-MRS analysis  
LCModel version 6.1-4F and version 6.3-0I (Provencher, 2015, 1993) were used to estimate 
the concentration of metabolites, by fitting the output to a basis set of 16 metabolites (L-
alanine, aspartate, creatine, phosphocreatine, GABA, glucose, Gln, glutamate, 
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glycerophosphocholine, glycine, myo-inositol, L-lactate, N-acetylaspartate, N-
acetylaspartylglutamate, phosphocholine, and taurine), acquired with the same field 
strength (3 Tesla), localization sequence (PRESS), and echo time (30 msec) (Provencher, 
2015). Poorly fitted metabolite peaks (Cramer–Rao minimum variance bounds (CRVB) >20% 
as reported by LCModel) were excluded from further analysis. LCM produces water-scaled 
values that are presented as ‘institutional units’. Metabolites are also reported as a 
concentration ratio to creatine. 
Water-scaled metabolite concentrations (institutional units) were CSF-corrected. 
Cerebrospinal fluid (CSF) contains lower metabolite concentrations and so large volumes of 
CSF in the ROI would underestimate the metabolite value in the specified brain region. CSF-
correction was carried out by segmenting IR-SPGR 3D images into grey, white and CSF 
volumes using Statistical Parametric Mapping 5 (SPM5; Wellcome Department of Imaging 
Neurosciences, University College London, UK). ROI co-ordinates were obtained from 
spectra file headers using General Electric’s spectroscopy processing tool Sage, to obtain 
brain tissue volumes from the same region in the IR-SPGR images. Grey matter and white 
matter volume in the ROI are added, and this value is used to correct metabolite values 
using the following calculation: 
Uncorrected metabolite x  [vol + 1.55 x (1 - vol)] / vol 
Vol = grey matter + white matter 
The inclusion of “1.55” in the above equation is to correct for the estimated water 
concentration of the voxel for partial volume CSF contamination, as the spectra are water-
scaled (this assumes a CSF water concentration of 55,556 mol/m3 and the LCModel default 
brain water concentration of 35,880 mol/m3).  
3.2.6. Statistical analysis of reproducibility and reliability 
CSF-corrected and Cr-scaled concentrations of glutamate, glutamine, and Glx in the ACC 
and thalamus at both timepoints, were entered into Microsoft Excel spreadsheets to 
perform the following reproducibility and reliability calculations: 
VAR% was used to test the reproducibility of metabolite measures between the baseline 
and follow-up scan with the following calculation:  
(retest mean value – test mean value)/ 0.5 (test mean value + retest mean value) × 100 
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VAR% is not a measure of reliability as it does take not into account individual subject 
variance, unlike within-subject CV%. 
The within-subject percentage coefficient of variation (CV%) was used to test the reliability 
of metabolite measures between the baseline and follow-up scan. 
The within-subject CV% was calculated using the root mean square approach, as an 
alternative to the logarithmic method (http://www-users.york.ac.uk/~mb55/meas/cv.htm)  
Within subject variance: s = (test-retest)2/2 
Subject mean: m = (test+retest)/2 
CV squared: s2m2 = s/m2 
CV% = √means2m2 x 100 
Power calculations were performed using ‘PS’ Software (Dupont and Plummer, 1990) at an 
alpha level of .05 and power of .80. An ability to detect a 15% change in the mean 
glutamate level in the anterior cingulate between patients and controls was chosen based 
on a previous 3T study, which reported a 16% change in Glu/Cr ratios in the anterior 






Results are listed in Table 5. In the ACC, within-subjects CV% values were between 10% and 
17% and variance (VAR%) was below 10% for glutamate, glutamine and Glx values. In the 
thalamus, within-subjects CV% values were between 16% and 23% and variance (VAR%) 
was below 20% for glutamate and Glx values. Glutamine could not be resolved in the 
thalamus at both timepoints in any subject. The reliability (within-subjects CV% of ~20%) 
and reproducibility (variance of <20%) was higher than that reported in previous studies 
that examined reliability over an inter-scan interval of days (Bartha et al., 2000; Srinivasan, 
2005; Taylor et al., 2010), probably due to the increased test-retest time interval, but was 
lower than a study examining reliability over 1 day to 2 months (Woermann et al., 1999).  
More reliable measures from the ACC in comparison to the thalamus were expected, as the 
structure of the thalamus is more homogeneous and thus is harder to acquire 1H-MRS data 
from. No significant differences between timepoints were found using paired t-tests, 
except for CSF-corrected Glx levels in the thalamus using LCModel version 6.3-0I which 
approached significance (P=0.052). However, the within-subjects CV% is a more suitable 
statistical assessment for determining the reliability of measures. Any variation between 
repeated measurements is unlikely to be due to variation in the manual placement of voxel 
regions of interest, as low within-subjects CV% were found for ACC white plus grey matter 
(7%), ACC CSF (17%) and thalamus white plus grey matter (5%). As the amount of CSF is 
negligible in the thalamic voxel, it is not appropriate to conduct within-subjects CV% 
calculations, as structural imaging software cannot accurately measure the degree of CSF at 
such low concentrations. In addition no significant differences in the volume of CSF or 
white matter plus grey matter were found using paired t-tests.  
When comparing metabolite correction methods, VAR% and CV% were comparable but 
somewhat lower for creatine (Cr)-scaled values than CSF-corrected values. Despite being 
reliable, Cr-scaled values may not be a suitable output measure for the longitudinal 1H-
MRS study in FEP, as creatine concentrations may change with antipsychotic treatment. 
Therefore, CSF-corrected values will be used as the primary output measure, as this 
correction method still shows good reliability and reproducibility.  
For the analysis software, LCModel 6.3-0I returned generally lower SD and CV%, but higher 
VAR% values than LCModel 6.1-4F. Version 6.3-0I also returned acceptable fits for 
glutamine in a higher number of subjects than version 6.1-4F (3 subjects using 6.1-4F in 
comparison to 13 subjects using 6.3-0I in the ACC). The low CV% values achieved with 
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LCModel 6.3-0I indicates good within subject reliability, and so will be suitable for the 
longitudinal study in FEP examining glutamate metabolite changes with antipsychotic 
treatment. Low VAR% values are less important as they indicate the precision of the mean 
between group measures but not within-subject reliability.  
For CSF-corrected values obtained using LCModel 6.3-0I, both glutamate and Glx show 
good reliability and reproducibility, with Glx showing slightly superior CV% and glutamate 
showing slightly superior VAR%. As the longitudinal study will be conducted at 3T, Glx is the 
most suitable primary output measure, as glutamate and glutamine peaks overlap by <30% 
in the 2.25–2.55 ppm range (Snyder and Wilman, 2010a). 
A power analysis at an alpha level of .05 and power of .80, indicated that sample sizes of 23 
patients and 23 controls are required to detect a 15% difference in CSF-corrected Glx levels 
in the ACC, and 32 patients and 30 controls to detect a 15% difference in Glx levels in the 
thalamus.  
For longitudinal analyses, the power analysis at an alpha level of .05 and power of .80, 
indicated that 13 patients are required to detect a 15% within-subjects difference in Glx 




Table 5 (overleaf) Reproducibility (VAR%) and reliability (CV%) of 1H-MRS measures of glutamate (glu), Glx 
and glutamine (Gln) in healthy controls.  
See next page. Both Creatine-scaled (Cr) and CSF-corrected measures are reported. SD = standard deviation, CV 
= % Coefficient of Variation, VAR% = Variance.  Sample size indicates power analysis calculations for between-




LCModel 6.1-4F                      
Brain region       Baseline   Follow-up       Sample size 
Metabolite Corr n Mean SD Mean  SD CV % VAR % Between Within 
Anterior cingulate 
Glu  CSF 31 13.3 2.6 13.2 2.4 15.8 0.8 26 14 
Glx CSF 31 18.2 4 17.9 3.8 16.6 1.7 34  18 
Gln  CSF 3 8.4 3.6 9.3 4.1 9.8 10.2 131 67 
Glu  Cr 31 1.35 0.2 1.37 0.21 13.7 1.5 18 10 
Glx Cr 31 1.85 0.38 1.85 0.31 16.4 0.0 26 14 
Gln  Cr 3 0.82 0.35 0.75 0.28 13.4 8.9 113 58 
Thalamus 
Glu CSF 30 7.4 1.5 7.0 1.6 21.5 7.6 33 18 
Glx CSF 30 9.2 2.6 8.4 1.8 20.3 9.2 45 24 
Glu Cr 30 1.03 0.16 1 0.23 23.0 18.2 29 16 
Glx Cr 30 1.27 0.3 1.23 0.28 22.8 18.3 38 20 
                        
LCModel 6.3-0I                     
Brain region       Baseline   Follow-up       Sample size 
Metabolite Corr n Mean SD Mean  SD CV % VAR % Between Within 
Anterior cingulate 
Glu  CSF 32 13.9 2.4 13.5 2.2 14.7 2.9 20  12 
Glx  CSF 32 19.7 3.4 19.1 3.5 14.3 3.1 23  13 
Gln  CSF 13 7.6 2.3 7.3 2.3 14.6 4.0 65  34 
Glu  Cr 32 1.34 0.17 1.34 0.19 12.3 0.0 14 8 
Glx Cr 32 1.91 0.28 1.88 0.28 14.3 1.6 16 9 
Gln  Cr 13 0.73 0.19 0.67 0.18 15.8 8.6 48 25 
Thalamus 
Glu  CSF 31 7.8 1.6 7.3 1.5 19.0 6.6 30 16 
Glx CSF 31 9.9 2.4 9 1.6 18.1 9.5 32  17 
Glu  Cr 31 1.05 0.16 1.03 0.21 16.0 1.9 23 13 





In this study the test-retest reproducibility (VAR%) and reliability (within-subjects CV%) of 
glutamate measurements over a period of several months was estimated, comparing  two 
correction methods, and two versions of the LCM analysis software. The results indicate 
that glutamate measures have a good reproducibility and reliability over long time periods.  
This study was conducted to inform the primary outcome measure and sample size needed 
for a longitudinal investigation of 1H-MRS glutamate measures and the acute and medium-
term response to antipsychotic medication (Chapter 4). The reliability of glutamate 
measures were examined in the same brain regions over a similar follow-up timescale to 
the proposed study. 
Based on the present findings, CSF-corrected Glx has been selected as the primary outcome 
measure for the longitudinal study. Glx was selected, as although the reliability of 
glutamate and Glx was comparable, Glx is the more accurate signal, as 10% of the 
glutamate signal is contaminated by glutamine at 3T (Snyder and Wilman, 2010b).  
Glutamine is not an appropriate outcome measure as it was not resolved in the thalamus, 
and was only acquired in half of the sample for the ACC. The latest version of LCModel (6.3-
0I) has been selected for the analysis of this data, as this was found to be more reliable 
than the previous version, likely due to improved fitting of spectra to the basis set. 
In earlier 1H-MRS studies, metabolites were typically scaled to creatine as it was thought 
that creatine levels are relatively stable in the brain. However, creatine differences 
between patients with schizophrenia and healthy controls have been reported, as well as 
changes with age (Tibbo et al., 2013). Thus there has been a shift in reporting practices as 
CSF-corrected metabolite values are thought to be more reliable than Cr-scaled values. 
Therefore it is of interest that Cr-scaled values were found to be slightly more reliable than 
CSF-corrected values in this analysis. However CSF-correction rather than Cr-scaling will be 
used in the longitudinal study, as medication may affect creatine levels.  
At least 17 patients will be required in the proposed longitudinal study (Chapter 4) in order 
to detect a 16% difference in Glx levels over time, as indicated by a power analysis of the 




CHAPTER 4 – Longitudinal investigation of 1H-MRS glutamate 
measures and the acute and medium-term response to 
antipsychotic medication. 
 
4.1. Introduction and Study Objectives 
This chapter outlines the study design and findings of a longitudinal 1H-MRS study that 
aims to determine the relationship between glutamate measures and the acute and 
medium-term response to antipsychotic medication.  
The meta-analysis in Chapter 2 found that schizophrenia is associated with elevations in 
glutamatergic metabolites. Glutamate levels have also been found to differentiate patients 
based on their clinical response, as evidenced by three previous studies comparing 
responders and non-responders to treatment (Demjaha et al., 2014; Egerton et al., 2012; 
Mouchlianitis et al., 2015). However, as these studies are cross sectional, it is not known 
whether between-group differences are present at the first onset of psychosis and 
therefore predict treatment response, or whether effective treatment is associated with a 
reduction in glutamate. 
To determine this, the present study examined glutamate measures in antipsychotic naive 
patients experiencing their first episode of psychosis and followed-up patients at a short (5 
weeks) and medium-term (10 months) timepoint following treatment with antipsychotic 
medication. A medium-term timepoint was added as response to medication and 
medication-effects on glutamatergic metabolites may take longer than 5 weeks to occur. 
The main output measure was CSF-corrected Glx levels, as informed by the reliability and 
reproducibility analysis of glutamate measures outlined in Chapter 3. Glutamate measures 
were obtained in the ACC and thalamus, consistent with previous studies comparing 
responder and non-responder groups (Demjaha et al., 2014; Egerton et al., 2012; 
Mouchlianitis et al., 2015), as NMDAR antagonist administration to healthy volunteers 
increases metabolism in these regions (Deakin et al., 2008; De Simoni et al., 2013; Holcomb 
et al., 2005, 2001) and increases glutamate and glutamine concentrations in the ACC 




Patients vs controls: 
• To identify differences in Glx between patients and controls.  
 
Responders versus non-responders to antipsychotic treatment: 
• To investigate whether Glx levels at baseline predict response to 5 weeks of 
antipsychotic treatment. 
• To investigate whether Glx declines with 5 weeks of treatment in responders but not in 
non-responders. 
• To investigate the effect of medication on group differences in Glx by controlling for 
medication adherence. 
 
Remission vs non-remission: 
• To investigate whether Glx levels at baseline predict remission at a 10 month follow up. 
• To investigate whether Glx declines over time in remission but not in non-remission 
patients. 
• To investigate the effect of medication on group differences in Glx by controlling for 
medication adherence. 
• To investigate the relationship between longitudinal change in Glx and the change in 
symptom severity over time. 
 
 
4.2. Study design  
Subjects were recruited from two studies: 15 patients were recruited from the OPTiMiSE 
clinical trial that involved a standardised treatment (amisulpride) and regular research 
assessments, and 6 patients were recruited from a study following a naturalistic treatment 
by clinicians with assessments limited to when subjects were scanned (TreatFEP study). 
Ethical approvals  
Both studies were granted ethical approval by the Institute of Psychiatry Ethics 
Committee/South London and Maudsley NHS Trust Ethics Committee. All data was stored 
according to the Data Protection Act 1998, under anonymous identification numbers in 




4.3. Participants  
4.3.1. Patient Recruitment 
Based on the reliability analysis from Chapter 3, 17 patients would provide adequate power 
to detect a 15% within-subjects difference in Glx levels in the thalamus, and 13 patients 
were required to detect a 15% within-subjects difference in Glx levels in the ACC between 
responders and non-responders. 
Patients were recruited from Early Intervention teams from the South London and 
Maudsley NHS Trust.  
Inclusion criteria:  
• Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder as defined by 
DSM-IV on the basis of the Mini International Neuropsychiatric Interview Plus (Sheehan 
et al., 1998). Schizophreniform disorder was assessed through a M.I.N.I. diagnosis of 
psychosis NOS complemented by a diagnosis of schizophreniform disorder according to 
DSM-IV criteria. 
• First episode of psychosis presented within the past 2 years.  
• Age 18-40 years. 
• Written informed consent. 
Exclusion criteria: 
• Currently taking antipsychotic medication, for the OPTiMiSE clinical trial, prior use of 
antipsychotic medication longer than an episode of two weeks in the previous year 
and/or six weeks lifetime. 
• Patients who are coercively treated at a psychiatric ward (based on a judicial ruling). 
• Patients who are represented by a legal guardian or under legal custody. 
• MRI contraindications including metal implants and pregnancy. 
 
4.3.2. Healthy Control Recruitment 
Healthy controls were obtained through poster and gumtree advertisements. Subjects 
were provided with written study information, and the study was explained in person, 
whereupon subjects were invited to give written consent. Subjects were aware that they 
could withdraw at any time, and that their details were confidential. Subjects agreed to 
their GP being contacted if medically significant results required further investigation.  
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Inclusion criteria:  
• Age 18-40 years. 
• Written informed consent. 
Exclusion criteria:  
• Diagnosis of a psychiatric disorder. 
• Current use of psychopharmacological medication. 
• Family history of schizophrenia or bipolar disorder. 
• MRI contraindications including metal implants and pregnancy. 
 
4.4. Assessments  
4.4.1. Patients  
The Positive and Negative Syndrome Scale (PANSS) assessment (Kay et al., 1987), and an 
MRI scan (see below for protocol) were conducted at baseline (timepoint 1), after 5 weeks 
of antipsychotic treatment (timepoint 2) and a minimum of 10 weeks after baseline 
(timepoint 3). At the baseline visit demographic data was collected, at timepoint 3 self-
report recreational drug use data was collected.  
4.4.2. Healthy controls 
Healthy controls underwent an MRI scan at baseline (timepoint 1), after 5 weeks (timepoint 
2) and a minimum of 10 weeks after baseline (timepoint 3). At the baseline visit 
demographic data was collected, and self-report recreational drug use data was collected 
at all timepoints. 
 
4.5. 1H-MRS protocol  
All investigations were performed on a 3 Tesla General Electric (Milwaukee, Wisconsin) 
magnetic resonance scanner. An initial localiser scan was used to identify the anterior 
commissure-posterior commissure line (AC-PC) and interhemispheric angle. Structural 
images were acquired using an axial 2D T2-weighted Fast Spin Echo scan and an axial fast 
fluid-attenuated inversion recovery (FLAIR) scan. A whole brain 3D coronal IR-SPGR 




1H-MRS spectra were acquired using a PRESS sequence (Point RESolved Spectroscopy), 
echo time TE=30msec; repetition time TR=3000msec, 96 averages. The standard GE PROton 
Brain Examination (PROBE) sequence was used to supress water signals via a standardised 
chemically selective suppression (CHESS) water suppression routine. Auto pre-scans were 
performed twice before each scan to optimise water suppression and shimming. Spectra 
were collected in left thalamus, where the ROI has a voxel resolution of 15 (right-left) x 20 
(anterior-posterior) x 20mm (superior-inferior), localised from sagittal and coronal 
localisers where the thalamus is widest with the least CSF contamination, obtaining a water 
linewidth (full-width half maximum) of 10Hz after shimming. Spectra were also obtained 
from the anterior cingulate, localised from the midline sagittal localizer, with the centre of 
the 20 x 20 x 20mm ROI being placed 13mm above the anterior portion of the genu of the 
corpus callosum, 90º to the anterior commissure-posterior commissure line (AC-PC), and 
making sure to avoid the corpus callosum, see Figure 20. A water linewidth (FWHM) below 
7Hz was obtained after shimming. 
After subject scanning, PRESS spectra from a phantom containing standardised 





Figure 20 Voxel selection in the anterior cingulate cortex (left image) and thalamus (right image). 
 
4.6. Data analysis 
4.6.1. Statistical analysis  
All statistical analyses were performed using SPSS version 22 (SPSS inc. Chicago, Illinois, 
USA). For demographic data, between group differences were assessed using Fisher’s Exact 
Test (2 sided) for categorical variables, and independent samples Student’s t-test for 
continuous variables. Equal variances were assumed unless Levene’s test for equality of 
variances was significant at the 95% confidence level. 
CSF-corrected Glx was the primary outcome measure, which measures the combined 
signals from both glutamate and glutamine, as glutamate and glutamine signals cannot be 
completely resolved at 3T. Repeated measures ANOVA assessed the effect of time and 
group on CSF-corrected Glx levels and whether there was a group x time interaction. This 
was assessed for 1) FEP patients and controls,2) responder and non-responders after 5 
weeks of treatment and 3) remission and non-remission patients after 10 months. If 
significant effects were found, post-hoc tests were conducted using univariate ANOVA. If 
significant effects were found with Glx, then secondary analyses would examine glutamate. 
Sphericity (equal variance of differences between groups) was assumed unless Mauchly’s 
Test of Sphericity was violated; in this case the Greenhouse-Geisser correction was used, 
unless the test statistic (epsilon) was larger than 0.75, in this case the less conservative 
Huynh-Feldt correction was used (Girden, 1992). 
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The percentage change in PANSS score between baseline and the 2nd or 3rd timepoint was 
calculated by first subtracting the minimum score from the PANSS data, as each PANSS 
item is scored from 1-7 instead of 0-6, before using the following calculation: 
((2nd or 3rd timepoint score - baseline score) / baseline score ) x 100 
The percentage change in Glx and glutamate used the following calculation: 
((2nd or 3rd timepoint metabolite value – baseline metabolite value) / baseline metabolite 
value ) x 100 
The relationship between the percentage change in PANSS score and the percentage 
change in Glx was assessed using Spearman bivariate correlations. Outliers were identified 
using Cook’s distance estimates, using the function on SPSS, and excluding values higher 
than 4/n, where n equals sample size.   
4.6.2. 1H-MRS analysis  
LCModel version 6.3-0I (Provencher, 2015, 1993) was used to estimate the concentration 
of metabolites, by fitting the output to a basis set of 16 metabolites (L-alanine, aspartate, 
creatine, phosphocreatine, GABA, glucose, Gln, glutamate, glycerophosphocholine, glycine, 
myo-inositol, L-lactate, N-acetylaspartate, N-acetylaspartylglutamate, phosphocholine, and 
taurine), acquired with the same field strength (3 Tesla), localization sequence (PRESS), and 
echo time (30 msec) (Provencher, 2015). Poorly fitted metabolite peaks (Cramer–Rao 
minimum variance bounds (CRVB) >20% as reported by LCModel) were excluded from 
further analysis.  
Metabolites are reported as CSF-corrected water-scaled metabolite concentration 
estimates (institutional units). Cerebrospinal fluid (CSF) contains lower metabolite 
concentrations and so large volumes of CSF in the ROI would underestimate the metabolite 
value in the specified brain region. CSF-correction was carried out by segmenting IR-SPGR 
3D images into grey, white and CSF volumes using Statistical Parametric Mapping 8, version 
6313 (SPM8; Wellcome Department of Imaging Neurosciences, University College London, 
UK). ROI co-ordinates were obtained from spectra file headers using General Electric’s 
spectroscopy processing tool SAGE, to obtain brain tissue volumes from the same region in 
the IR-SPGR images. Grey matter and white matter volume in the ROI are added, and this 
value is used to correct metabolite values using the following calculation: 
Uncorrected metabolite x  [vol + 1.55 x (1 - vol)] / vol 
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Vol = grey matter + white matter 
The inclusion of “1.55” in the above equation is to correct for the estimated water 
concentration of the voxel for partial volume CSF contamination, as the spectra are water-
scaled (this assumes a CSF water concentration of 55,556 mol/m3 and the LCModel default 




4.7. Results: Subject demographics 
See Table 6 and Table 7 for subject demographic data. Control and FEP patients did not 
differ in age, sex or ethnicity. Control subjects had significantly more years of education 
than FEP patients, and significantly more FEP patients were currently unemployed. At the 
third timepoint (10 months), control and FEP patients did not differ in their intake of 
tobacco, alcohol, and recreational drugs. 
21 FEP patients were scanned at all three timepoints; antipsychotic-naïve at baseline, after 
5 weeks of treatment with antipsychotic medication and at a 3rd timepoint that was a mean 
of 10 months after the baseline scan. 21 control subjects were scanned at baseline and 
rescanned 5 weeks later, and 15 of the 21 were scanned at the 3rd timepoint a mean of 9 
months after the baseline scan. There were no significant differences in the between-
scanning intervals in the two groups (Table 6)  
Patients were categorised into medication responders and non-responders after 5 weeks of 
antipsychotic treatment at the 2nd timepoint, with response defined as a 50% reduction in 
positive symptoms. After 10 months, at the 3rd timepoint, patients were divided into 
remission and non-remission groups, with remission defined as a 50% reduction in positive 
symptoms. There were no significant differences in the number of days between the 
scanning follow-up timepoints between responder and non-responder groups, and 
between remission and non-remission groups (Table 6).  Remission and non-remission 
patients did not differ in their intake of tobacco, alcohol, and recreational drugs, with the 
exception of cannabis, which was used at a higher frequency in non-remission relative to 
remission patients (Table 7). Patient groups did not differ in their previous exposure to 
medication at baseline (only three patients had previous antipsychotic use) and duration of 
medication usage (Table 8).  
At baseline no significant differences in PANSS scores were found between responder and 
non-responder, and remission and non-remission groups. As expected, PANSS scores were 
significantly higher in the non-responder and non-remission groups at the follow-up time 
points, although PANSS negative score did not differ between remission and non-remission 
patients at 10 months (3rd timepoint) (Table 9). 
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2nd timepoint (5 weeks) 3rd timepoint (~10 months) 
 Control 
n=15 









Remission n=11 Non remission vs 
Remission  
Age, years; mean (SD) 24.5 (4.5) 25.4 (5.3) T (34)=-0.51; P=0.62 24.2 (5.9) 26.3 (4.8) T (19)=-0.86; P=0.40 24.3 (5.7) 26.4 (5.0) T (19)=-.887; P=0.39 
Gender, male/female 12/3 15/6 X2 P=0.71 8/1 7/5 X2 P=0.18  9/1  6/5 X2 P=0.15 
Education, years; mean (SD) 14.5 (2.7) 12 (2.4) T (34)=3.01; P=0.005 11.9 (2.5) 12.0 (2.4) T (19)=-0.10; P=0.92 11.5 (2.2) 12.4 (2.5) T (19)=-.83; P=0.42 
Highest level education 
commenced; University / 
Professional training / 
Highschool 
7/1/7 5/6/10 X2 P=0.17 2/2/5 3/4/5 X2 P=0.86  1/3/6 4/3/4 X2 P=0.45 
Currently employed Y/N 14/1 11/10 X2 P=0.011  3/6 8/4 X2 P=0.20 4/6 7/4 X2 P=0.40 
Ethnicity 
(White/Black/Asian/Other) 
8/3/2/2 8/8/1/4 X2 P=0.51 3/2/1/3 5/6/0/1 X2 P=0.28 3/3/1/3 5/5/0/1 X2 P=0.44 
Days between Baseline and 









T (19)=-0.65; P=0.52 38 (19) 26-89 69 (125) 25-444 T (19)=-.780; P=0.45 
Days between Scan 2 and Scan 











T (19)=-1.22; P=0.24 215 (170) 42-506 258 (198) 41-552 T (19)=-.533; P=0.60 
Table 6 Subject demographics.  
Differences between controls and FEP patients, and between non-remission and remission patients, were determined using Student’s t test (T) or Fisher’s Exact test, 2 tailed (X2). Significant results 
P=<0.05 are highlighted in bold.
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  Control 
n=15 




Non remission vs 
Remission 
Current smoker: no/yes 6/9 8/13 X2 P=1.00 2/8 6/5 X2 P=0.18 
Cigarettes/day, mean (SD) 4 (6) 4 (5) T (34)=-0.07; P=0.95 5 (5) 4 (5) T (19)=0.599; P=0.56 
Current alcohol drinker: no/yes 3/12 9/12 X2 P=0.28 4/6 5/6 X2 P=1.0 
Alcohol units/week, mean (SD) 5.9 (7.6) 3.1 (4.7) T (34)=1.35; P=0.19 2.6 (3.3) 3.5 (5.8) T (19)=-0.45; P=0.66 
Cannabis, frequency of use: 0/monthly/weekly/3 times per 
week/daily 
8/0/2/3/2 13/1/0/5/2 X2 P=0.43 4/0/0/5/1 9/1/0/0/1 X2 P=0.03 
Amphetamine, frequency of use: 0/monthly/2xmonth/weekly 15/0/0 21/0/0 NS 10/0/0/0 11/0/0/0 NS 
Cocaine, frequency of use: 0/monthly/2xmonth/weekly 12/1/1/1/0 17/3/1/0/0 X2 P=0.59 9/0/1/0 8/3/0/0 X2 P=0.21 
Ecstasy/MDMA, frequency of use: 0/monthly/2xmonth/weekly 13/0/2/0 20/1/0/0 X2 P=0.17 10/0/0/0 10/1/0/0 X2 P=1.0 
Ketamine, frequency of use: 0/monthly/2xmonth/weekly 14/0/1/0 20/1/0/0 X2 P=0.35 10/0/0/0 10/1/0/0 X2 P=1.0 
Table 7 Recreational drug use.  
Differences between controls and FEP patients, and between non-remission and remission patients, were determined using Student’s t test (T) or Fisher’s Exact test, 2 tailed (X2). Significant results P=<0.05 










   
2nd timepoint (5 weeks) 3rd timepoint (10 months) 











Non remission vs 
Remission 
Baseline More than 2 weeks previous antipsychotic medication use: Yes/No 3/18 1/8 2/10 X
2 P=1.00 1/9 2/9 X2 P=1.00 
  Duration of current treatment at baseline: mean days (SD) range 10 (9) 0-40 11 (12) 0-40 9 (7) 0-17 T (19)=0.49, P=0.63 9 (12) 0-40 11 (6) 0-17 T (19)=-0.58, P=0.57 
Baseline – 
5 weeks 
Duration of treatment; mean days (SD) range 32 (14) 10-80 
32 (6) 22-43 32 (18) 10-80 
T (19)=-0.06, 
P=0.95 
30 (7) 16-43 34 (18) 10-80 T (19)=-0.64, P=0.53 










T (19)=0.06, P=0.96 
Only used Amisulpride:  Yes/No 14/7 5/4 9/3 X
2 P=0.40 6/4 8/3 X2 P=0.66 
Antipsychotic medication:  Amisulpride only/Amisulpride+another 
antipsychotic/Aripiprazole+Risperidone/Aripiprazole 




Duration of treatment; mean days (SD) range   
    






%  days on medication   
  
 






Antipsychotic medication:  Amisulpride only/Amisulpride+another 
antipsychotic/Olanzapine/Aripiprazole/Risperidone/None 




Duration of treatment; mean (SD) range   
    




T (19)=-1.02, P=0.32 
% days on medication   
  
 
  67 (30) 9-100 80 (32) 17-
100 
T (19)=-0.91, P=0.37 
Antipsychotic medication at 10 months:  
None/Amisulpride/Olanzapine/Risperidone/Quetiapine/Aripiprazol
e 
       5/1/3/0/1/0 3/4/2/1/0/1 X2 P=0.62 
Table 8 Summary of medication information in FEP patients; responder and non-responders at 5 weeks, and remission and non-remission groups at 10 months.  






2nd timepoint; 5 weeks 3rd timepoint; 10 months 
PANSS Score FEP n=21 Non-Responders n=9 Responders n=12 Responders vs Non-Responders Non remission n=10 Remission n=11 Non remission vs Remission 
Positive 19.6 (4.8) 20.0 (4.9) 19.3 (4.8) T (19)=0.31; P=0.76 20.0 (4.9) 19.3 (4.9) T (19)=0.34; P=0.74 
Negative 14.5 (5.4) 15.4 (4.6) 13.8 (6.0) T (19)=0.67; P=0.51 14.7 (4.9) 14.4 (6.0) T (19)=0.14; P=0.89 
General 34.9 (8.8) 37.0 (5.8) 33.3 (10.4) T (19)=0.97; P=0.35 35.7 (5.5) 34.1 (11.2) T (19)=0.41; P=0.69 
Total 69.0 (16.3) 72.4 (10.1) 66.4 (19.9) T (19)=0.83; P=0.42 70.4 (10.6) 67.7 (20.7) T (19)=0.37; P=0.72 
Positive 13.3 (5.4) 17.9 (4.6) 9.9 (2.7) T (19)=4.99; P=<0.001       
Negative 13.3 (6.2) 17.4 (6.6) 10.3 (4.6) T (19)=2.95; P=0.01 
  
  
General 27.5 (8.8) 35.0 (7.6) 21.9 (4.3) T (19)=5.04; P=<0.001 
  
  
Total 54.2 (18.8) 70.3 (16.1) 42.1 (8.9) T (19)=5.16; P=<0.001 
  
  
Positive 13.8 (6.1)       18.4 (5.1) 9.5 (2.9) T (19)=4.91; P=<0.001 
Negative 11.1 (3.7)   
 
  12.0 (4.1) 10.3 (3.4) T (19)=1.06; P=0.30 
General 28.4 (7.4)   
 
  33.8 (5.6) 23.5 (5.1) T (19)=4.40; P=<0.001 
Total 53.3 (14.6)       64.2 (11.6) 43.4 (9.0) T (19)=4.63; P=<0.001 
Table 9 Mean and (standard deviation) of PANSS scores in FEP patients; responder and non-responders at 5 weeks, and remission and non-remission groups at 10 months.  








4.8. Group differences in voxel tissue content  
There were no significant differences in ACC voxel tissue content between control and FEP 
patient groups. In the thalamic voxel, patients had significantly lower grey matter volume 
(T(40)=2.026, P=0.050) but a trend for greater white matter volume than controls at 
baseline (T(40)=-1.945, P=0.059). No differences in voxel tissue content were apparent 
between patient groups at any timepoint (responder vs non-responder, remission vs non-
remission). 
 
4.9. Glutamatergic metabolites in patients with first episode psychosis versus 
controls.  
Anterior cingulate cortex 
There were no significant main effects of group (controls vs FEP) (F(1,34)=0.048, P=0.828) 
or time (3 levels; baseline, 5 weeks, 10 months) (F(2,68)=0.558, P=0.575) on CSF-corrected 
Glx in the ACC, and no group by time interaction (F(2,68)=1.255, P=0.292). 
 
Thalamus 
There were no significant main effects of group (controls vs FEP) (F(1,33)=0.000, P=0.993) 
or time (3 levels) (F(2,66)=1.952, P=0.150) on CSF-corrected Glx in the thalamus, and no 






4.10. Relationship between glutamate metabolites and antipsychotic response 
after 5 weeks of treatment 
4.10.1. Reduction in symptoms over 5 weeks of antipsychotic treatment 
Over the first 5 weeks of antipsychotic treatment, symptoms improved in patients as 
evidenced by an overall reduction in PANSS total, positive and general scores (Table 10). 
PANSS negative symptoms did not differ between baseline and the 5 week follow-up. One 
patient did not show an improvement in PANSS positive symptom score, however this 
patient had poor medication adherence. 
Patients were classified into responder and non-responder groups according to the 
reduction in PANSS positive symptoms, as antipsychotic medication primarily targets this 
symptom domain. The mean reduction in positive symptoms was 52% (median = -60%); 
this corresponds to the literature which recommends a 50% cut-off in the reduction of 
symptoms when assessing treatment response in first episode psychosis patients (Kahn et 




% Change in symptoms: Baseline - 5 weeks                
Mean (SD) Range 
PANSS-Positive -52 (38) -100 to 40 T (20)=5.75; P=<0.001 
PANSS-Negative -10 (87) -100 to 300 T (20)=1.13; P=0.27 
PANSS-General -39 (48) -88 to 112 T (20)=3.29; P=0.004 
PANSS-Total -40 (45) -93 to 103 T (20)=3.71; P=0.001 
Table 10 Percentage change in PANSS symptom scores over 5 weeks of treatment with antipsychotic 
medication.  





4.10.2. Glx levels in responders and non-responders to 5 weeks of antipsychotic 
treatment 
ACC 
There was no significant difference between responders and non-responders 
(F(1,19)=0.381, P=0.545), no significant effect of time (F(1,19)=0.012, P=0.914) or group x 
time interaction (F(1,19)=1.657, P=0.213) for CSF-corrected Glx levels over the first 5 weeks 
of treatment, see Figure 23 for mean metabolite values.  
 
Thalamus 
There was no main effect of group (F(1,19)=1.945, P=0.179) or time (F(1,19)=2.735, 
P=0.115)  for CSF-corrected Glx, but there was a significant group x time interaction 
(F(1,19)=6.007, P=0.024) see Figure 21. In the responder group, there was a significant 
effect of time (F(1,11)=23.149, P=0.001), reflecting a decrease in Glx between baseline and 
5 weeks.  There was no significant effect of time in the non-responder group (F(1,8)=0.155, 
P=0.704). At baseline, Glx levels in responders and non-responders did not differ 
(F(1,19)=0.008, P=0.930), but after 5 weeks of treatment, Glx concentrations were 
significantly lower in responders than non-responders (F(1,19)=7.497, P=0.013), see Figure 
23 for mean metabolite values. 
For Cr-scaled Glx the same results were found; there was no main effect of group 
(F(1,19)=1.592, P=0.222) or time (F(1,19)=2.006, P=0.173), but there was a significant group 
x time interaction (F(1,19)=4.959, P=0.038). In the responder group, there was a significant 
effect of time (F(1,11)=10.572, P=0.008), reflecting a decrease in Glx/Cr between baseline 
and 5 weeks.  There was no significant effect of time in the non-responder group 
(F(1,8)=0.210, P=0.659). At baseline, Glx/Cr levels in responders and non-responders did 
not differ (F(1,19)=0.009, P=0.924), but after 5 weeks of treatment, Glx/Cr concentrations 






Figure 21 Mean CSF-corrected Glx (institutional units) in the left thalamus, in medication responder and non-
responder patient groups at baseline and after 5 weeks of treatment with antipsychotic medication.  
Error bars represent the standard deviation. A significant interaction between group and time was found 
(P=0.024). * denotes a significant group difference in the post-hoc analysis (P=0.013). 
 
 
As a significant interaction was found for Glx, associations for glutamate were also 
investigated. For CSF-corrected glutamate levels, there was a significant effect of time in 
both groups, with higher glutamate at baseline compared to the 5 week timepoint 
(F(1,19)=10.283, P=0.005) but there was no effect of group (F(1,19)=0.936, P=0.345), and 




4.10.3. Controlling for medication adherence 
The original analysis was repeated after excluding patients whose self-reported adherence 
to medication was less than 50% of the time (n=5). Medication adherence was measured as 
the percentage number of days of medication use from baseline to the 5 week timepoint. 
Dates of medication use were acquired through patient self-report, corroborated by 
electronic patient notes. 10 responders and 7 non-responders were investigated in the 
following analysis. 
ACC 
There was no effect of group (F(1,15)=0.795, P=0.387), time (F(1,15)=0.005, P=0.946) or a 
group x time interaction (F(1,15)=2.581, P=0.129) for CSF-corrected Glx. 
 
Thalamus 
For CSF-corrected Glx, there was a trend for an effect of time (F(1,15)=4.123, P=0.060) and 
a trend for a group x time interaction (F(1,15)= 3.466, P=0.082). There was no effect of 
group (F(1,15)=2.971, P=0.105), see Figure 22.  
 
For CSF-corrected glutamate levels, there was a significant effect of time, with higher 
glutamate concentrations at the 1st timepoint compared to the 2nd in both groups 
(F(1,15)=8.863, P=0.009). There was no effect of group (F(1,15)=0.430, P=0.522) and no 







Figure 22 Mean CSF-corrected Glx (institutional units) in the left thalamus, in medication responder and non-
responder patient groups at baseline and after 5 weeks of treatment with antipsychotic medication, 
excluding 4 patients taking medications less than 50% of the time.  
Error bars represent the standard deviation. There was a trend for an effect of time (P=0.060) and a group x 




4.10.4. Summary of findings: Glx levels in responders and non-responders to 5 weeks of 
antipsychotic treatment.  
Glx levels in the thalamus were reduced after 5 weeks of antipsychotic medication in 
responders, but not in non-responders. When the analysis was restricted to medication-
adherent patients (10 responders and 7 non-responders), the same pattern of results were 
evident despite the loss of power, with the interaction between time and group for Glx in 
the thalamus persisting at trend level. The latter is consistent with an effect of 
antipsychotic treatment on Glx levels in responders. There was no indication that regional 
Glx or glutamate levels at baseline differed in patients who would or would not 






Baseline     5 weeks     
 
Responder n=12 Non-Responder n=9 Statistic Responder n=12 Non-Responder n=9 Statistic 
ACC             
Glx 17.22 (2.45) 18.90 (3.59) T (19)=1.278; P=0.22 18.37 (2.60) 17.94 (3.32) T (19)=-0.337; P=0.74 
Glutamate 12.24 (1.49) 13.03 (1.52) T (19)=1.193; P=0.25 12.51 (1.96) 13.21 (1.53) T (19)=0.886; P=0.39 
Left thalamus             
Glx 9.95 (0.97) 9.89 (2.48) T (19)=-0.088; P=0.93 8.41 (1.20) 10.18 (1.77) T (19)=2.738; P=0.01 
Glutamate 7.69 (0.95) 7.81 (1.43) T (19)=0.229; P=0.82 6.62 (0.94) 7.29 (1.04) T (19)=1.551; P=0.14 
Figure 23 Glx and glutamate concentrations, Mean (SD), in the anterior cingulate cortex and thalamus in treatment responders and treatment non-responders.  




4.11. Relationship between remission status at 10 months and brain Glx levels   
4.11.1. Reduction in symptoms over 10 months  
Between baseline and the 10 month follow up, symptoms improved in patients as 
evidenced by an overall reduction in PANSS total, positive, negative and general scores 
(Table 11).  
Patients were classified into remission and non-remission groups according to a 50% 
reduction in PANSS positive symptoms. The mean reduction in positive symptoms was 41%, 
(median = -53%). 11 remission and 10 non-remission patients were identified. 
 
  
% Change in symptoms: Baseline - 10 months 
Mean (SD) Range 
PANSS-Positive -41 (78) -100 to 267 T (20)=4.04; P=0.001 
PANSS-Negative -25 (80) -100 to 200 T (20)=2.85; P=0.010 
PANSS-General -30 (43) -100 to 65 T (20)=3.11; P=0.006 
PANSS-Total -38 (43) -100 to 96 T (20)=4.01; P=0.001 
Table 11 Percentage change in PANSS symptom scores over 10 months since first presentation with psychotic 
symptoms.  
Differences between PANSS scores at baseline and 10 months were determined using Student’s t test (T) 
 
 
4.11.2. Glx levels in remission and non-remission patients at 10 months 
ACC  
There were no significant main effects of group (remission vs non-remission) 
(F(1,19)=0.547, P=0.469), or time (2 levels; baseline and ~10 months) (F(1,19)=0.125, 
P=0.727) on CSF-corrected Glx in the ACC, and no group x time interactions (F(1,19)=0.000, 
P=0.984), see Figure 26 for mean metabolite values. 
 
Thalamus 
There was no significant main effect of group (F(1,19)=0.002, P=0.962) or time 
(F(1,19)=0.194, P=0.665) on CSF-corrected Glx, but there was a significant group x time 
interaction (F(1,19)=11.610, P=0.003), see Figure 24. In the non-remission group, there was 
a significant effect of time (F(1,9)=6.701, P=0.029), reflecting an increase in Glx between 
baseline and ~10 months.  There was a strong trend for an effect of time in the remission 
group (F(1,10)=4.860, P=0.052), reflecting a decrease in Glx between baseline and ~10 
months. Glx levels did not differ between groups at baseline (F(1,19)=3.313, P=0.085), but 
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showed a trend for higher Glx in the non-remission than the remission group at ~10 
months (F(1,19)=3.436, P=0.079), see Figure 26 for mean metabolite values. 
 
For Cr-scaled Glx the same results were found; there was no significant main effect of 
group (F(1,19)=0.010, P=0.920) or time (F(1,19)=0.239, P=0.630), but there was a significant 
group x time interaction (F(1,19)=6.423, P=0.020). In the non-remission group, there was 
no longer a significant effect of time (F(1,9)=2.634, P=0.139). There was now a significant 
effect of time in the remission group (F(1,10)=5.370, P=0.043), reflecting a decrease in 
Glx/Cr between baseline and ~10 months. Glx/Cr levels did not differ between groups at 
baseline (F(1,19)=2.995, P=0.102), and no longer significantly differed at ~10 months 
(F(1,19)=1.359, P=0.258). 
 
As a significant interaction was found for Glx, associations for glutamate were also 
investigated. There were no significant main effects of group (F(1,19)=0.136, P=0.717), or 
time (F(1,19)=0.234, P=0.634) on CSF-corrected glutamate, and no group x time 
interactions (F(1,19)=2.293, P=0.146), see Figure 26 for mean metabolite values. 
 
As the frequency of cannabis use significantly differed between remission and non-
remission groups at 10 months (see Table 7 above), analyses were repeated with cannabis 
frequency entered as a co-variate. For Glx in the ACC and for glutamate in the thalamus no 
significant effects were found. For Glx in the thalamus, there was no significant main effect 
of group (F(1,18)=0.028, P=0.869) or time (F(1,18)=0.172, P=0.683) but there was a 
significant group x time interaction (F(1,18)=6.273, P=0.022). In the non-remission group, 
there was no longer a significant effect of time (F(1,8)=1.554, P=0.248).  There was now a 
significant effect of time in the remission group (F(1,9)=6.970, P=0.027), reflecting a 
decrease in Glx between baseline and ~10 months. Glx levels did not differ between groups 









Figure 24 Mean CSF-corrected Glx (institutional units) in the left thalamus at baseline and 10 months, in 
remission and non-remission groups.  
Error bars represent the standard deviation. There was a significant group x time interaction (P=0.003), and a 




4.11.3. Controlling for medication adherence  
The original analysis was repeated after excluding patients whose self-reported adherence to 
medication was less than 50% of the time (n=6). Medication adherence was measured as the 
percentage number of days of medication use from the 1st to the 3rd timepoint. Dates of 
medication use were acquired through patient self-report, corroborated by electronic patient 
notes. 9 remission and 6 non-remission were investigated in the following analysis. 
ACC 
There were no significant main effects of group (remission vs non-remission) (F(1,13)=0.538, 
P=0.476), or time (2 levels; baseline and ~10 months) (F(1,13)=0.001, P=0.981) on CSF-
corrected Glx in the ACC, and no group x time interactions (F(1,13)=1.097, P=0.314). 
 
Thalamus 
There was no significant main effects of group (F(1,13)=0.223, P=0.645) or time (F(1,13)=0.033, 
P=0.859) on CSF-corrected Glx, but there was a significant interaction between group and time 
(F(1,13)=9.377, P=0.009), see Figure 25. Post-hoc tests revealed a significant effect of time in 
the remission group (F(1,8)=9.152, P=0.016), reflecting a decrease in Glx between the baseline 
and ~10 months. In the non-remission group, there was no significant effect of time 
(F(1,5)=2.384, P=0.183). Glx levels did not differ between groups at baseline (F(1,13)=1.161, 
P=0.301), but showed a trend for higher Glx in the non-remission than the remission group at 
~10 months (F(1,13)=3.834, P=0.072). 
 
For glutamate, there was no significant main effect of group (F(1,13)=0.148, P=0.706) or time 
(F(1,13)=0.554, P=0.470), but there was a trend for an interaction between group and time 






Figure 25 Mean CSF-corrected Glx (institutional units) in the left thalamus at baseline and ~10 months, in 
remission and non-remission groups, excluding 6 patients taking medications less than 50% of the time.  
Error bars represent standard deviation. There was a significant group x time interaction (P=0.009), and a trend for 




4.11.4. Summary of findings: Glx levels in remission and non-remission at the 10 month 
follow-up. 
For Glx in the thalamus, a significant interaction between remission groups over ~10 months 
was found, which was driven by a trend for higher Glx concentrations in non-remission patients 
at the 10 month timepoint relative to remission patients. This finding was not attributable to an 
effect of variations in adherence to medication. When the analysis was restricted to 
medication-adherent patients (9 remission and 6 non-remission), the same pattern of results 
were evident despite the loss of power, with the interaction between time and group for Glx in 
the thalamus remaining significant. The latter is consistent with an effect of antipsychotic 
treatment on Glx levels in patients who enter remission. Furthermore, for glutamate, a trend 
for an interaction between remission groups emerged when the analysis was restricted to 
medication adherent patients. There was no indication that regional Glx or glutamate levels at 









Baseline     10 months     
 
Remission n=11 No Remission n=10 Statistic Remission n=11 No Remission n=10 Statistic 
ACC             
Glx 17.59 (2.79) 18.34 (3.38) T (19)=0.557; P=0.58 17.41 (1.59) 18.14 (2.34) T (19)=0.843; P=0.41 
Glutamate 12.41 (1.66) 12.76 (1.41) T (19)=0.529; P=0.60 11.65 (1.68) 12.36 (1.80) T (19)=0.933; P=0.36 
Left thalamus             
Glx 10.54 (1.90) 9.24 (1.27) T (19)=-1.820; P=0.09 9.39 (1.68) 10.74 (1.8) T (19)=1.854; P=0.08 
Glutamate 8.04 (1.37) 7.41 (0.79) T (19)=-1.269; P=0.22 7.71 (1.34) 8.05 (0.91) T (19)=0.684; P=0.50 
Figure 26 1H-MRS metabolite levels, mean (SD), in the anterior cingulate cortex and thalamus in patients who enter remission, and in patients who do not enter remission at the 10 
month follow-up.  




4.12. The relationship between longitudinal changes in Glx levels and longitudinal 
changes in symptom severity. 
4.12.1. Change from baseline to 5 weeks  
The association between the percentage change in Glx levels between baseline and 5 weeks 
with the change in PANSS positive score was assessed, as antipsychotic treatment is proposed 
to primarily affect this symptom domain.   
ACC 
The percentage change in Glx levels between baseline and 5 weeks did not correlate with the 
percentage change in the PANSS positive score (rho=-.174, P=0.451). Secondary analyses found 
no significant correlations with the PANSS total score (rho=-.130, P=0.575) and PANSS negative 
score (rho=.051, P=0.827). 
Thalamus 
There was a positive correlation between the percentage change in Glx levels and the change in 
PANSS positive score (rho=.486, P=0.026; Figure 27). Secondary analyses found no significant 
correlations with the PANSS total or negative score (rho=.378, P=0.091 and rho=.209, P=0.364 
respectively).  
As a significant result for Glx was found, correlations with glutamate were also examined. There 
was a positive correlation between the percentage change in glutamate levels and the change 
in PANSS positive score (rho=.498, P=0.022; Figure 28). Secondary analyses found no significant 
correlations with the PANSS total or negative score (rho=.331, P=0.143 and rho=.215, P=0.350 
respectively).  
For the significant correlations with PANSS positive score, Cook’s distance estimates identified 
1 outlier for Glx and 2 outliers for glutamate. When these outliers were excluded, the positive 
correlation between PANSS positive score and percentage change in Glx and glutamate 





Figure 27 The relationship between the change in thalamic Glx from baseline to 5 weeks (%baseline) and the 
percentage change in PANSS positive score (rho=.486, P=0.026). One outlier is highlighted in red. 
 
 
Figure 28 The relationship between the change in thalamic glutamate from baseline to 5 weeks (%baseline) and 
the percentage change in PANSS positive score (rho=.498, P=0.022). Two outliers are highlighted in red. 
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4.12.2. Change from baseline to 10 months  
 
ACC 
The percentage change in Glx levels between baseline and 10 months did not correlate with the 
percentage change in the PANSS positive score (rho=.063, P=0.786). Secondary analyses found 
no significant correlations with the PANSS total score and PANSS negative score (rho=.134, 
P=0.563 and rho=.125, P=0.589 respectively). 
 
Thalamus 
There was a positive correlation between the percentage change in Glx levels between baseline 
and 10 months and the percentage change in PANSS positive score (rho=.601, P=0.004; Figure 
29). Secondary analyses found a positive correlation for the PANSS total (rho=.528, P=0.014; 
Figure 31) but not the PANSS negative score (rho=.161, P=0.485).  
 
As a significant result for Glx was found, correlations with glutamate were also examined. The 
percentage change in glutamate levels in the thalamus between baseline and the 3rd timepoint 
did not correlate with the change in the PANSS positive score (rho=.166, P=0.473). Secondary 
analyses found no significant correlations with the PANSS total or negative score (rho=.260, 
P=0.256 and rho=.086, P=0.710 respectively).  
 
For the significant correlations with PANSS positive score, Cook’s distance estimates identified 
1 outlier for Glx. When the outlier was excluded, the positive correlation between PANSS 
positive score remained significant for Glx (rho=.552, P=0.012), see Figure 30. For significant 
correlations between the change in Glx and the change in PANSS total score, Cook’s distance 
estimates identified the same outlier. When excluded, the positive correlation with PANSS total 






Figure 29 The relationship between the percentage change in thalamic Glx from baseline to ~10 months and the 
percentage change in PANSS positive score. One outlier is highlighted in red. 
 
Figure 30 The relationship between the percentage change in thalamic Glx from baseline to ~10 months and the 




Figure 31 The relationship between the percentage change in thalamic Glx from baseline to ~10 months and the 
percentag change in PANSS total score. One outlier is highlighted in red. 
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4.13. Summary of findings  
This longitudinal study examined glutamate metabolite changes during antipsychotic treatment 
in patients with first episode psychosis who had previously received minimal or no treatment. 
The main finding was that thalamic Glx concentrations decreased over the first 5 weeks of 
antipsychotic treatment in the subgroup of patients whose symptoms improved, and remained 
lower at the ~10 month follow-up in the subgroup of patients who were in remission. However, 
there was no change in thalamic Glx levels in patients who did not respond to treatment. 
Glutamate/Glx concentrations at baseline did not predict the subsequent response to 
treatment, and there were minimal differences in Glx and glutamate in the patient group as a 
whole compared to controls. These findings suggest that clinically effective antipsychotic 
treatment is associated with a longitudinal reduction in thalamic Glx levels, but that this 
reduction is not evident in patients whose psychotic symptoms do not improve with treatment.  
A limitation of this study is that it is not possible to determine whether antipsychotic 
medication causes the reduction in thalamic Glx levels, rather than being a natural progression 
of the illness. Although the findings remained significant at trend level when the analyses were 
restricted to patients who were adherent to treatment, patient self-reports of medication 
adherence may not be reliable, and blood monitoring of medication adherence would have 
been preferable. In order to determine whether antipsychotic medication mediates the 
reduction in Glx, a group of first-episode psychosis patients not receiving antipsychotic 
medication would be required. This would present with significant ethical challenges as 
treatment would be withheld for at least 5 weeks. 
The finding of no significant difference in Glx between first episode psychosis patients and 
healthy controls in the ACC is consistent with the meta-analysis (Chapter 2.2), as no significant 
differences between FEP patients and controls were detected in the medial frontal cortex. 
However two studies at 4T found elevated glutamine levels in FEP (Chapter 2.2). Similarly in the 
thalamus, the present study did not detect differences in Glx between FEP patients and healthy 
controls. The meta-analysis identified case-control differences in thalamic glutamine levels but 
not in glutamate or Glx concentrations. As the present study was conducted at 3T it was not 
possible to resolve glutamine in the ACC or thalamus. In the meta-analysis there were 
insufficient studies to assess thalamic glutamine levels in first episode patients separately, and 
so future studies at 4T in this clinical group will help to clarify the nature of glutamatergic 
abnormalities in both the ACC and thalamus. Significant differences in glutamine, but not 
glutamate or Glx, may be detected as glutamate release into the synapse is rapidly metabolised 
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to glutamine, and so glutamine may be a more sensitive marker of neurotransmission turnover 
(Rothman et al., 2011). 
There was large variation in the timing of the third timepoint (~10 months), which may affect 
the findings as glutamatergic differences vary with the stage of the disorder, as shown in the 
meta-analysis in Chapter 2.2. However the findings from the 2nd timepoint (at 5 weeks) were 
largely consistent with those at the 3rd timepoint (~10 months), and there was no significant 
difference in the time to follow-up between remission and non-remission groups. 
Data on recreational drug use was available at baseline and the 2nd timepoint for 15 patients 
recruited from the OPTiMiSE clinical trial but was not available for the 6 patients recruited from 
the TreatFEP study. Therefore significant differences in recreational drug use between 
responder and non-responder groups at baseline and the 2nd timepoint could not be assessed, 
and if present, may mediate the significant difference in thalamic Glx levels between the 
patient groups. However data on recreational drug use was available for all patients at the 3rd 
timepoint, and although significant differences in cannabis use were found between remission 
and non-remission groups, the significant interaction between group and time for thalamic Glx 
levels remained when cannabis use was entered as a covariate.  
It is of interest that Glx levels in the ACC did not differ between responders and non-
responders, and instead differences were only found in the thalamus, contrary to three 
previous reports of higher levels of glutamate in the ACC of treatment-resistant patients (this 
will be discussed at greater length in the discussion chapter below, section 5.2.2) (Demjaha et 
al., 2014; Egerton et al., 2012; Mouchlianitis et al., 2015). This may be due to the low severity of 
negative symptoms in the present sample, as they are found to correlate with glutamate levels 
in the ACC (Egerton et al., 2012), consistent with the role of the ACC in modulating affect 
(Fornito et al., 2009). Furthermore chronic patients rather than first episode psychosis patients 
were examined in two of the three previous studies examining treatment response (Demjaha 
et al., 2014; Mouchlianitis et al., 2015). The ACC is connected to cognitive prefrontal and 
emotional limbic regions, and is proposed to modulate affect.  
This study only examined glutamatergic metabolites in the ACC and thalamus. Thalamic Glx 
levels were negatively correlated with the change in positive symptoms, and were higher in 
non-responders compared to responders, and in non-remission patients compared to those in 
remission. Elevated thalamic Glx levels in non-responders may underlie positive symptoms, as 
the thalamus is an integral gateway in sensory processing (Pergola et al., 2015). The thalamus 
integrates sensory input with information from a number of higher-order limbic regions via a 
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series of thalamo-cortical loops, and so abnormalities in this brain region would likely impact 
upon functioning in other brain areas (please see chapter 5 below for a detailed discussion 
regarding the possible neuro-circuitry of glutamatergic abnormalities in non-responders, and 
their relation to the dopamine hypothesis of schizophrenia). Thalamo-cortical projections are 
glutamatergic, whereas thalamic tone is maintained by GABAergic interneurons (Clinton and 
Meador-Woodruff, 2004b). Abnormalities in GABA are thought to also play a role in 
schizophrenia, as elevated glutamate release is proposed to result from disinhibited GABAergic 
interneurons (Lisman et al., 2008). Future 1H-MRS studies using edited acquisition sequences 
that are able to measure GABA concentrations in the brain may further elucidate the pathways 
involved. 
The meta-analysis in Chapter 2.2 found that glutamate measures were elevated in the medial 
temporal lobe, basal ganglia and thalamus of patients. It therefore would be of interest to 
determine whether Glx levels in the medial temporal lobe and basal ganglia relate to treatment 
response. The latter is supported by one report of reduced glutamate levels in medication-
naïve FEP patients in the striatum following 4 weeks of treatment with risperidone (de la 
Fuente-Sandoval et al., 2013). Although the patient sample was not subdivided according to 
response, there was a 30% reduction in PANSS total score in the sample as a whole, suggesting 
that most patients were treatment responders. In Chapter 2.3, the multicentre analysis found 
that medial temporal Glx levels correlated with negative symptoms, but no studies to date have 
investigated its relation to treatment response. It would also be of interest to incorporate 
measures of cognitive performance in a future study, as glutamatergic abnormalities in the 
medial temporal lobe are suitably placed to underlie cognitive deficits in schizophrenia.
 161 
 
CHAPTER 5 – Discussion 
5. Summary of findings  
This thesis examined the use of proton magnetic resonance spectroscopy to measure 
glutamate function in psychosis. In Chapter 2, a meta-analysis of 1H-MRS studies indicated 
that schizophrenia is associated with elevations of glutamatergic metabolites in the medial 
temporal cortex, the thalamus, and the basal ganglia (section 2.2). There was also some 
evidence that alterations in glutamate metabolite levels varied according to clinical stage: 
elevated medial frontal levels were evident in high risk and FEP patients but not in chronic 
schizophrenia; conversely, medial temporal Glx levels were elevated in chronic patients but 
were not altered in high risk or FEP groups. Overall, a systematic review (section 2.1) and a 
multicentre analysis (section 2.3) did not find robust associations between glutamate 
measures and symptom scores, although these analyses could not assess whether 
longitudinal changes in glutamate levels were related to changes in symptom severity over 
time. The effect of medication on glutamate measures was less clear; glutamate measures 
were not related to CPZ dose equivalents in the meta-analysis, but a more sensitive analysis 
of multicentre data revealed a trend for a negative correlation with medial frontal 
glutamate (section 2.3). Chapter’s 1 and 2 concluded that, although glutamate alterations 
are present in schizophrenia, and have been found to differentiate patients based on their 
clinical response, it is still unclear whether glutamate levels predict the therapeutic 
response or whether effective treatment is associated with a reduction in glutamate. To 
address this question, raised in the meta-analysis and multicentre data analysis, a 
longitudinal 1H-MRS study of antipsychotic response in first episode psychosis was 
conducted.  Firstly, to examine the feasibility and determine the sample size for this study, 
in Chapter 3 the test-retest reproducibility and reliability of longitudinal 1H-MRS glutamate 
measures was determined. Chapter 4 outlined the methodology and the results of a 1H-
MRS study that aimed to examine the relationship between 1H-MRS glutamate measures 
and the acute and medium-term response to antipsychotic medication in first episode 
schizophrenia.  
5.1.1. Initial response to treatment  
The main finding of the 1H-MRS study of antipsychotic response in first episode psychosis 
(Chapter 4) was that longitudinal changes in Glx levels in the thalamus were related to the 
therapeutic effectiveness of antipsychotics. Prior to treatment, thalamic Glx levels were 
similar in patients who subsequently responded to medication and in those who did not 
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respond. However, after 5 weeks of antipsychotic treatment, Glx levels were lower than at 
baseline in responders, but not in non-responders. These findings remained significant at 
trend level when analysis was limited to only medication adherent patients, suggesting that 
the changes in thalamic Glx were related to the degree of response to the antipsychotic 
medication, as opposed to the natural course of the illness or between group differences in 
medication-adherence.  
In accordance with the reduction in thalamic Glx in the treatment responder group, a direct 
correlation between the longitudinal reduction in PANSS positive score over the first 5 
weeks of treatment and the reductions in both thalamic glutamate and thalamic Glx levels 
over the same time period was observed. These correlations were specific to positive 
psychotic symptoms: there were no correlations with the change in either negative 
symptoms or the total PANSS score. As the main effect of antipsychotic medication is on 
positive symptoms, this is also in line with an effect of treatment.  
5.1.2. Remission after 10 months 
Consistent with the observations over five weeks of treatment, the second major finding 
was that patients who were in remission after 10 months of treatment had lower thalamic 
Glx levels than patients who were not in remission. Over 10 months, thalamic Glx levels 
reduced in remitted patients, but increased in patients who were not in remission. 
Furthermore, the reduction in thalamic Glx levels over 10 months correlated with the 
reduction in PANSS total score over the same period, which was again driven by changes in 
the positive symptom domain. 
 
Although it is not possible to determine whether the longitudinal change in thalamic Glx in 
responders was an effect of antipsychotic treatment specifically, as opposed to the natural 
course of the illness, the fact that the finding remained significant when the analysis was 
restricted to patients who were adherent to treatment supports this interpretation. 
Furthermore, a trend for longitudinal thalamic glutamate changes to relate to remission 
status only emerged when the analysis was restricted to medication adherent patients, 
implying that glutamate levels are also related to the therapeutic effectiveness of 
antipsychotics. The change in Glx was also not attributable to group differences in cannabis 




5.1.3. Summary of Glx findings relating to clinical status 
Taken together, the data suggest that at both 5 weeks and at 10 months, longitudinal 
changes in thalamic Glx levels were related to the clinical status of the patients at follow 
up. At both timepoints, reductions in Glx levels from baseline were associated with a good 
clinical response and / or remission. On the other hand there was no reduction, or an 
increase in Glx levels in the patients who had a relatively poor outcome. In addition, across 
all patients, the improvement in positive symptoms following treatment for both 5 weeks 
and 10 months was directly correlated with the longitudinal reductions in thalamic Glx 
levels. These findings indicate that in patients with a schizophreniform psychosis, a good 
response to the initial treatment with antipsychotic medication is associated with 
longitudinal reductions in thalamic Glx levels. 
5.2.  Comparison with previous studies  
5.2.1. Previous studies of glutamate in first episode psychosis   
Previous studies of antipsychotic naïve/minimally treated FEP have reported higher ACC 
glutamine levels than in controls (Bartha et al., 1997; Bustillo et al., 2010; Theberge et al., 
2002), which was also detected in my meta-analysis (Chapter 2.2).  Longitudinal studies 
suggest that this elevation in glutamine levels is still evident after 6 - 10 months of 
antipsychotic treatment (Bustillo et al., 2010; Theberge et al., 2002). The present 
longitudinal 1H-MRS study at 3T was unable to evaluate glutamine specifically. However, in 
both the meta-analysis (Chapter 2.2) and my present study I did not detect differences in 
ACC Glx concentrations between FEP patients and controls. 
Similarly, I did not detect differences in Glx between patients and controls in the thalamus. 
Thalamic glutamate function has not been extensively studied in FEP patients, but most 
studies have not found differences in glutamate or Glx levels between FEP patients and 
controls (Bustillo et al., 2010; Galińska et al., 2009; Szulc et al., 2004; Theberge et al., 2002). 
One previous study reported that thalamic glutamine levels were elevated in antipsychotic-
naïve FEP patients (Theberge et al., 2002), and that these were reduced after 30 months of 
treatment (Theberge et al., 2007). This is consistent with the meta-analysis finding of 
elevated thalamic glutamine in cases, although the meta-analysis was unable to assess FEP 
patients separately (Chapter 2.2).   
One potential factor that may have contributed to the absence of differences in 1H-MRS 
measures at baseline in the present study is that the control group was relatively small 
(n=15), but nonetheless comparable with other studies. I cannot therefore exclude the 
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possibility that true differences were not detected because of a lack of statistical power, 
although the absence of significant differences in ACC and thalamic Glx levels is consistent 
with the meta-analysis (Chapter 2.2). The modest size of the control group reflects the fact 
that the study was designed to compare glutamate measures in responders and non-
responders to treatment within the patient sample, rather than in patients with 
schizophrenia and controls (see the power analysis in Chapter 3). A further consideration 
with respect to measures of glutamine is that in the present study, which was conducted 
using a 3T scanner, it was not possible to assess glutamine in every subject, due to a poor 
signal to noise ratio.  
Notwithstanding the lack of case-control differences, the data from the present study 
clearly suggest that in the first episode of psychosis, glutamate dysfunction is more evident 
in patients in whom antipsychotic treatment is relatively ineffective than in the patient 
sample as a whole. The absence of significant longitudinal differences in 1H-MRS measures 
within the control sample indicates that these were stable over time, and did not vary for 
technical or other non-specific reasons. This is consistent with the test-retest analysis, 
which showed a good reproducibility and reliability of glutamate measures in healthy 
controls over an equivalent time-period (Chapter 3). This is important, as it could otherwise 
have been a confounding factor in the interpretation of the longitudinal changes in the 
patient sample. 
5.2.2. Previous studies of glutamate measures relating to clinical status 
No studies have previously assessed whether ACC or thalamus glutamate levels in 
unmedicated FEP patients predict the subsequent response to antipsychotic treatment. 
One cross-sectional study has compared glutamate function in the thalamus and ACC in 
patients with first episode psychosis who were or were not in remission following 
treatment (Egerton et al., 2012), and two cross-sectional studies examined ACC glutamate 
levels in chronic patients after they had been defined as treatment resistant on the basis of 
previous treatments (Demjaha et al., 2014; Mouchlianitis et al., 2015). The former study 
found higher ACC glutamate levels in patients who were not in remission following 
treatment, relative to those in remission (Egerton et al., 2012), with no group difference in 
the thalamus. The latter studies found higher ACC glutamate levels in patients who had 
failed to respond to previous treatment with at least two antipsychotic drugs, relative to 
those in remission (Mouchlianitis et al., 2015) and to healthy controls (Demjaha et al., 
2014) (also with no difference in the thalamus). A key issue in the interpretation of these 
previous studies was that it was not possible to determine whether the group differences 
 165 
 
predated antipsychotic treatment or were secondary to this. My findings suggest that 
differences in glutamate metabolites between responders and non-responders are not 
present prior to treatment, but emerge after it has been delivered.  
The patients in the Egerton et al., study were examined on average 10 months after first 
presentation, which is similar to the ~10 month timepoint in the present study. However, 
the present study detected a difference in the thalamus but not the ACC at 10 months, 
whereas Egerton et al., found differences in the ACC but not in the thalamus. It is unclear 
why the location of the differences in the two studies should be different. The respective 
remission and non-remission samples were comparable in size, and both studies used the 
same scanner and the same 1H-MRS protocol. However, the present study was restricted 
to patients that were minimally medicated or mediation-naïve at first presentation, and 
most of the patients were treated with the same antipsychotic drug (amisulpride) following 
a standardised dosing protocol.  In contrast, the Egerton et al., study was open to any 
patient with a recent first episode of psychosis, regardless of what treatment they had 
been given. Thus, patients had been treated by clinical teams using a variety of different 
antipsychotics, with no restriction on type or dose. In the present study, antipsychotic use 
in the majority of patients was monitored for the first 5 weeks as part of a clinical trial, and 
so medication adherence may be higher in this sample compared to the Egerton et al. 
study. As the present sample is more homogenous in their medication exposure and 
duration of psychosis, this may increase the power to detect differences in the thalamus. 
Indeed, in the Egerton et al., study, the same pattern is present; Glx/Cr levels were lower in 
the remission group, although this did not reach significance. 
Egerton et al., reported that high ACC glutamate levels correlated with a greater severity of 
negative symptoms, whereas in the present study, high thalamic Glx levels correlated with 
a greater severity of positive symptoms. Symptom scores at the time of scanning were 
similar between studies, except that non-remission patients had more severe negative 
symptoms in the Egerton study. This may explain why correlations with negative symptoms 
were not detected in the present sample. Furthermore, the Egerton study classified 
patients into remission and non-remission groups according to Andreasen’s remission 
criteria (Andreasen et al., 2005) (see section 5.5.1 below for further discussion of the 
definition of response), whereas the present study classified patients according to the 
reduction in positive symptoms. This suggests that glutamate in the ACC may mediate 
negative aspects of disease, which is consistent with its role in emotional processing, 
whereas the thalamus is indicated in positive symptoms.   
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Differences in the way that the samples were ascertained and were treated also applies to 
the discrepancy between the findings from the present study and the two studies in 
chronic patients with treatment resistance (Demjaha et al., 2014; Mouchlianitis et al., 
2015). A further consideration in relation to these studies is that the duration of 
antipsychotic treatment and of the disorder was much longer (16 and 14 years, 
respectively) in these chronic patients than in a first episode sample. Another study in 
chronic patients, following a minimum 7 day medication washout, and after 4 weeks of 
antipsychotic treatment, reported that baseline Glx/Cr levels in the frontal lobe, but not 
thalamus or medial temporal lobe, were higher in patients that did not go on to show more 
than a 20% reduction in total PANSS score (Szulc et al., 2013). However, these patients 
were temporarily medication-free rather than medication-naïve, and the extent to which 
the ‘baseline’ measures were affected by previous antipsychotic exposure is unclear.  
5.2.3. Previous studies of the relationship between glutamate measures and symptom 
severity 
A number of cross-sectional studies have examined the relationship between thalamic 
glutamate measures and either PANSS scores (Egerton et al., 2012; Yoo et al., 2009) or 
SANS and SAPS scores (Bustillo et al., 2010; Theberge et al., 2002) in patients with 
psychosis. None of these found significant correlations (see section 2.1 for a systematic 
review). One study differentiated patients based on symptom exacerbation; patients 
currently experiencing exacerbated psychotic symptoms had increased Glx levels in inferior 
parietal, but not frontal, white matter relative to both stable patients and healthy controls 
(Ota et al., 2012). 
Only two previous studies have examined the association between longitudinal changes in 
glutamate measures and symptom severity. One study assessed antipsychotic-naïve FEP 
patients at presentation and following 4 weeks of treatment with risperidone. A reduction 
in glutamate and Glx levels in the associative striatum was correlated with an improvement 
in the PANSS general score (de la Fuente-Sandoval et al., 2013). The other study examined 
chronic patients who were medication-free for 6 months, although the majority were 
medication-naïve (Choe et al., 1996). A longitudinal reduction in prefrontal white matter 
Glx was correlated with a reduction in BPRS scores, following 4 weeks to 6 months of 
treatment with haloperidol, trifluoperazine, pimozide, or clozapine. Despite the differences 
in brain region, patient group and antipsychotic medication examined in these two studies, 
it is of interest that both reported that reductions in glutamate metabolites following 
antipsychotic treatment were correlated with symptomatic improvement. This is broadly 
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consistent with the findings of the present study, and suggests that clinically effective 
antipsychotic treatment is associated with a reduction in regional glutamate metabolite 
levels. This might explain why so few correlations between symptom scores and glutamate 
measures have been found in cross-sectional studies (see Chapter 2; Section 2.1 for 
systematic review, Section 2.2 for meta-regression, and Section 2.3 for multicentre 
analyses). 
5.2.4. Previous studies examining the effect of medication on glutamate measures 
Previous 1H-MRS studies examining glutamate measures before and after antipsychotic 
treatment did not classify patients according to response, and so the effects of treatment 
on thalamic glutamate measures may have been masked. One study found significantly 
lower thalamic glutamine levels after 30 months, but not 10 months of treatment, 
compared to baseline, when patients were antipsychotic-naïve (Theberge et al., 2007). The 
reduction in thalamic glutamine levels with antipsychotic treatment is consistent with my 
finding of reduced thalamic Glx levels after both 5 weeks and ~10 months of treatment, 
although it is of interest that glutamine reductions were not detected at 10 months, as the 
reduction in SAPS (Scale for the Assessment of Positive Symptoms) score indicate that the 
majority of patients were responders at this timepoint. Another study found no difference 
in thalamic Gln/Glu ratios in patients with schizophrenia relative to controls after 6 and 12 
months of treatment (Bustillo et al., 2010).  
Previous studies have not found evidence for reductions in glutamate metabolites in the 
ACC following antipsychotic treatment. In antipsychotic naïve/minimally treated FEP 
patients, ACC Gln/Glu ratio did not change after 6 and 12 months of treatment (Bustillo et 
al., 2010), and ACC glutamine levels did not change after 10 and 34 months of treatment 
(Theberge et al., 2007). In chronic patients, ACC Glx/Cr levels did not change following a 
switch from conventional antipsychotics to 8 weeks of treatment with olanzapine. 
However, in the latter study, when patients were split into responders and non-responders 
according to the change in negative symptoms, an increase in ACC Glx/Cr was seen in 
patients whose negative symptoms improved (Goff et al., 2002). This highlights the 
potential importance of defining patients according to therapeutic response, although this 
is in contrast with the results of the Egerton et al. study described above, as higher levels of 
ACC glutamate were associated with a greater severity of negative symptoms (Egerton et 
al., 2012).  
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Longitudinal reductions in glutamate levels in medication-naïve FEP patients have been 
reported in the striatum following 4 weeks of treatment with risperidone (de la Fuente-
Sandoval et al., 2013). The patient sample was not subdivided according to response, but 
there was a 30% reduction in PANSS total score in the sample as a whole, suggesting that 
most patients were responsive. A preliminary study which did not specify the response of 
patients found reduced DLPFC glutamine in 8 FEP patients following ~14 weeks of 
antipsychotic treatment (Stanley et al., 1996).  
5.3. Possible mechanisms  
There is some evidence that psychotic disorders are associated with progressive brain 
changes (Hulshoff Pol and Kahn, 2008), although this remains controversial (Zipursky et al., 
2013). Longitudinal reductions in thalamic Glx could therefore reflect changes linked to the 
natural history of the disorder, as opposed to an effect of treatment. However, this seems 
unlikely, as longitudinal reductions in Glx were not evident in the patient sample as a 
whole, but were limited to those that responded to treatment. Nevertheless, I cannot 
exclude the possibility that there is subtype of schizophrenia that has a poor prognosis, is 
unresponsive to antipsychotic treatment and is associated with persistently high Glx levels. 
However, if this were the case, one would expect it to be associated with high Glx levels 
prior to treatment.  
If antipsychotic medication is responsible for longitudinal changes in thalamic glutamate 
function in patients that respond to treatment, what might be the mechanism? 
Antipsychotic treatment targets D2 receptors in the striatum to reduce the downstream 
effects of excessive dopamine release in this region. Efferents from the striatum project to 
the thalamus via the pallidum. In patients who respond to antipsychotics, the normalisation 
of the effects of excessive dopamine activity in the striatum may lead to a reduction in 
thalamic glutamate levels, via the cortico-striatal-midbrain-thalamic circuit, see Figure 32 
(Alexander et al., 1986; Haber, 2003). In non-responders, striatal dopamine function may 
be relatively normal, and antipsychotics may therefore have little effect, allowing thalamic 




Figure 32 A model of the circuitry linking prefrontal glutamatergic activity to the control of striatal dopamine 
levels, which in turn feedback to the thalamus to affect glutamate levels in this region. Adapted from 
Modinos et al., TINS 2014.  
 
The above findings, and the association between longitudinal changes in thalamic 
glutamate measures and symptomatic improvement suggest that pharmacological 
interventions aimed at reducing glutamate levels may help to alleviate symptoms in 
schizophrenia. However, to date, clinical trials of glutamatergic agents have shown only 
small to modest effects (see reviews Keefe et al., 2013; Papanastasiou et al., 2013; Singh 
and Singh, 2011). These disappointing results might reflect the involvement of chronic 
patients in all studies to date. My meta-analysis suggests that there are differences in the 
glutamatergic abnormalities in patients in the early and chronic stages of schizophrenia, 
and the present findings indicate that antipsychotic treatment has significant effects on 
these measures. Evaluating novel glutamatergic compounds in high risk or first episode 
patients, who have been minimally treated, may be more effective. 
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5.4.  Prediction of psychosis 
The present results are relevant to ongoing efforts to develop clinical tools that can be used 
to facilitate the prediction of treatment response in schizophrenia (Dazzan et al, 2015; 
McGuire et al, 2015). At present it is not possible to predict whether a given patient will or 
will not respond to antipsychotic medication. This can only be determined empirically, on 
the basis of a lengthy evaluation of the effectiveness of one or more courses of treatment. 
If brain glutamatergic measures differ in responders and non-responders, this suggests that 
they could be incorporated in to a predictive tool. The present findings suggest that 
repeated 1H-MRS scanning may be necessary to differentiate these subgroups, but further 
studies with larger patient samples are required to clarify whether a single baseline 
assessment might be sufficient. Using biological measures to stratify patients according to 
future response to antipsychotic medication would allow probable non-responders to be 
given alternative treatments, such as clozapine, at an earlier stage. At present, even in 
major clinical-academic centres, there is still a delay of around five years between patients 
being identified as treatment unresponsive and the initiation of treatment with clozapine 
(Howes et al., 2012b; McGuire et al., 2015).  
1H-MRS glutamate measures may also be useful in clinical trials of novel therapeutic agents 
that are designed to act on the glutamatergic system. First, scanning patients before and 
after administration of a novel drug can be used to test whether it alters brain glutamate 
function (Egerton et al, 2016). 1H-MRS measurements may also reveal whether the 
response to the drug is related to glutamatergic measures at baseline and / or changes in 
these measures over the course of treatment. Finally, 1H-MRS glutamate scanning could 
also be used to identify subsets of patients with marked glutamatergic dysfunction: these 
subjects can then be used to form ‘enriched’ samples in whom a clinical effect of the drug 
may be more detectable.  
5.5.  Methodological considerations 
5.5.1. Definition of response and remission 
In the present study, the response to treatment was defined in terms of the reduction in 
PANSS positive symptom score, as opposed to the PANSS total symptom score, because 
antipsychotic medication mainly affects this symptom domain. In studies of antipsychotic 
treatment in patients with chronic schizophrenia, response is often defined as a reduction 
in symptoms of 20% or more (Leucht et al., 2007). However, because the symptomatic 
response is relatively good in first episode patients, a higher cut-off of 50% has been 
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recommended (Kahn et al., 2008; Leucht et al., 2007). I therefore used a 50% threshold in 
the present study, which yielded subgroups of approximately equal sizes (n=12 and n=9 at 
5 weeks, and n=11 and n=10 at 10 months). The median reduction in positive symptoms in 
the sample was 60% at 5 weeks and 53% at 10 months. If a 20% threshold had been used, 
at 5 weeks most of the sample (n= 15) would have been responders, with only a minority 
(n= 6) non-responders, and at 10 months, 3 non-responders and 18 responders. This would 
have reduced the power to detect statistical differences between these subgroups.  
An alternative approach to defining treatment response is to classify patients according to 
whether they are in symptomatic remission. The most widely used remission criteria are 
those defined by Andreasen et al (2005). These define remission in terms of ratings of mild 
or lower on 8 PANSS items that are thought to be specific for schizophrenia, and that the 
ratings are at these low levels for at least 6 months (Andreasen et al., 2005). The latter 
duration criterion could not be applied in the present study, as patients had not been 
regularly assessed for 6 months prior to the follow-up points. One potential advantage of 
using remission criteria as opposed to a percentage severity reduction criterion is that it 
avoids the possibility that a highly symptomatic patient could show a 50% reduction in 
symptoms yet still be symptomatic and, from a clinical perspective, unwell. However this 
does not appear to have been an issue in the present study: comparison of the subgroups 
defined using a 50% reduction in positive symptoms and by the remission criteria revealed 
that they largely comprised the same patients: after 5 weeks of treatment, 10 of 12 
patients who show more than a 50% reduction in PANSS positive symptoms meet 
Andreasen criteria for remission, and at 10 months, 9 of 11 patients who show more than a 
50% reduction in PANSS positive symptoms meet Andreasen criteria for remission. 
5.5.2. Measurement of medication adherence 
In the present study, the assessment of medication adherence relied on patient self-report 
and information in their medical records. Although this provides useful information on the 
extent to which patients were taking their treatment, there is a possibility that the 
differences between responders and non-responders were related to differing levels of 
adherence, rather than a difference in the effect of the medication. Recording pill 
dispensing and measuring blood antipsychotic levels could have provided a more accurate 
measure of adherence.  
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5.5.3. Limitations of 1H-MRS 
The main findings in the present study involved measurements of Glx, as opposed to 
glutamate or glutamine. The data were acquired at a field strength of 3T and using a short 
echo time (30ms), and with these parameters, glutamate and glutamine signals cannot be 
completely resolved from each other, as their peaks overlap by <30% in the 2.25–2.55 ppm 
range (Snyder and Wilman, 2010a). Glx is therefore a more valid measure than glutamate 
and glutamine using the protocol that was employed in the study. Nevertheless, it is still 
notable that no differences in glutamate levels were detected, as glutamate makes up 
~90% of the Glx signal. This could be because the differences in Glx were driven by changes 
in glutamine rather than glutamate. This would be consistent with the results of the meta-
analysis, which indicated that patients with schizophrenia had higher thalamic glutamine 
but not glutamate levels (see Chapter 2). Further 1H-MRS studies using higher field 
strengths and that can quantify glutamine are needed to address this issue. However, at 
present, MRI scanners with field strengths of 4T or above are relatively uncommon. 
CSF-corrected rather than creatine-scaled data were examined in the present study, as 
creatine scaled data relies on the assumption that creatine levels are stable in the brain and 
do not differ between clinical groups. In the present study, voxel CSF, grey and white 
matter content did not differ between clinical groups, and the main interaction findings in 
the thalamus remained significant when creatine-scaled data were assessed. This indicates 
that the main findings are robust and are not an artefact of variability in voxel CSF content. 
Furthermore, creatine levels did not differ between patients and controls or between 
clinical groups in the present study. 
1H-MRS is unable to differentiate intracellular and extracellular glutamate metabolite 
measures, and thus the cellular location of Glx changes cannot be established. 
Furthermore, it is not known whether Glx differences between groups represent an 
alteration in glutamate used for metabolism or neurotransmission. Future studies able to 
measure glutamine at 4T will provide a more reliable indicator of glutamate 
neurotransmission, as the majority of glutamine is sourced from the metabolism of 
neurotransmitter glutamate. Many of these issues could be overcome by using PET or SPET 
ligands with a molecular level of specificity for elements of the glutamate 
neurotransmission system, such as the NMDA receptor. However, despite a great deal of 
research, there are still no PET or SPET tracers for glutamatergic receptors that have been 
validated. Pilowsky et al., (1993) reported plausible results in schizophrenia using a SPET 
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ligand, but it is not considered specific for the NMDAR.  A number of candidate PET tracers 
for the NMDAR are currently being evaluated (McGinnity et al., 2015, 2014). 
5.6.  Future work  
A causal association between antipsychotic treatment and a reduction in thalamic Glx 
levels cannot be shown by this study. To definitively determine whether the natural history 
of schizophrenia, as opposed to antipsychotic medication, mediates longitudinal changes in 
glutamatergic metabolites, would require a longitudinal 1H-MRS study in medication-naïve 
patients who remained medication-free. This would be challenging to conduct, as it would 
require the recruitment of first episode patients who either refused to take antipsychotic 
medication or in whom treatment was withheld. In most developed countries it would be 
regarded as unethical to withhold antipsychotic treatment, even if the patient refused 
treatment, especially if this was to be for a long period. An alternative method to decipher 
medication effects on glutamate would be to examine 1H-MRS measures longitudinally as 
patients discontinue medication. 
Future 1H-MRS work using MRI scanners with a field strength of 4T or more would clarify 
the extent to which findings involving Glx reflected alterations in glutamate or glutamine 
(Theberge et al., 2007, 2002). The meta-analysis suggests that significant differences in 
glutamine, but not glutamate or Glx, are present in first episode patients compared to 
healthy controls in the ACC. Similarly in the thalamus, differences in glutamine, but not 
glutamate or Glx, are detected in cases in comparison to controls. Therefore further work 
at 4T may detect case-control differences which were not found in the present study.  
The meta-analysis found elevations in glutamatergic metabolites in the medial temporal 
lobe and the basal ganglia of patients (Chapter 2.2), but no studies to date have 
investigated their relation to treatment response. It would therefore be of interest to 
examine glutamatergic concentrations in these regions, as the multicentre analysis 
reported a correlation between medial temporal Glx levels and negative symptoms 
(Chapter 2.3), and a recent study found that treatment normalised striatal glutamate levels 
in FEP patients (de la Fuente-Sandoval et al., 2013). In addition, abnormalities in GABA are 
thought to also play a role in schizophrenia, as elevated glutamate release is proposed to 
result from disinhibited GABAergic interneurons (Lisman et al., 2008). Future 1H-MRS 
studies using edited acquisition sequences that are able to measure GABA concentrations 
in the brain may further elucidate the pathways involved in schizophrenia aetiology. 
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The meta-analysis (Chapter 2.2) and the longitudinal study of 1H-MRS glutamate measures 
and their relation to treatment response (Chapter 4) conclude that schizophrenia is 
associated with elevations in glutamatergic metabolites, and that patients who respond to 
antipsychotic medication show a reduction in thalamic Glx levels whereas Glx levels do not 
change in treatment non-responders. These results indicate that novel compounds that 
reduce glutamatergic metabolites may be therapeutically beneficial in the non-responder 
group. Therefore future work should identify novel therapeutic compounds that reduce 
glutamate metabolite levels using 1H-MRS, and investigate their relationship to symptoms. 
5.7. Conclusions 
This thesis suggests that alterations in glutamatergic function are evident in a number of 
brain regions in schizophrenia, and that these differ between patients who do and do not 
respond to treatment with antipsychotic medication. The longitudinal 1H-MRS study 
indicates that in patients with first episode schizophrenia, a good response to treatment 
with drugs that block dopamine D2 receptors is associated with a longitudinal reduction in 
thalamic Glx levels. These findings have implications for our understanding of the 
pathophysiology of the disorder, the stratification of patients, and the development of 
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In this thesis I have discussed a neurochemical approach to schizophrenia. Schizophrenia 
however is a highly complex disorder, with no single causative gene or mechanistic 
pathway. I think it is important to consider the wider socioeconomic context of a mental 
health disorder after reducing it down to its molecular level.  So, for the final page of my 
thesis, I would like to bring your attention to the lyrics of Skepta, a successful grime artist 
based in Tottenham, of Nigerian descent.  
 
Skepta often refers to “underground psychosis” in his lyrics. This does not directly refer to 
psychosis, instead it refers to the vulnerable mental state that individuals enter into when a 
society does not believe they can provide anything of worth, and the vicious cycle that 
ensues where the individual gives up. I think we can learn something from Skepta’s insight 
into the socioeconomic factors that increase the risk of schizophrenia, factors which may 
impact upon the physical pathways that have been discussed in this thesis.  
 
Skepta himself does not suffer from a mental illness, however these lyrics do lead you to 
question what he may have encountered, had he not successfully transformed himself 
from a young black male disempowered by society into a pioneer of grime music in the UK 
in the early 2000s. 
